Clinical trial NCT02644278
Conditions: Advanced Solid Tumor
Keywords: VX15-984-001 VX-984 M9831 Advanced Solid Tumor Pegylated liposomal doxorubicin
Sponsor: EMD Serono Research & Development Institute, Inc.
Start date: 2016-02-29; Completion date: 2017-10-19
Enrollment: 15 participants; Allocation: ; Intervention model: SEQUENTIAL

Brief summary:
The purpose of this study was to evaluate the safety and tolerability of VX-984 (M9831) administered alone and in combination with pegylated liposomal doxorubicin (PLD), and to determine the maximum tolerated dose (MTD) and preliminary evidence of efficacy of VX-984 in combination with PLD in participants with advanced solid tumors.

Detailed description:

Arms: arm 1: None arm 2: None arm 3: None arm 4: None
Interventions: intervention 1: VX-984 120 mg + PLD 40 mg/m^2 intervention 2: VX-984 240 mg + PLD 40 mg/m^2 intervention 3: VX-984 480 mg + PLD 40 mg/m^2 intervention 4: VX-984 720 mg + PLD 40 mg/m^2
Intervention descriptions: intervention 1: Participants received VX-984 orally 120 milligram (mg) orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 120 mg in combination with pegylated liposomal doxorubicin (PLD) 40 milligram per square meter (mg/m\^2) administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2. intervention 2: Participants received VX-984 orally 240 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 240 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2. intervention 3: Participants received VX-984 orally 480 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 480 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2. intervention 4: Participants received VX-984 orally 720 mg orally once daily alone on Days -14 to -12 of a 14-day Lead-in Period, followed by VX-984 720 mg in combination with PLD 40 mg/m\^2 administered intravenous infusion, with PLD administered on Day 1 and VX-984 administered on Day 2 to Day 4 for up to six 28-day cycle or until disease progression unacceptable toxicities, withdrawal of consent, or until exposure to PLD exceeded 550 mg/m\^2.

Protocol documents:
Prot_000.pdf: 
Page 1 of 79
1
TITLE PAGE
Clinical Study Protocol
Clinical Study Protocol Number
VX15-984-001
EMD Serono Internal Study Number: 
MS201926-0001
Title
An Open-Label, Phase I, First in Human Study of 
the Safety, Tolerability, and 
Pharmacokinetic/Pharmacodynamic Profile of 
VX-984 in Combination With Chemotherapy in 
Subjects With Advanced Solid Tumors
Phase
I
IND Number
EudraCT Number
Not applicable
Coordinating Investigator
 
Tel: 
Fax: 
Sponsor
EMD Serono Research & Development Institute, 
Inc., Billerica, MA, USA
Medical Responsible:
Merck KGaA, Global Clinical Development, 
Frankfurter Strasse 250, 64293 Darmstadt, Germany
Tel: 
Fax: 
Sponsor Legal Representative in 
the European Union
Merck KGaA
Frankfurter Strasse 250
64293 Darmstadt, Germany
Clinical Study Protocol Version
21 August 2017 / Version 4.0 including 
Amendment 1 and 2
Replaces Version
21 April 2016 / Version 3.0
-
 –
This document is the property of Merck KGaA, Darmstadt, Germany, or one of its subsidiaries. It is 
intended for restricted use only and may not – in full or part – be passed on, reproduced, published or 
used without express permission of Merck KGaA, Darmstadt, Germany, or its subsidiary. Copyright 
© 2017 by Merck KGaA, Darmstadt, Germany, or its subsidiary. All rights reserved.
'RFXPHQW1R

2EMHFW1R

PPD
PPD
PPD
PPD
PPD
PPD
CCI
CCI
CCI
PPD


Protocol VX15-984-001, Version 4.0
Page 2 of 79
EMD Serono Research & Development Institute
Summary of Changes to the Protocol
The previous version of this protocol (Version 3.0, 21 April 2016) was amended to create the 
current version (Version 4.0, 21 August 2017).
Protocol History
Version and Date of Protocol
Comments
Version 1.0, 11 August 2015
Original version
Version 2.0, 23 September 2015
!
In response to regulatory feedback, the following changes were made:
o
Clarification was added to dose escalation guidelines
o
Eligibility criterion 2 was modified to clarify that subjects in Part 
B must have confirmed advanced primary endometrial cancer 
(locally advanced and incurable endometrial cancer) that has 
been treated with surgery and/or radiation or is ineligible for such 
treatment in order to participate in this study
o
Dose modification and delay criteria were clarified and revised to 
include guidelines for hand foot syndrome and stomatitis
!
Based on Investigator feedback, eligibility criteria were revised as 
follows:
o
Inclusion criterion 6a was changed from hemoglobin ≥8.0 g/dL 
to ≥9.0 g/dL for all subjects
o
Clarified that subjects receiving potassium, magnesium, or other 
supplementation for an otherwise controlled condition would be 
eligible for the study
o
Exclusion criterion 2 was updated to exclude subjects with 
uterine carcinosarcoma.
!
Based on Investigator feedback, added that repetition of screening 
assessments that do not meet eligibility criteria in subjects who receive 
red blood cell transfusions or fluid replacement therapy will not require 
authorization from the medical monitor.
! The timing of urine β-hCG testing was clarified.
! Footnote “n” of Table 3-3 was revised to clarify PK sample collection 
for subjects in Part A. 
Version 3.0, 21 April 2016
!
Due to sponsor decision, subjects with lymphomas will no longer be 
included in the study.
!
Safety clinical laboratory assessments were clarified as follows:
o
Coagulation parameter testing will be performed only at 
Screening
o
If blood urea nitrogen (BUN) cannot be collected, urea may be 
substituted.
!
Clarified that assessments to be performed at the “end of cycle” may be 
performed up to 5 days before Day 1 of the subsequent cycle.
!
Study drug dispensation and preparation instructions were revised to 
enable immediate dosing at study sites.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 3 of 79
EMD Serono Research & Development Institute
!
Minor updates were made to the definitions of analysis sets and 
planned analyses for clarity and consistency.
Version 4.0, 21 August 2017
Current version
The following changes were made in the current version:
Change and Rationale
Affected Sections
Due to the study being transitioned from Vertex Pharmaceuticals Incorporated, 
Sponsor name changed to: EMD Serono Research & Development Institute, Inc., 
Billerica, MA, USA, Legal representative in the European countries: Merck 
KGaA, Frankfurter Strasse 250
64293 Darmstadt, Germany 
Cover page
EMD Serono internal study number: MS201926-0001
Cover page
Coordinating Investigator has been identified as per Merck KGaA requirement: 
Tel: 
Fax: 
Cover Page
Medical Responsible has been identified as per Merck KGaA requirement: 
Merck KGaA, Global Clinical Development, Frankfurter Strasse 250, 64293 
Darmstadt, Germany
Tel: 
Fax:
Cover page
Due to the changes in Sponsor, reference to “Vertex” changed to “the Sponsor”
Throughout protocol
Add EMD Serono compound code: M9831
Synopsis (Objectives, 
Investigational drug), 
Section 5
Due to the transition, Sponsor name changed from Vertex Pharmaceuticals 
Incorporated, Sponsor name changed to: EMD Serono Research & Development 
Institute
Section 9.5
The SAE reporting process was changed to comply with standard operating 
procedure
Section 13.1.2.3
Typographical and administrative changes were also made to improve the clarity of the 
document.
'RFXPHQW1R

2EMHFW1R

PPD
PPD
PPD
PPD
PPD
CCI
PPD
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 4 of 79
EMD Serono Research & Development Institute
2
PROTOCOL SYNOPSIS
Title
An Open-Label, Phase I, First-in-Human Study of the Safety, Tolerability, and 
Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With 
Chemotherapy in Subjects With Advanced Solid Tumors
Brief Title
A Study to Evaluate Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic 
Profile of VX-984 in Combination With Chemotherapy
Clinical Phase and 
Clinical Study Type 
Phase I, first-in-human (FIH)
Objectives
PART A
Primary
!
To evaluate the safety and tolerability of VX-984 (EMD Serono internal 
compound code: M9831) administered alone and in combination with 
pegylated liposomal doxorubicin (PLD) in subjects with advanced solid 
tumors
!
To determine the maximum tolerated dose (MTD) of VX-984 in combination 
with PLD in subjects with advanced solid tumors.
Secondary
!
To evaluate the pharmacokinetics (PK) of VX-984 when administered alone 
and in combination with PLD in subjects with advanced solid tumors
!
To evaluate the PK of PLD when administered in combination with VX-984 
in subjects with advanced solid tumors
!
To evaluate preliminary antitumor activity of VX-984 in combination with 
PLD in subjects with advanced solid tumors.
Exploratory
!
 
 
!
To assess tumor response by tumor volume and tumor necrosis in subjects 
administered VX-984 in combination with PLD
!
To assess correlations between prior treatment response and treatment 
outcome.
PART B
Primary
!
To evaluate the safety and tolerability of VX-984 administered in 
combination with PLD in subjects with recurrent or metastatic endometrial 
cancer who have progressed on a prior platinum regimen
!
To assess the overall response to VX-984 administered in combination with 
PLD in subjects with recurrent or metastatic endometrial cancer who have 
progressed on a prior platinum regimen.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 5 of 79
EMD Serono Research & Development Institute
Secondary
!
To assess progression free survival (PFS) in subjects with recurrent or 
metastatic endometrial cancer who have progressed on a prior platinum 
regimen administered VX-984 in combination with PLD
!
To assess response duration (RD) in subjects with recurrent or metastatic 
endometrial cancer who have progressed on a prior platinum regimen 
administered VX-984 in combination with PLD
!
To assess overall survival (OS) in subjects with recurrent or metastatic 
endometrial cancer who have progressed on a prior platinum regimen 
administered VX-984 in combination with PLD
!
To assess clinical benefit in subjects with recurrent or metastatic endometrial 
cancer who have progressed on a prior platinum regimen administered 
VX-984 in combination with PLD as measured by complete response (CR), 
partial response (PR), or stable disease (SD) of 4 months or greater
!
To evaluate the PK of VX-984 when administered in combination with PLD 
in subjects with recurrent or metastatic endometrial cancer who have 
progressed on a prior platinum regimen.
Exploratory
!
 
!
To assess tumor response by tumor volume and tumor necrosis in subjects 
with previously-treated endometrial cancer, administered VX-984 in 
combination with PLD
!
To assess correlations between prior treatment response and treatment 
outcome
!
 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 6 of 79
EMD Serono Research & Development Institute
Endpoints
PART A
Primary
!
Safety parameters, including adverse events (AEs), dose-limiting toxicities 
(DLTs), clinical laboratory values (serum chemistry and hematology), vital 
signs, echocardiogram, and electrocardiogram (ECG) assessments
!
MTD of VX-984 in combination with PLD.
Secondary
!
Plasma PK parameter estimates of VX-984, administered alone and in 
combination with PLD, derived from plasma concentration-time data
!
Plasma PK parameter estimates of PLD administered in combination with 
VX-984, derived from plasma concentration-time data
!
Preliminary evidence of anti-tumor activity, including tumor response as 
evaluated by Response Criteria Evaluation RECIST 1.1 and tumor markers.
Exploratory
!
 
!
Tumor response as assessed by tumor volume and tumor necrosis using 3D 
computed tomography (CT) scans
!
Tumor response as assessed by historical and on-treatment tumor growth 
dynamics
!
 
 
PART B
Primary
!
Safety parameters, including AEs, clinical laboratory values (serum chemistry 
and hematology), vital signs, echocardiogram, and ECG assessments
!
Objective response rate (ORR) as evaluated by CT scan per RECIST 1.1.
Secondary
!
PFS
!
RD as evaluated by CT scan and quantified by RECIST 1.1
!
OS
!
Clinical benefit (CR + PR + SD of at least 4 months)
!
Plasma PK parameter estimates of VX-984 when administered in 
combination with PLD, derived from plasma concentration-time data.
Exploratory
!
!
Tumor response as assessed by tumor volume and tumor necrosis using 3D 
CT scans
!
Tumor response as assessed by historical and on-treatment tumor growth 
dynamics
!
 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 7 of 79
EMD Serono Research & Development Institute
Number of Subjects
Part A: approximately 50 subjects 
Part B: approximately 40 subjects
Study Population
At least 18 years of age, with tumors measurable by RECIST 1.1
Part A: male and female subjects with advanced solid tumors who have 
progressed through standard therapeutic options and for whom no standard 
therapy is available or PLD may be considered standard of care 
Part B: female subjects with recurrent or metastatic endometrial cancer who have 
progressed on a prior platinum regimen
Investigational Drug
Active substance: VX-984 (EMD Serono internal compound code: M9831)
Activity: DNA-dependent protein kinase (DNA-PK) inhibitor
Strength and Route of Administration: VX-984 suspension (in 0.5% methyl 
cellulose) for oral administration
Dose: up to 3000 mg
Study Duration
Screening:
All subjects will have a Screening Visit within 14 days before the first dose of 
study drug.
Treatment Periods:
Part A: Subjects in Part A will receive VX-984 as a single agent on 
Days -14 to -12 in a 14-day lead-in followed by VX-984 in combination with PLD 
for up to six 28-day cycles (PLD on Day 1 and VX-984 on Days 2 to 4). Subjects 
with tumors responding to treatment may continue on treatment past 6 cycles, 
with the agreement of the Investigator and medical monitor until disease 
progression, unacceptable toxicities, withdrawal of consent, or until exposure to 
PLD exceeds 550 mg/m2.
Part B: Subjects in Part B will receive VX-984 in combination with PLD in 
28-day cycles until disease progression, unacceptable toxicity, or withdrawal of 
consent.
Follow-up: 
All subjects will have a Safety Follow-up Visit 28 (±7) days after the last dose of 
study drug.
For Parts A and B, when possible, a follow-up CT scan will be performed 
5 (± 1) weeks after the end of therapy unless the subject had progressive disease at 
the time of treatment discontinuation or subject has initiated a new treatment in 
the interim. In Part B, for subjects without disease progression, long-term follow-
up, including as indicated staging CT scans and/or follow-up communications, 
may continue for up to 1 year.
Study Design
This is an open-label, multicenter, single-arm, FIH, dose-escalation study in 
subjects with solid tumors (Part A) followed by an expansion phase in subjects 
with recurrent or metastatic endometrial cancer who have progressed on a prior 
platinum regimen (Part B).
Part A
Part A will be a dose escalation study to evaluate the safety, tolerability, and PK 
of VX-984 when administered in combination with PLD in subjects with 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 8 of 79
EMD Serono Research & Development Institute
advanced solid tumors who have progressed through standard therapeutic options 
and for whom no standard therapy is available or PLD may be considered 
standard of care. This part will establish the MTD of VX-984 in combination with 
PLD.
Starting dose and dosing schedule
For each VX-984 dose level tested, subjects will receive VX-984 once daily (qd) 
alone on Days -14 to -12 of a 14-day Lead-in Period. Following the single agent 
Lead-in Period, subjects will receive PLD on Day 1 and VX-984 qd on Days 2 to 
4 of a 28-day cycle. The starting doses will be 120 mg qd of VX-984 and 40 
mg/m2 of PLD. The Lead-in Period will be required only if the dose of VX-984 is 
escalated beyond the highest dose of VX-984 previously tolerated in a Lead-in 
Period.
Guidelines for dose escalation and determination of the MTD: 
Three subjects will be enrolled at the starting dose of VX-984 (120 mg) and PLD 
(40 mg/m2). If the starting dose of VX-984 is tolerated alone in the 14-day Lead-
in Period and in combination with PLD through 1 cycle (28 days) without a DLT 
or CTCAE Grade 3 or worse toxicities in any of these 3 subjects and without a 
CTCAE Grade 2 toxicity in 2 subjects, the dose of VX-984 may be increased by 
up to 100% while holding the dose of PLD constant in a subsequent cohort of 3 
subjects. Safety data, including AEs, laboratory values, and ECG results, obtained 
through the end of Cycle 1, as well as available PK data, will be assessed to 
determine the dose of VX-984 for the next cohort. 
In this way, the dose of VX-984 will be escalated with 40 mg/m2 of PLD in 
subsequent cohorts of 3 subjects until 1 subject has a treatment-related or 
possibly-related DLT or toxicity of CTCAE Grade 3 or worse; or 2 subjects (who 
may be in different cohorts) have a toxicity of CTCAE Grade 2. 
Subsequent dose escalation will proceed depending on the toxicity as described:
!
In the event of a treatment-related or possibly-related toxicity of CTCAE 
Grade 3 or worse in 1 subject (that is not considered a DLT), or 
treatment-related or possibly-related toxicity of CTCAE Grade 2 or 
worse (but not a DLT) in 2 subjects (who may be in different cohorts), 
the dose escalation will continue with a more conservative dose 
escalation (up to 50%). The dose of VX-984 will continue to be escalated 
in subsequent cohorts of 3 subjects until there is a DLT through the end 
of Cycle 1
!
In the event of a DLT, an adaptive Bayesian logistic regression model 
(BLRM) will be used to determine the dose for the subsequent cohorts or 
determine if the current dose level should be expanded. At each predicted 
dose, 3 to 6 subjects will be enrolled in each cohort at the discretion of 
the sponsor and Investigators. If more than 3 subjects are enrolled, the 
first 3 subjects will receive VX-984 in the Lead-in Period and if no DLT 
is observed with VX-984 dosing then the additional subjects in the cohort 
will not have the Lead-in Period. The Lead-in Period will be required 
only if the dose of VX-984 is escalated beyond the highest dose of 
VX-984 previously tolerated in a Lead-in Period
!
If 2 subjects in a previously untested dose level experience a DLT, 
enrollment to that cohort will stop, the BLRM will be updated and the 
next cohort will be opened at a lower dose level or an intermediate dose 
level that satisfies the escalation overdose control (EWOC) criteria. 
However, if 2 subjects in a new cohort at a previously tested dose level 
experience a DLT (e.g., a total of 8 subjects are tested on this dose level 
with 2 DLTs observed), further enrollment to that cohort will stop, the 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 9 of 79
EMD Serono Research & Development Institute
BLRM will be updated with this new information and re-evaluation of 
the available safety, PK and PD data will occur. By incorporating 
information gained at the preceding dose levels, additional subjects may 
be enrolled into the current dose level only if the dose still meets the 
EWOC criteria and as agreed by the sponsor and Investigators.
Subjects will be considered as evaluable for dose determination if they have a 
DLT during Cycle 1 or the preceding Lead-in Period or meet the minimum 
treatment and safety evaluation requirements for the first cycle as outline in the
protocol.
After completion of Cycle 1 of each cohort (3 to 6 subjects), available safety, PK, 
and efficacy information as well as recommendations from the Bayesian model 
will be used to determine the dose for the next cohort. The adaptive BLRM will be 
guided by the EWOC principle to control the risk of DLT in future subjects (see 
Statistical Analysis section for details). 
After repeating the above steps, the dose escalation of VX-984 will continue with 
a constant dose of PLD at 40 mg/m2 until MTD of VX-984 with PLD at 40 mg/m2
is achieved. The maximum planned dose of VX-984 is 2000 mg; however, higher 
doses up to 3000 mg may be allowed depending on the observed safety, PK, and 
PD, and based on recommendation of the BLRM. 
If a dose of VX-984 is not tolerated with PLD at 40 mg/m2, then the VX-984 dose 
will be reduced by up to 50% with a constant dose of PLD at 40 mg/m2 or the 
dose of PLD will be reduced by 25% (30 mg/m2) or lower with a constant dose of 
VX-984. These doses will be explored in subsequent cohorts at the discretion of 
the Investigators and sponsor until the MTD is established with PLD at 30 mg/m2 
or lower. If daily dosing of VX-984 for 3 days after PLD is not tolerated during 
initial dose escalation, less frequent dosing of VX-984 may be explored in 
subsequent cohorts.
Treatment duration and disease assessments:
At all dose levels of VX-984, subjects will complete a total of up to six 28-day 
cycles of VX-984 and PLD combination therapy. Subjects with tumors responding 
to treatment may continue on treatment past 6 cycles with the agreement of the 
Investigator and medical monitor until disease progression, unacceptable toxicity, 
or withdrawal of consent. CT scans will be performed at the end of every 2 cycles 
(see Table 3-3). If there is evidence of progressive disease as determined using 
RECIST 1.1, the subject’s treatment will be discontinued. In addition, 
transthoracic echocardiograms will be performed at baseline and at the end of 
every 2 cycles (see Table 3-3). After 6 cycles, CT scans will be performed at the 
end of every 2 to 3 cycles (see Table 3-3).
Part B
Part B will be an expanded cohort study to confirm the safety, tolerability, PK, 
and potential anti-tumor activity of VX-984 in combination with PLD in female 
subjects with recurrent or metastatic endometrial cancer who have progressed on a 
prior platinum regimen.
During each cycle, subjects will be administered PLD on Day 1, and VX-984 will 
be dosed on Days 2 to 4 of a 28-day cycle unless in Part A the number of days 
was decreased due to tolerability. Approximately 40 subjects will receive VX-984 
with PLD at the MTD or lower, as determined during the dose escalation phase. 
Subjects will continue to receive treatment until disease progression, unacceptable 
toxicities, or withdrawal of consent. Subjects will be evaluated by CT scans at the 
end of every 2 cycles for the first 6 cycles and every 2 to 3 cycles thereafter (see 
Table 3-3). If there is evidence of progressive disease as determined using 
RECIST 1.1, treatment will be discontinued. In addition, subjects will be 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 10 of 79
EMD Serono Research & Development Institute
evaluated by transthoracic echocardiogram at baseline and at the end of every 
2 cycles (see Table 3-3).
Pharmacokinetic 
Assessments
Part A:
Blood samples for measurement of VX-984 PK (in plasma) will be collected 
during the Lead-in Period Days -12 to -11 and during Cycle 1 on Day 2 and on 
Days 4 to 5.
Urine samples for measurement of VX-984 PK will be collected during the Lead-
in Period on Days -12 to -11.
Blood samples for measurement of PLD PK (in plasma) will be collected at 
Cycle 1 on Days 1, 2, 4, and 5.
Part B: 
Blood samples for measurement of VX-984 PK (in plasma) will be collected 
during Cycle 1 on Day 4.
Blood sample for measurement of PLD PK (in plasma) will be collected during 
Cycle 1 on Day 4.
PK sampling may be conducted on Day 2 or Day 3 if subjects are unable to come 
to the clinic for PK sampling on Day 4.
These PK samples will be required in a minimum of 20 subjects. VX-984 dose 
will be administered in the clinic on the day of PK sampling.
Efficacy Assessments
CT scans will be performed at Screening and at the end of every 2 cycles for the 
first 6 cycles and every 2 to 3 cycles thereafter, and at 5 (± 1) weeks after the last 
dose of study drug (excluding subjects with progressive disease on previous 
CT scan) (see Table 3-3). For subjects with bony metastases, bone scans will be 
performed every 4 to 6 cycles or more frequently if clinically indicated. 
Safety Assessments
AEs; clinical laboratory values (serum chemistry and hematology studies); 
standard 12-lead ECGs; echocardiograms; vital signs; and physical examinations.
Exploratory 
Assessments
 
 
Statistical Analyses
Bayesian Adaptive Model:
The adaptive BLRM with EWOC principle will be used, with the following 
2 exceptions:
1.
For cohorts requiring 3 or more evaluable subjects, if only 2 evaluable 
subjects are available for assessment (all others drop out), and neither subject 
has had a treatment-related or possibly-related toxicity greater than CTCAE 
Grade 1, then 2 subjects will be considered sufficient for decision-making
2.
If the first 2 subjects in a cohort have DLTs, no additional subjects will be 
enrolled into that cohort until the Bayesian model has been updated with this 
new information. Likewise, the model will be re-evaluated if 2 subjects in a 
cohort have DLTs before the enrollment of any additional subjects.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 11 of 79
EMD Serono Research & Development Institute
Model:
	
, , … ,  = log() +  log 
∗ + ! "#

#$
#
Under-dosing:

() ∈[0.00, 0.166)
Target toxicity:      

() ∈[0.166, 0.333)
Excessive toxicity : 

() ∈[0.333, 1.00]
The recommended dose for the next cohort will fulfill the following 2 criteria:
1.
Dose that maximizes probability that true DLT rate is in the target toxicity 
interval [0.166, 0.333)
2.
With overdose control: less than 25% probability of the true DLT rate in the 
excessive toxicity interval [0.333, 1].
Data Analyses:
Analysis of all data will be performed by the sponsor or designee. The 
demographics and baseline characteristics will be summarized by dose group, by 
concurrent regimen and study part, and overall. Baseline characteristics will 
include but will not be limited to the following variables: type of cancer, tumor 
stage at baseline, World Health Organization (WHO) performance status at 
baseline, time elapsed since cancer diagnosis, prior chemotherapy and radiation 
therapy, and duration of most recent cancer therapy.
The overall safety profile of VX-984 will be assessed in terms of the following 
primary safety endpoints: 
!
Incidence of treatment-emergent AEs (TEAEs), including AEs leading to 
dose modifications or discontinuations
!
Incidence of DLTs (Part A)
!
Clinical laboratory values
!
ECG outcomes
!
Echocardiogram outcomes
!
Vital signs.
Safety data will be summarized by dose group, by concurrent regimen and study 
part, and overall. In general, safety analyses will be based on the Safety Set 
defined as all subjects who have received any study drug. 
The summary of DLTs will be based on the DLT Evaluable Set. The BLRM will 
be used to estimate the posterior distributions for the probabilities of DLT events 
at various combination dose levels after each cohort of subjects. The MTD is 
defined as the combination dose associated with the highest probability that DLT 
events will occur in 16.6% to less than 33.3% subjects and as the combination 
dose that will not exceed the overdose criterion (< 25% probability that DLT 
events will occur in ≥33% of subjects).
Efficacy data will be summarized by dose group, by concurrent regimen and study 
part, and overall. For Part B, the proportion of subjects demonstrating ORR, 
together with exact 90% CI, will be presented.
VX-984 PK data will be analyzed on an ongoing basis during dose escalation in 
Parts A and B using standard noncompartmental methods. PK data for VX-984 
will be reviewed with safety data to inform dose escalation.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 12 of 79
EMD Serono Research & Development Institute
3
SCHEDULE OF ASSESSMENTS
Schedules of Assessments are shown in Table 3-1, Table 3-2, and Table 3-3.
Table 3-1
Study VX15-984-001: Screening (Parts A and B)
Assessment
Screening Visit
Day -28 to Day -15 (Part A with Lead-in Period)
Day -14 to Day -1 (Part A without Lead-in 
Period and Part B)
Informed consent 
X
Demographics
X
Medical history
X
Prior and concomitant medications
X
Height, weight, BMI, and vital signs
X
Physical examinationa
X
Radiological (CT) disease assessmentb
X
Bone scanc
X
Transthoracic echocardiogramd
X
Clinical disease assessmente
X
WHO performance status
X
Standard 12-lead electrocardiogram (ECG)
X
Serum FSH (postmenopausal female subjects only)
X
Serum β-HCG (all female subjects)
X
Serum chemistry
X
Hematology
X
Coagulation
X
Urinalysis
X
Thyroid-stimulating hormone
X
a
Physical examination of all body systems.
b
Subjects will have a chest and abdominal CT scan and, if clinically indicated, a pelvic CT scan. Radiologic 
scans performed within 2 weeks of Screening may substitute for assessment of eligibility; however, for 
Part B, CT scan must be repeated during Screening according to the Imaging Manual unless discussed with 
the sponsor.
c
For all subjects with prostate cancer or for subjects with other malignancies in whom bony metastases have 
been previously documented or are highly suspected. Results of a bone scan performed within 4 weeks 
before Screening may substitute for the Screening bone scan. If results from a PET CT scan are available, 
they may be used to substitute for a bone scan.
d
If an echocardiogram or nuclear scan has been performed within 1 month before Screening, these results 
may be used, unless repetition of the assessment is clinically indicated.
e
Assessment includes tumor staging (I to IV) and Tumor-Node-Metastasis.
f
 
 
.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 13 of 79
EMD Serono Research & Development Institute
Table 3-1
Study VX15-984-001: Screening (Parts A and B)
Assessment
Screening Visit
Day -28 to Day -15 (Part A with Lead-in Period)
Day -14 to Day -1 (Part A without Lead-in 
Period and Part B)
Historical CT scans (optional)g
X
Adverse events
Continuous from signing of Informed Consent 
Form (ICF) through Safety Follow-up Visit
g
If accessible, the last 2 CT scans taken before the Screening scan will be collected from enrolled subjects.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 14 of 79
EMD
& Development Institute
Table 3-2
Study VX15-984-001: Lead-in Period With VX-984 (Part A)
Assessment
Lead-in (Part A)a
Day -14
Day -13
Day -12
Day -11
Day -10
Day -9
Outpatient Visit 
X
X
X
Safety Assessments
Physical examinationb
X
WHO performance status
X
Vital signs
Xc
12-lead ECG
Xd
Serum chemistrye
X
X
Hematologye
X
X
Urine β-hCGf
X
Urinalysis
X
Concomitant medications and 
AEs
Continuous from signing of ICF through Safety Follow-up Visit
Study Drug Administration
VX-984 dosingg
X
X
X
Pharmacokinetic Assessments
VX-984 (Plasma PK collection)
Xh
Xh
VX-984 (Urine PK collection)
Xi
Xi
Exploratory Assessments
a There will be a Lead-in Period of VX-984 monotherapy for all cohorts in Part A in which the administered 
dose will be higher than any previously evaluated dose of VX-984 as monotherapy in at least 3 subjects.
b Symptom-directed physical examinations will be performed as clinically indicated in the Investigator’s 
judgment.
c Vital signs will be measured before dosing and 4 (± 1) hours after dosing.
d 12-lead ECG will be measured up to 60 minutes before dosing and 2 and 4 hours after dosing (± 60 minutes).
e Laboratory results should be reviewed before dosing on days of study drug administration. To facilitate timely 
administration of study drug, safety labs may be performed the day before dosing. If labs are drawn the 
evening before, they should be recorded as corresponding to day of planned drug administration. Laboratory 
values must conform to inclusion/exclusion criteria for study drug administration.
f Female subjects of childbearing potential only. Assessment should be performed before dosing.
g Subjects will receive study drug in the clinic on Days -14 and -12; and at home on Day -13. Subjects will take 
study drug at home per instructions provided in Section 10.3.
h Plasma PK samples will be collected on Day -12 before dosing (0 hour) and at 0.5, 1, 2, 4, 8, and 24 hours 
(Day -11) after dosing.
i Urine PK samples will be collected before dosing (0 hour) and from 0 to 4, 4 to 8, and 8 to 24 hours (Day -11) 
after dosing.
j
k
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 15 of 79
EMD Sero
evelopment Institute
Table 3-3
Study VX15-984-001: VX-984 and PLD Combination Therapy and Follow-up (Parts A and B)
Event/Assessment 
During Each Cycle 
(Except as Noted)
Day 1
Day 2
Day 3
Day 4
Day 5
Day 8
Day 15
Follow-upa
28 days
(± 7 days)
5 weeks 
(± 1 week)
Outpatient visits
X
Xb,c
Xb
Xb
X
X
X
X
Safety Assessments
Physical examinationd
X
X
CT scan disease assessmente
At the end of every 2 cycles for first 6 cycles then at the end of every 2 to 3 cycles until 
disease progressionf
X
Clinical disease assessmentg
X
X
Bone scanh
At the end of every 4 to 6 cycles until disease progressionf
Transthoracic echocardiogram
At the end of every 2 cycles until disease progressionf
WHO performance status
X
X
Weight
X
X
Vital signs
Xi
Xb,i
X
12-lead ECG
Xj
Xb,j
X
Serum chemistry
Xk
Xb
X
X
X
Hematology
Xk
X
X
X
Urine β-hCGl
X
X
Concomitant medications 
Continuous from signing of ICF through Safety Follow-up Visit
X
AEs
Continuous from signing of ICF through Safety Follow-up Visit
X
Study Drug Administration
VX-984m
X
X
X
PLD
X
Pharmacokinetic Assessments
a Follow-up will include a Safety Follow-up Visit 28 (± 7) days after the last dose of study drug and a radiologic Follow-up Visit 5 (±1) weeks after the last 
cycle of chemotherapy, and survival follow-up assessment at the last subject last visit. In Part B, for subjects without disease progression, long-term follow-up, 
including as indicated staging CT scans and/or follow-up communications, may continue for up to 1 year. See Section 8.1.4 for additional details.
b Cycle 1 only.
c Day 2 visit is required for Part A only.
d Symptom-directed physical examinations will be performed as clinically indicated in the Investigator’s judgment.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 16 of 79
EMD Sero
evelopment Institute
Table 3-3
Study VX15-984-001: VX-984 and PLD Combination Therapy and Follow-up (Parts A and B)
Event/Assessment 
During Each Cycle 
(Except as Noted)
Day 1
Day 2
Day 3
Day 4
Day 5
Day 8
Day 15
Follow-upa
28 days
(± 7 days)
5 weeks 
(± 1 week)
Part A
VX-984 (Plasma PK collection)
Xn
Xn
Xn
Part A
PLD (Plasma PK collection)
Xo
Xo
Xo
Xo
Part B
VX-984 (Plasma PK collection)
Xp
e CT scan of chest, abdomen, and pelvis should be performed, in addition to CT scan of other body areas, as clinically indicated.
f End of cycle assessments may be performed up to 5 days before Day 1 of subsequent cycle.
g Assessment includes tumor staging (I to IV) and Tumor-Node-Metastasis.
h For all subjects with prostate cancer or for subjects with other malignancies in whom bony metastases have been previously documented or are highly 
suspected; or if clinically indicated.
i Vital signs will be measured on Day 1 up to 60 minutes before administration of PLD and on Day 2 up to 60 minutes before administration of VX-984 and at 2 
(± 1) hours after administration of VX-984. 
j 12-lead ECG will be measured on Day 1 up to 60 minutes before administration of PLD. ECG will be measured on Day 2 only during Cycle 1 and will be 
measured up to 60 minutes before administration of VX-984, and 2 and 4 hours (± 60 minutes) after administration of VX-984.
k To facilitate timely administration of study drug on Day 1, safety lab samples may be collected up to 3 days before Day 1. If safety lab samples are collected 
before Day 1, they should be recorded as corresponding to Day 1.
l Female subjects of childbearing potential only.
m For Part A: For Cycle 1, subjects will receive VX-984 in the clinic on Days 2 and 4; and at home on Day 3. After Cycle 1, subjects will be instructed to take all 
VX-984 doses at home per instructions provided in Section 10.3.
For Part B: For Cycle 1, subjects will receive VX-984 in the clinic on Day 4 or the day subjects come in for PK assessment; and at home on Days 2 and 3. 
After Cycle 1, subjects will be instructed to take all VX-984 doses at home per instructions provided in Section 10.3.
n Cycle 1 only. VX-984 plasma PK samples will be collected on Day 2 before dosing (0 hour) and at 0.5, 1, 2, and 4 hours after dosing; and on Day 4 before 
dosing (0 hour) and at 0.5, 1, 2, 4, 8, and 24 hours (Day 5) after dosing.
o Cycle 1 only. PLD plasma PK samples will be collected on Day 1 before beginning of infusion (BOI) and at 1, 2, 4, 6, 24 hours (Day 2), 72 hours (Day 4) and 
96 hours (Day 5) after BOI.
p Cycle 1 only. VX-984 plasma PK samples will be collected on Day 4 before dosing (0 hour) and at 0.5, 1, 2, 4, and 8 hours after dosing. PK sampling may 
occur on Days 2 or 3 if subjects are unable to come to the clinic on Day 4. PK samples are required from a minimum of 20 subjects.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
PPD


Protocol VX15-984-001, Version 4.0
Page 17 of 79
EMD Sero
evelopment Institute
Table 3-3
Study VX15-984-001: VX-984 and PLD Combination Therapy and Follow-up (Parts A and B)
Event/Assessment 
During Each Cycle 
(Except as Noted)
Day 1
Day 2
Day 3
Day 4
Day 5
Day 8
Day 15
Follow-upa
28 days
(± 7 days)
5 weeks 
(± 1 week)
Part B
PLD (Plasma PK collection)
Xq
Exploratory Assessments
q Cycle 1 only. One PLD plasma PK sample will be collected on Day 4 before VX-984 dosing. PK sampling may occur on Days 2 or 3 if subjects are unable to 
come to the clinic on Day 4. PK samples are required from a minimum of 20 subjects.
 
'RFXPHQW1R

2EMHFW1R

CCI
CCI
PPD
CCI
C
C
I


Protocol VX15-984-001, Version 4.0
Page 18 of 79
EMD Serono Research & Development Institute
4
TABLE OF CONTENTS
1
Title Page.......................................................................................................................... 1
Clinical Study Protocol........................................................................................................... 1
2
Protocol Synopsis............................................................................................................. 4
3
Schedule of Assessments................................................................................................ 12
4
Table of Contents........................................................................................................... 18
List of Tables...................................................................................................................... 22
List of Figures .................................................................................................................... 22
5
Introduction.................................................................................................................... 23
6
Study Objectives ............................................................................................................ 24
6.1
Part A........................................................................................................................ 24
6.1.1
Primary Objectives ........................................................................................... 24
6.1.2
Secondary Objectives ....................................................................................... 24
6.1.3
Exploratory Objectives..................................................................................... 25
6.2
Part B........................................................................................................................ 25
6.2.1
Primary Objectives ........................................................................................... 25
6.2.2
Secondary Objectives ....................................................................................... 25
6.2.3
Exploratory Objectives..................................................................................... 25
7
Study Endpoints............................................................................................................. 26
7.1
Part A........................................................................................................................ 26
7.1.1
Primary Endpoints ............................................................................................ 26
7.1.2
Secondary Endpoints ........................................................................................ 26
7.1.3
Exploratory Endpoints...................................................................................... 26
7.2
Part B........................................................................................................................ 26
7.2.1
Primary Endpoints ............................................................................................ 26
7.2.2
Secondary Endpoints ........................................................................................ 27
7.2.3
Exploratory Endpoints...................................................................................... 27
8
Study Design................................................................................................................... 27
8.1
Overview of Study Design ....................................................................................... 27
8.1.1
Screening (Parts A and B) ................................................................................ 28
8.1.2
Treatment Period .............................................................................................. 29
8.1.2.1
Part A ......................................................................................................... 29
8.1.2.1.1
Starting Dose and Dosing Schedule...................................................... 29
8.1.2.1.2
Guidelines for Dose Escalation............................................................. 30
8.1.2.1.3
Dose Escalation Levels ......................................................................... 32
8.1.2.1.4
Treatment Duration and Disease Assessments...................................... 32
8.1.2.1.5
Determination of MTD.......................................................................... 32
8.1.2.1.6
Definition of Dose-Limiting Toxicity................................................... 33
8.1.2.1.7
Subject Evaluability .............................................................................. 35
8.1.2.1.8
Dose Escalation Process/Decision Making........................................... 36
8.1.2.1.9
Intra-Subject Dose Escalation............................................................... 36
8.1.2.2
Part B.......................................................................................................... 36
8.1.3
Stopping Rules (Parts A and B)........................................................................ 37
8.1.4
Follow-up (Parts A and B)................................................................................ 37
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 19 of 79
EMD Serono Research & Development Institute
8.1.5
Early Treatment Termination (Parts A and B) ................................................. 38
8.1.6
Definition of End of Study ............................................................................... 38
8.2
Rationale for Study Design and Study Drug Regimens ........................................... 38
8.2.1
Rationale for Study Design............................................................................... 38
8.2.2
Rationale for Study Drug Starting Dose and Duration..................................... 39
8.2.3
Rationale for Study Assessments ..................................................................... 40
9
Study Population............................................................................................................ 40
9.1
Inclusion Criteria...................................................................................................... 40
9.2
Exclusion Criteria..................................................................................................... 41
9.3
Study Restrictions..................................................................................................... 44
9.3.1
Additional Dietary Restrictions........................................................................ 44
9.3.2
Activity............................................................................................................. 44
9.4
Prior and Concomitant Medications......................................................................... 44
9.5
Removal of Subjects................................................................................................. 45
9.6
Replacement of Subjects .......................................................................................... 46
10
Study Drug Administration and Management ........................................................... 46
10.1 Preparation and Dispensing...................................................................................... 46
10.2 Criteria for Study Drug Administration ................................................................... 46
10.3 Administration.......................................................................................................... 47
10.4 Method of Assigning Subjects to Treatment Groups ............................................... 48
10.5 Dose Modification and Dose Delay for Toxicity ..................................................... 48
10.6 Missed Doses and Study Visits ................................................................................ 49
10.7 Stopping Rules.......................................................................................................... 50
10.8 Packaging and Labeling ........................................................................................... 50
10.9 Study Drug Supply, Storage, and Handling ............................................................. 50
10.10 Drug Accountability................................................................................................. 50
10.11 Disposal, Return, or Retention of Unused Drug....................................................... 50
10.12 Compliance............................................................................................................... 51
10.13 Blinding and Unblinding.......................................................................................... 51
11
Assessments .................................................................................................................... 51
11.1 Timing of Assessments............................................................................................. 51
11.2 Subject and Disease Characteristics ......................................................................... 51
11.3 Pharmacokinetics...................................................................................................... 51
11.3.1
Blood Sampling................................................................................................ 51
11.3.2
Urine Sampling................................................................................................. 52
11.3.3
Processing and Handling of Pharmacokinetic Samples ................................... 52
11.3.4
Bioanalysis........................................................................................................ 52
11.4 Pharmacodynamics................................................................................................... 52
11.5 Exploratory............................................................................................................... 52
11.6 Efficacy..................................................................................................................... 53
11.7 Safety........................................................................................................................ 54
11.7.1
Adverse Events................................................................................................. 54
11.7.2
Clinical Laboratory Assessments ..................................................................... 54
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 20 of 79
EMD Serono Research & Development Institute
11.7.3
Physical Examinations and Vital Signs............................................................ 56
11.7.4
Electrocardiograms........................................................................................... 56
11.7.5
Echocardiogram................................................................................................ 56
11.7.6
Contraception and Pregnancy........................................................................... 57
11.7.6.1
Contraception............................................................................................. 57
11.7.6.2
Pregnancy................................................................................................... 58
12 Statistical and Analytical Plans.................................................................................... 58
12.1 Sample Size and Power ............................................................................................ 59
12.2 Analysis Sets ............................................................................................................ 59
12.3 Statistical Analysis ................................................................................................... 60
12.3.1
General Considerations..................................................................................... 60
12.3.2
Background Characteristics.............................................................................. 60
12.3.2.1
Subject Disposition .................................................................................... 60
12.3.2.2
Demographics and Baseline Characteristics.............................................. 60
12.3.2.3
Prior and Concomitant Medications........................................................... 60
12.3.2.4
Study Drug Exposure and Compliance...................................................... 61
12.3.3
Determination of the MTD............................................................................... 61
12.3.3.1
MTD........................................................................................................... 61
12.3.3.2
Statistical Model and Method of Analysis................................................. 61
12.3.3.3
Dose Recommendation .............................................................................. 62
12.3.4
Efficacy Analysis.............................................................................................. 63
12.3.4.1
Analysis of Primary Variables ................................................................... 63
12.3.4.2
Analysis of Secondary Efficacy Variables................................................. 63
12.3.4.3
Analysis of Other Variables....................................................................... 64
12.3.5
Safety Analysis................................................................................................. 64
12.3.5.1
Adverse Events........................................................................................... 64
12.3.5.2
Clinical Laboratory Assessments............................................................... 65
12.3.5.3
Electrocardiogram...................................................................................... 65
12.3.5.4
Echocardiogram ......................................................................................... 65
12.3.5.5
Vital Signs.................................................................................................. 65
12.3.5.6
Physical Examination................................................................................. 65
12.3.5.7
Other Safety Analysis ................................................................................ 65
12.3.6
Handling of Missing Values/Censoring/Discontinuations ............................... 66
12.3.7
Interim and IDMC Analyses............................................................................. 66
12.3.7.1
Interim Analysis......................................................................................... 66
12.3.7.2
IDMC Analysis .......................................................................................... 66
12.4 Clinical Pharmacology Analysis .............................................................................. 66
12.4.1
Pharmacokinetic Analysis ................................................................................ 66
13 Procedural, Ethical, Regulatory, and Administrative Considerations..................... 67
13.1 Adverse Event and Serious Adverse Event Documentation, Severity Grading, and 
Reporting .................................................................................................................. 67
13.1.1
Adverse Events................................................................................................. 67
13.1.1.1
Definition of an Adverse Event.................................................................. 67
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 21 of 79
EMD Serono Research & Development Institute
13.1.1.2
Clinically Significant Assessments............................................................ 67
13.1.1.3
Documentation of Adverse Events............................................................. 68
13.1.1.4
Adverse Event Severity.............................................................................. 68
13.1.1.5
Adverse Event Causality............................................................................ 69
13.1.1.6
Study Drug Action Taken .......................................................................... 69
13.1.1.7
Adverse Event Outcome ............................................................................ 70
13.1.1.8
Treatment Given......................................................................................... 70
13.1.2
Serious Adverse Events.................................................................................... 70
13.1.2.1
Definition of a Serious Adverse Event....................................................... 70
13.1.2.2
Documentation of Serious Adverse Events................................................ 71
13.1.2.3
Reporting Serious Adverse Events............................................................. 71
13.1.2.4
Expedited Reporting and Investigator Safety Letters ................................ 72
13.2 Administrative Requirements................................................................................... 72
13.2.1
Ethical Considerations...................................................................................... 72
13.2.2
Subject Information and Informed Consent ..................................................... 73
13.2.3
Investigator Compliance................................................................................... 73
13.2.4
Access to Records............................................................................................. 73
13.2.5
Subject Privacy................................................................................................. 73
13.2.6
Record Retention.............................................................................................. 74
13.2.7
Study Termination............................................................................................ 74
13.3 Data Quality Assurance............................................................................................ 74
13.4 Monitoring................................................................................................................ 75
13.5 Electronic Data Capture ........................................................................................... 75
13.6 Publications and Clinical Study Report.................................................................... 75
13.6.1
Publication of Study Results............................................................................. 75
13.6.2
Clinical Study Report ....................................................................................... 76
14 References....................................................................................................................... 77
15 Protocol Signature Pages .............................................................................................. 78
15.1 Sponsor Signature Page............................................................................................ 78
15.2 Investigator Signature Page...................................................................................... 79
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 22 of 79
EMD Serono Research & Development Institute
List of Tables
Table 3-1
Study VX15-984-001: Screening (Parts A and B).......................................... 12
Table 3-2
Study VX15-984-001: Lead-in Period With VX-984 (Part A)....................... 14
Table 3-3
Study VX15-984-001: VX-984 and PLD Combination Therapy and Follow-up 
(Parts A and B)................................................................................................ 15
Table 8-1
Provisional Dose Levels ................................................................................. 32
Table 8-2
Criteria for Defining Dose-Limiting Toxicities.............................................. 34
Table 9-1
Study VX15-984-001: Study Restrictions ...................................................... 44
Table 10-1
Laboratory Values Required for Administration of Chemotherapy or VX-984
......................................................................................................................... 47
Table 11-1
Acceptable Pharmacokinetic Sampling Windows.......................................... 52
Table 11-2
Safety Laboratory Test Panels ........................................................................ 55
Table 12-1
Power Consideration With Historical Response Rate of 10%........................ 59
Table 13-1
Grading Scale for AEs That Are Not in CTCAE Scale.................................. 69
Table 13-2
Classifications for AE Causality..................................................................... 69
Table 13-3
Classifications for Study Drug Action Taken With Regard to an AE............ 70
Table 13-4
Classifications for Outcome of an AE ............................................................ 70
List of Figures
Figure 8-1
Overview of Study Design.............................................................................. 28
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 23 of 79
EMD Serono Research & Development Institute
5
INTRODUCTION
DNA-dependent protein kinase (DNA-PK) plays an important role in cellular survival after 
DNA damage via its activity repairing rare but lethal double strand breaks (DSBs) by 
non-homologous end joining (NHEJ), as the catalytic subunit of a complex of proteins.1,2
This activity is crucial because the DSBs rapidly lead to cell death if not quickly and 
efficiently repaired. Targeting DNA-PK provides a striking opportunity to improve cancer 
patient outcomes because the majority of cancer patients will receive therapies whose sole 
objective is to induce DSBs in tumor cells. These therapies include radiation therapy (RT) 
and certain chemotherapies such as the topoisomerase II inhibitors etoposide and 
anthracylines such as pegylated liposomal doxorubicin (PLD). While these therapies have 
achieved some success clinically, ultimately many of these treatments fail due to insufficient 
local control, local recurrence, and disseminated disease. It is therefore critical to develop 
new therapeutic strategies to improve loco-regional control as well to impact disseminated 
disease.
VX-984 (EMD Serono internal compound code: M9831) is a novel potent and selective 
inhibitor of DNA-PK (median inhibition constant [Ki] = 2 nM) with minimal activity against 
related and unrelated kinases. This includes 4 highly-related phosphatidylinositol-3-kinase 
(PI3K) isoforms as well as the other class members ataxia telangiectasia mutated kinase 
(ATM), ataxia telangiectasia muted and Rad3-related kinase (ATR), and mammalian target 
of rapamycin (mTor). VX-984 inhibits DNA-PK function in cells with a concentration 
associated with 50% inhibition [IC50] of 88 nM and sensitizes most cancer cell lines and 
primary patient derived tumor cells to the lethal effects of RT and to chemotherapies that 
cause DSBs in DNA. Importantly, additivity to strong synergy is also observed with some 
DSB-inducing agents such as doxorubicin.3
VX-984 is deuterated, which offers the possibility to decrease metabolism by aldehyde 
oxidase to increase stability in human hepatocytes and, thereby, potentially substantially 
lowering the required efficacious dose.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In patient-derived xenograft models using ovarian cancer and in multiple cancer cell line 
models, VX-984 in combination with PLD significantly enhanced the anticancer activity of 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 24 of 79
EMD Serono Research & Development Institute
PLD when VX-984 was administered 16 hours after PLD, and was generally well-tolerated. 
VX-984 showed no single-agent efficacy in the tumor models evaluated.3
Based on the nonclinical observations, VX-984 had the potential to have a substantial 
therapeutic impact on malignancies with high unmet need and in which DSB inducers such 
as PLD is used as standard of care (SOC), such as recurrent or metastatic endometrial cancer.
Endometrial cancer accounts for the 90% of uterine cancers.4 There are approximately 
50,000 newly diagnosed patients in the US and 44,000 in the 5 most populous EU countries 
(EU5) expected in 2015.5 Less than a quarter of endometrial cancer presents in an advanced 
stage, where it is generally treated with platinum-based chemotherapy alone or following 
surgery.6 Approximately 60% of these patients ultimately go on to receive subsequent 
treatment, representing approximately 3,800 patients in the US and 3,100 patients in the EU5 
annually.5 Treatment guidelines recommend single-agent chemotherapy in the second-line 
setting, though there is no currently approved treatment.7
Study VX15-984-001 (Study 001) is an open-label, first-in-human (FIH) study comprised of 
2 parts (Part A and Part B). The purpose of Part A is to determine the maximum tolerated 
dose (MTD) and to characterize the safety, tolerability, and pharmacokinetic (PK) profile of 
VX-984 administered orally in multiple doses after PLD in adult patients with advanced solid 
tumors who have progressed through standard therapeutic options and for whom no standard 
therapy is available or PLD may be considered SOC. After the MTD of VX-984 in 
combination with PLD has been determined, Part B will evaluate the anti-tumor potential and 
safety of VX-984 in combination with PLD in subjects with recurrent or metastatic 
endometrial cancer who have progressed on a prior platinum regimen. 
This study will support the development of VX-984 in combination with DNA DSB-inducing 
agents by providing preliminary safety and efficacy data to guide subsequent development.
6
STUDY OBJECTIVES
6.1
Part A
6.1.1
Primary Objectives
!
To evaluate the safety and tolerability of VX-984 administered alone and in combination 
with PLD in subjects with advanced solid tumors
!
To determine the maximum tolerated dose (MTD) of VX-984 in combination with PLD 
in subjects with advanced solid tumors.
6.1.2
Secondary Objectives
!
To evaluate the pharmacokinetics (PK) of VX-984 when administered alone and in 
combination with PLD in subjects with advanced solid tumors
!
To evaluate the PK of PLD when administered in combination with VX-984 in subjects 
with advanced solid tumors
!
To evaluate preliminary anti-tumor activity of VX-984 in combination with PLD in 
subjects with advanced solid tumors.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 25 of 79
EMD Serono Research & Development Institute
6.1.3
Exploratory Objectives
!
 
 
 
!
To assess tumor response by tumor volume and tumor necrosis in subjects administered 
VX-984 in combination with PLD
!
To assess correlations between prior treatment response and treatment outcome.
6.2
Part B
6.2.1
Primary Objectives
!
To evaluate the safety and tolerability of VX-984 administered in combination with PLD 
in subjects with recurrent or metastatic endometrial cancer who have progressed on a 
prior platinum regimen
!
To assess the overall response to VX-984 administered in combination with PLD in 
subjects with recurrent or metastatic endometrial cancer who have progressed on a prior 
platinum regimen.
6.2.2
Secondary Objectives
!
To assess progression free survival (PFS) in subjects with recurrent or metastatic 
endometrial cancer who have progressed on a prior platinum regimen administered 
VX-984 in combination with PLD
!
To assess response duration (RD) in subjects with recurrent or metastatic endometrial 
cancer who have progressed on a prior platinum regimen administered VX-984 in 
combination with PLD
!
To assess overall survival (OS) in subjects with recurrent or metastatic endometrial 
cancer who have progressed on a prior platinum regimen administered VX-984 in 
combination with PLD
!
To assess clinical benefit in subjects with recurrent or metastatic endometrial cancer who 
have progressed on a prior platinum regimen administered VX-984 in combination with 
PLD as measured by complete response (CR), partial response (PR), or stable disease 
(SD) of 4 months or greater
!
To evaluate the PK of VX-984 when administered in combination with PLD in subjects 
with recurrent or metastatic endometrial cancer who have progressed on a prior platinum 
regimen.
6.2.3
Exploratory Objectives
!
 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 26 of 79
EMD Serono Research & Development Institute
!
To assess tumor response by tumor volume and tumor necrosis in subjects with 
previously-treated endometrial cancer, administered VX-984 in combination with PLD
!
To assess correlations between prior treatment response and treatment outcome
!
 
7
STUDY ENDPOINTS
7.1
Part A
7.1.1
Primary Endpoints
!
Safety parameters, including adverse events (AEs), dose-limiting toxicities (DLTs), 
clinical laboratory values (serum chemistry and hematology), vital signs, 
echocardiograms, and electrocardiogram (ECG) assessments
!
MTD of VX-984 in combination with PLD.
7.1.2
Secondary Endpoints
!
Plasma PK parameter estimates of VX-984, administered alone and in combination with 
PLD, derived from plasma concentration-time data
!
Plasma PK parameter estimates of PLD administered in combination with VX-984, 
derived from plasma concentration-time data
!
Preliminary evidence of anti-tumor activity, including tumor response as evaluated by 
Response Criteria Evaluation RECIST 1.1 and tumor markers.
7.1.3
Exploratory Endpoints
!
 
!
Tumor response as assessed by tumor volume and tumor necrosis using 3D computed 
tomography (CT) scans
!
Tumor response as assessed by historical and on-treatment tumor growth dynamics
!
 
 
7.2
Part B
7.2.1
Primary Endpoints
!
Safety parameters, including AEs, clinical laboratory values (serum chemistry and 
hematology), vital signs, and ECG assessments
!
Objective response rate (ORR) as evaluated by CT scan per RECIST 1.1.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 27 of 79
EMD Serono Research & Development Institute
7.2.2
Secondary Endpoints
!
PFS
!
RD as evaluated by CT scan and quantified by RECIST 1.1
!
OS
!
Clinical benefit (CR + PR + SD of at least 4 months)
!
Plasma PK parameter estimates of VX-984 when administered in combination with PLD, 
derived from plasma concentration-time data.
7.2.3
Exploratory Endpoints
!
 
!
Tumor response as assessed by tumor volume and tumor necrosis using 3D CT scans
!
Tumor response as assessed by historical and on-treatment tumor growth dynamics
!
 
8
STUDY DESIGN
8.1
Overview of Study Design
This is an open-label, multicenter, single-arm, FIH, dose-escalation study in subjects with 
solid tumors who have progressed through standard therapeutic options and for whom no 
standard therapy is available or PLD may be considered SOC (Part A) followed by an 
expansion phase in subjects with recurrent or metastatic endometrial cancer who have 
progressed on a prior platinum regimen (Part B). 
Part A will be a dose escalation study to evaluate the safety, tolerability, and PK of VX-984 
when administered in combination with PLD. At each VX-984 dose level tested, subjects 
will receive VX-984 once daily (qd) alone on Days -14 to -12 of a 14-day Lead-in Period 
before receiving combination treatment with PLD. Following the single agent Lead-in 
Period, subjects will receive PLD on Day 1 and VX-984 qd on Days 2 to 4 of a 28-day cycle. 
The Lead-in Period will be required only if the dose of VX-984 is escalated beyond the 
highest dose of VX-984 previously tolerated in a Lead-in Period. This part will establish the 
MTD of VX-984 in combination with PLD (Figure 8-1). 
Part B will be an expanded cohort study to confirm the safety, tolerability, PK, and potential 
anti-tumor activity of VX-984 in combination with PLD at the MTD or lower, as determined 
during Part A (Figure 8-1). 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 28 of 79
EMD Serono Research & Development Institute
Figure 8-1
Overview of Study Design
a.
The Lead-in Period will be required only if the dose of VX-984 exceeds a dose previously tolerated in a 
Lead-in Period.
b.
Subjects in Part A will receive up to 6 cycles of treatment. Subjects with tumors responding to treatment 
may continue on treatment past 6 cycles with the agreement of the Investigator and medical monitor.
c.
Subjects in Part B will receive treatment until disease progression, unacceptable toxicity, or withdrawal of 
consent.
d.
Follow-up will include a Safety Follow-up Visit 28 (± 7) days after the last dose of study drug and a 
radiologic follow-up visit 5 (± 1) weeks after the last cycle of chemotherapy, and survival follow-up 
assessment at the last subject last visit. In Part B, for subjects without disease progression, long-term 
follow-up, including, as indicated, staging CT scans and/or follow-up communications, may continue for 
up to 1 year.
8.1.1
Screening (Parts A and B)
Screening Visit assessments are listed in Table 3-1.
Screening will occur within 14 days before administration of study drug. The Investigator (or 
an appropriate authorized designee at the study site) will obtain informed consent from each 
subject. If the time between screening and dosing exceeds 14 days as a result of unexpected 
operational delays (e.g., delayed drug shipment), then subjects do not require re-screening if 
laboratory results within 7 days of the first dose of study drug meet the eligibility criteria. 
Subjects who are unable to dose within the screening window because of substantial 
complications or disease progression will be replaced. 
To prepare for study participation, subjects will be instructed on the study restrictions 
(Section 9.3).
A subject who qualified but did not enroll for an earlier cohort may be enrolled in a 
subsequent cohort with no required re-screening if predose laboratory results and World 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 29 of 79
EMD Serono Research & Development Institute
Health Organization (WHO) performance status meet the eligibility criteria. Baseline CT 
scan will need to be repeated if more than 28 days have passed since most recent CT scan.
Subjects who do not meet the eligibility criteria may not be rescreened, with the following 
exceptions:
!
Subjects who receive red blood cell transfusion or fluid replacement therapy
!
In the Investigator’s opinion, the reason for initial screen failure is due to a clearly 
temporary condition (e.g., incomplete recovery from recent surgery; inadequate time 
frame since prior chemotherapy)
!
Subjects who met all eligibility criteria but are not able to obtain required documentation 
within the allotted screening window
!
Subjects who met all eligibility criteria but transiently (for personal reasons) are unable to 
commit to all study procedures
!
Subjects who were screened under a prior version of the protocol and did not meet any 
exclusion criterion, with the exception of a criterion that was updated in a subsequent 
version of the protocol.
The medical monitor must authorize re-testing in all cases except when subjects need to 
receive red blood cell transfusion or fluid replacement therapy. In this case, medical monitor 
approval is not required for re-testing. Any subject granted approval by the medical monitor 
for the exceptions listed above may have the screening window extended by 1 week before 
needing to undergo any rescreening assessments. If more than 35 days have elapsed from 
screening before first dose of study drug, all screening assessments need to be repeated. 
Repetition of any screening assessment that did not meet eligibility criteria is not permitted, 
unless there is clear evidence of a laboratory error (e.g., hemolysis of sample).
8.1.2
Treatment Period
8.1.2.1
Part A
Treatment Period assessments are listed in Table 3-2 for the single agent Lead-in Period and 
in Table 3-3 for the combination treatment of VX-984 with PLD in Part A.
8.1.2.1.1
Starting Dose and Dosing Schedule
The starting dose of VX-984 will be 120 mg qd and PLD will be 40 mg/m2. The rationale for 
selection of the starting dose and dosing schedule for VX-984 and PLD is provided in 
Section 8.2.2. 
For each VX-984 dose level tested, subjects will receive VX-984 qd alone on Days -14 to -12 
of a 14-day Lead-in Period. Following the single agent Lead-in Period, subjects will receive 
PLD on Day 1 and VX-984 qd on Days 2 to 4 of a 28-day cycle. The Lead-in Period will be 
required only if the dose of VX-984 is escalated beyond the highest dose of VX-984 
previously tolerated in a Lead-in Period.
Criteria for study drug administration on Day 1 of Cycle 1 and subsequent cycles are 
summarized in Section 10.2. 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 30 of 79
EMD Serono Research & Development Institute
8.1.2.1.2
Guidelines for Dose Escalation 
Three subjects will be enrolled at the starting dose of VX-984 and PLD. If the starting dose 
of VX-984 is tolerated alone in the 14-day Lead-in Period and in combination with PLD 
through 1 cycle (28 days) without a DLT or Common Terminology Criteria for Adverse 
Events (CTCAE) Grade 3 or worse toxicities in any of these 3 subjects and without a 
CTCAE Grade 2 toxicity in 2 subjects, the dose of VX-984 may be increased by up to 100% 
in a subsequent cohort of 3 subjects while holding the dose of PLD constant. Safety data, 
including AEs, laboratory values, and ECG results, obtained through the end of Cycle 1, as 
well as available PK data, will be assessed to determine the dose of VX-984 that will be used 
for the next cohort. 
In this way, the dose of VX-984 will be escalated with 40 mg/m2 of PLD in subsequent 
cohorts of 3 subjects until:
!
1 subject has a treatment-related or possibly-related DLT or toxicity of CTCAE 
Grade 3 or worse; or 
!
2 subjects (who may be in different cohorts) have a toxicity of CTCAE Grade 2.
Subsequent dose escalation will proceed depending on the toxicity as described:
!
In the event of a treatment-related or possibly-related toxicity of CTCAE Grade 3 or 
worse toxicity in 1 subject (that is not considered a DLT), or treatment-related or 
possibly-related toxicity of CTCAE Grade 2 in 2 subjects (who may be in different 
cohorts), the dose escalation will continue with a more conservative dose escalation 
(up to 50%). The dose of VX-984 will continue to be escalated with 40 mg/m2 of 
PLD in subsequent cohorts of 3 subjects until there is a DLT through the end of 
Cycle 1
!
In the event of a DLT, an adaptive Bayesian logistic regression model (BLRM) will
be used to determine the dose for the subsequent cohorts or determine if the current 
dose level should be expanded. The adaptive BLRM will be guided by the escalation 
overdose control (EWOC) principle to control the risk of DLT in future subjects as 
described in Section 12.3.3.2. At each predicted dose, 3 to 6 subjects will be enrolled 
in each cohort at the discretion of the sponsor and Investigators as described in 
Section 8.1.2.1.8. If more than 3 subjects are enrolled, the first 3 subjects will receive 
VX-984 in the Lead-in Period and if no DLT is observed with VX-984 dosing then 
the additional subjects in the cohort will not have the Lead-in Period. The Lead-in 
Period will be required only if the dose of VX-984 is escalated beyond the highest 
dose of VX-984 previously tolerated in a Lead-in Period
!
If 2 subjects in a previously untested dose level experience a DLT, enrollment to that 
cohort will stop, the BLRM will be updated and the next cohort will be opened at a 
lower dose level or an intermediate dose level that satisfies the EWOC criteria. 
However, if 2 subjects in a new cohort at a previously tested dose level experience a 
DLT (e.g., a total of 8 subjects are tested on this dose level with 2 DLTs observed), 
further enrollment to that cohort will stop, the BLRM will be updated with this new 
information and re-evaluation of the available safety, PK and PD data will occur. By 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 31 of 79
EMD Serono Research & Development Institute
incorporating information gained at the preceding dose levels, additional subjects 
may be enrolled into the current dose level only if the dose still meets the EWOC 
criteria and as agreed by the sponsor and Investigators.
A subject will be considered as evaluable for dose determination if they have a DLT during 
Cycle 1 or the preceding Lead-in Period, or meet the minimum treatment and safety 
evaluation requirements for the first cycle as outlined in Subject Evaluability.
After completion of Cycle 1 of each cohort (3 to 6 subjects), available safety, PK, and 
efficacy information as well as recommendations from the Bayesian model will be used to 
determine the dose for the next cohort, with the following 2 exceptions:
1. For cohorts requiring 3 or more evaluable subjects, if only 2 evaluable subjects are 
available for assessment (all others drop out), and neither subject has had a 
treatment-related or possibly-related toxicity greater than CTCAE Grade 1, then 2 
subjects will be considered sufficient for decision-making
2. If the first 2 subjects in a cohort have a DLT, further enrollment to the study will be 
temporarily suspended and the Bayesian model will be updated with this new 
information. If the Bayesian model supports enrolling the next cohort at the dose level 
where 2 DLTs occurred, or at a higher dose level, the relevant data and rationale will be 
discussed and agreed upon by sponsor and the Investigators of the escalation phase. If
sponsor and the Investigators agree that it is medically appropriate to enroll an additional 
cohort at the dose level where 2 DLTs occurred or at a higher dose, the data and rationale 
supporting this decision will be documented.
Following the principle of escalation with overdose control (EWOC), after each cohort the 
recommended dose will be the one with the highest posterior probability of the DLT rate 
falling in the target toxicity interval [0.166, 0.333) among the doses fulfilling EWOC. Per 
EWOC, it should be unlikely (< 25% posterior probability) that the DLT rate at the dose will 
exceed 0.333.
For further understanding of the safety, tolerability, and PK of VX 984 in combination with 
PLD, additional cohorts of subjects may be enrolled at preceding dose levels, or to 
intermediate dose levels before or while proceeding with further dose escalation. The 
maximum planned dose of VX-984 is 2000 mg during escalation, however, higher doses up 
to 3000 mg may be allowed depending on the observed safety, PK, and PD, and based on 
recommendation of the BLRM.
After repeating the above steps, the dose escalation of VX-984 will continue with a constant 
dose of PLD at 40 mg/m2 until MTD is achieved.
If a dose of VX-984 is not tolerated with PLD at 40 mg/m2, then the VX-984 dose may be 
reduced by up to 50% with a constant dose of PLD at 40 mg/m2 or the dose of PLD will be 
reduced by 25% (30 mg/m2) or lower with a constant dose of VX-984. These doses will be 
explored in subsequent cohorts at the discretion of the Investigators and sponsor. If daily 
dosing of VX-984 for 3 days after PLD is not tolerated during initial dose escalation, less 
frequent dosing of VX-984 may be explored in subsequent cohorts.
Details on dose modifications for drug-related toxicity are provided in Section 10.5.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 32 of 79
EMD Serono Research & Development Institute
8.1.2.1.3
Dose Escalation Levels
The provisional doses to be administered during dose escalation are listed in Table 8-1.
Table 8-1
Provisional Dose Levels
Dose Level
Proposed
VX-984 Dose (mg)a
Proposed
PLD Dose (mg/m2)a
-1b
120
30
1 (Starting Dose)
120
40
2
240
40
3
480
40
4
720
40
a.
Proposed dose levels assume 100% escalation will be possible initially followed by up to 50% escalation. 
Doses beyond these levels are expected to be dictated by the BLRM.
b.
Dose level -1 represents a dose that may be evaluated if dose level 1 (starting doses of VX-984 and PLD) is 
poorly tolerated.
8.1.2.1.4
Treatment Duration and Disease Assessments
At all dose levels of VX-984, subjects will complete a total of up to six 28-day cycles of 
VX-984 and PLD combination therapy. Subjects with tumors responding to treatment may 
continue treatment past 6 cycles with the agreement of the Investigator and medical monitor 
until disease progression, unacceptable toxicity, withdrawal of consent, or until exposure to 
PLD exceeds 550 mg/m2. Staging CT scans will be performed at the end of every 2 cycles 
(see Table 3-3). If there is evidence of progressive disease as determined using RECIST 1.1, 
the subject’s treatment will be discontinued. In addition, transthoracic echocardiograms will 
be performed at baseline and at the end of every 2 cycles (see Table 3-3). After 6 cycles, CT 
scans will be performed at the end of every 2 to 3 cycles (see Table 3-3).
8.1.2.1.5
Determination of MTD
Definition of MTD: The MTD is defined as the highest dose combination for a given 
schedule that causes DLTs in no more than 33.3% of subjects during the first cycle of 
treatment. 
Dose escalation will continue until the identification of MTD or a suitable lower dose for 
Part B. This will occur when the following conditions are met:
1. at least 6 subjects have been treated at this dose
2. the dose satisfies one of the following conditions:
a.
the posterior probability of targeted toxicity at this dose exceeds 50% and is the 
highest among potential doses, or
b. at least 15 subjects have been treated
The DLT Evaluable Set will be used for the determination of the MTD.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 33 of 79
EMD Serono Research & Development Institute
8.1.2.1.6
Definition of Dose-Limiting Toxicity
DLTs will be identified throughout the dosing cycles. DLTs will be defined using the 
National Cancer Institute (NCI) CTCAE (Version 4.0). 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 34 of 79
EMD Serono Research & Development Institute
Table 8-2
Criteria for Defining Dose-Limiting Toxicities
Toxicity
Any of the Following Criteria
Hematology
!
Neutropenia Grade 4 for > 7 days durationa
!
Febrile neutropenia (fever of unknown origin without clinically or 
microbiologically documented infection)
!
Thrombocytopenia Grade 3:
o
associated with clinically significant bleeding
o
requiring platelet transfusion
!
Thrombocytopenia Grade 4
Cardiac
!
QTc prolongation (any QTc interval ≥500 msec or any change in 
QTc interval ≥60 msec from baseline) on ECG, unless related to an 
electrolyte abnormality and prolongation resolves with correction of 
electrolyte abnormality
!
Any of the following (CTCAE criteria): Grade 2 or greater ventricular 
arrhythmia (second or third degree AV block), severe 
sustained/symptomatic sinus bradycardia less than 45 beats per 
minute (bpm) or sinus tachycardia > 120 bpm not due to other causes 
(e.g., fever), persistent supraventricular arrhythmia 
(e.g., uncontrolled/new atrial fibrillation, flutter, atrioventricular nodal 
tachycardia, etc.) lasting more than 24 hours, ventricular tachycardia 
defined as > 9 beats in a row or any length of torsades de pointes 
(polymorphic ventricular tachycardia with long QTc), or unexplained 
recurrent syncope
!
Symptoms suggestive of congestive heart failure with confirmed 
ejection fraction (EF) < 40% (by 2D-echocardiogram or multiple 
gated acquisition [MUGA] scan) or a relative decrease > 20% from 
historical assessment of EF performed within 12 months
!
Troponin T: level that is confirmed with myocardial infarction
Hepatic
!
Any Grade 4 elevation of AST or ALT of any duration
!
Any Grade 3 elevation of AST or ALT lasting more than 7 days
!
Any Grade 3 elevation of AST or ALT concomitant with Grade 2 
elevation of bilirubin (for subjects with normal baseline bilirubin) or 
Grade 3 elevation of bilirubin (for subjects with Grade 1 bilirubin 
abnormality at baseline)
!
Any Grade 3 elevation in bilirubin
Dermatologic
!
Grade 3 rash for > 7 consecutive days, despite skin toxicity treatment 
(as per local practice) or any Grade 4 rash
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 35 of 79
EMD Serono Research & Development Institute
Toxicities 
resulting in 
treatment 
interruption
!
Any drug-related toxicity that causes interruption of treatment for 
> 2 weeks (14 successive days)
Other adverse 
events
!
Infection (documented clinically or microbiologically) with Grade 3 
or 4 neutropenia (absolute neutrophil count < 1.0 ∀109/L)
!
Grade 3 or 4 toxicity to organs other than the bone marrow, including 
Grade 3 and 4 biochemical AEs
!
Death due to drug-related complications
Exceptions to 
DLT criteria
!
Grade 3 nausea
!
Grade 3 vomiting in subjects who have not received optimal treatment 
with anti-emetics
!
Grade 3 diarrhea in subjects who have not received optimal treatment 
with antidiarrheal
!
Any Grade 3 elevation of AST or ALT lasting ≤7 daysb
!
Any elevation of ALP
!
Acute infusion-related reactions
a
In the event of a Grade 4 neutropenia, a complete blood count (CBC) must be performed no more than 
7 days after the onset of the event to determine if a DLT has occurred. Continue to monitor the subject 
closely until resolution to Grade 3 or lower.
b
In the event of a Grade 3 or higher elevation in ALT or AST, follow-up laboratory assessments should be 
performed every 48 to 72 hours until reduced to Grade 2 or lower.
If any change is made to the grade or causality of an AE during the study that may alter its 
DLT status, the sponsor must be informed immediately because this may affect dose 
escalation decisions.
8.1.2.1.7
Subject Evaluability
All subjects who meet the eligibility criteria and receive at least 1 dose of VX-984 will be 
evaluable for safety. 
In order for subjects to be evaluable for dose escalation decisions: 
!
Subject must receive PLD on Day 1 and receive all 3 doses of VX-984 within 5 days 
(Days 2 to 6) with the first dose of VX-984 on Day 2; or
!
The subject must have had a DLT during Cycle 1.
Subjects who do not fulfill at least 1 of the 2 above criteria will not be evaluable for dose 
escalation decisions and will be replaced.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 36 of 79
EMD Serono Research & Development Institute
8.1.2.1.8
Dose Escalation Process/Decision Making
At the end of each treatment cohort, the sponsor will convene a teleconference with the 
Investigators of the escalation phase. At the dose escalation teleconference, the clinical 
course (safety information including both DLTs and all CTCAE Grade ≥2 toxicity data 
during Cycle 1 as well as PK data) for each subject in the current dose cohort will be 
discussed. Updated safety data on other ongoing subjects, including data in later cycles, will 
be discussed as well.
Safety laboratory results and AEs occurring up to and including Day 28 of Cycle 1 will be 
reviewed as soon as they are available for a given cohort. Assessments for Day 28 of Cycle 1 
must take place before dosing on Day 1 of Cycle 2. In this case, predose assessments on 
Day 1 of Cycle 2 will be used for DLT evaluation. DLTs that may have occurred through 
Day 28 of Cycle 1 of the current cohort, as well as DLTs that have occurred in prior cohorts 
in later cycles, will be identified.
To determine the dose regimen for the next cohort, the available toxicity information 
(including DLTs, AEs that are not DLTs, and AE information post-Cycle 1), PK, PD, and 
anti-tumor activity information, as well as the recommendations from the BLRM will be 
evaluated by the Investigators and sponsor study personnel (including the sponsor physician 
and statistician responsible for this study) at the dose decision meeting. The parties must 
reach a consensus on whether to declare MTD, escalate the dose any further, or whether to 
de-escalate and/or expand recruitment into particular cohorts.
8.1.2.1.9
Intra-Subject Dose Escalation
Intra-subject dose escalation is not permitted during the first 4 cycles of treatment. After the 
fourth cycle is completed, individual subjects may be considered for treatment at a dose of 
VX-984 in combination with PLD higher than the dose to which they were initially assigned.
In order for a subject to be treated at a higher dose of VX-984 in combination with PLD, the 
subject must have received a lower dose for at least 4 cycles without a treatment-related or 
possibly-related toxicity of CTCAE Grade ≥2. Moreover, the new, higher dose with which 
the subject is to be treated must be a dose that has completed evaluation in a dose escalation 
meeting and that has not exceeded the MTD estimated by the BLRM. Any further increases 
after the initial intra-subject dose escalation will follow the same rules as for the initial 
intra-subject escalation. Consultation with the sponsor must occur before any intra-subject 
dose escalation decision. 
8.1.2.2
Part B
During each cycle, subjects will be administered PLD on Day 1, and VX-984 will be dosed 
on Days 2 to 4 of a 28-day cycle unless in Part A the number of days was decreased due to 
tolerability. Treatment Period assessments are listed in Table 3-3. Approximately 40 subjects 
will receive VX-984 with PLD at the MTD or lower, as determined during the dose 
escalation phase. 
Upon completion of the first cycle of treatment for at least 10 subjects within Part B, if the 
observed DLT rate exceeds 33.3%, the BLRM will be re-run to confirm that the estimated 
MTD still satisfies the overdose criteria of the model. If the dose fails to satisfy the criteria, a 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 37 of 79
EMD Serono Research & Development Institute
change to the dose under study may be made according to the BLRM recommendation after 
review of the clinical data.
Subjects will continue to receive treatment until disease progression, unacceptable toxicities, 
or withdrawal of consent. Subjects will be evaluated by CT scans at the end of every 2 cycles 
for the first 6 cycles and every 2 to 3 cycles thereafter (see Table 3-3). If in the opinion of the 
Investigators, subjects may benefit with continued treatment with PLD and VX-984, subjects 
may continue to receive treatment beyond the total exposure of 550 mg/m2 PLD. If there is 
evidence of progressive disease as determined using RECIST 1.1, treatment will be 
discontinued. In addition, subjects will be evaluated by transthoracic echocardiogram at 
baseline and at the end of every 2 cycles (see Table 3-3).
All subjects who meet the eligibility criteria and are administered at least 1 dose of VX-984 
will be evaluable for safety. Subjects who meet the eligibility criteria, are administered at 
least 1 cycle of study drug, and have a baseline scan will be evaluated for efficacy. 
For subjects requiring palliative radiotherapy, irradiated lesions will be evaluable for 
progression, not response.
8.1.3
Stopping Rules (Parts A and B)
Subjects may be discontinued from study drug as follows:
!
Subjects experiencing a non-reversible or life-threatening DLT may be discontinued from 
study drug at the Investigator’s discretion, but will continue to complete follow-up 
assessments until documented progressive disease. Subjects who have a reversible and 
non-life threatening DLT and, in the judgment of the Investigator, may be exhibiting 
clinical benefit, may resume therapy after the toxicity has decreased to Grade < 2
!
Subjects with progressive disease before the end of Cycle 1 may be discontinued from 
study drug at the discretion of the Investigator. Subjects with progressive disease beyond 
Cycle 1 will be discontinued from study drug. In cases where progression is not clear and 
in the opinion of the Investigator, the subject may be having clinical benefit, at the 
discretion of the Investigator, the subject may continue treatment but must be reimaged 
within 2 cycles of treatment
!
For dose delays of more than 4 weeks due to drug-related toxicity other than Hand-Foot 
Syndrome (HFS) and stomatitis: Discontinue treatment, unless in the opinion of the 
Investigator, the subject is experiencing clinical benefit and it is in their best interest to 
continue treatment. For these subjects treatment may continue at a reduced dose at the 
discretion of the Investigator and sponsor
!
Part A only: Exposure to PLD exceeds 550 mg/m2.
8.1.4
Follow-up (Parts A and B)
All subjects, regardless of reason for discontinuation, will have a Safety Follow-up Visit 
28 (± 7) days following the last dose of study drug, during which the procedures listed in 
Table 3-3 will be completed. In addition, all subjects who receive all scheduled study drug 
doses through Cycle 1, have not had evidence of disease progression, and have not initiated 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 38 of 79
EMD Serono Research & Development Institute
cancer therapy outside of the study protocol will have radiologic follow-up 5 weeks 
(± 1 week) after the last cycle of chemotherapy.
A survival follow-up assessment will be performed for all subjects at the last subject last visit 
for that part. For the survival follow-up assessment, every subject who is not known to have 
died during the course of the study will be called to ascertain whether the subject is alive, if 
the subject has initiated another therapy, or if the subject died. If the subject has initiated 
another therapy or died, the date of initiation of the other therapy or date of death will be 
confirmed.
Subjects in Part B who complete at least 6 cycles of treatment, discontinue for reasons other 
than disease progression, and do not have disease progression on the radiologic follow-up 
visit will be followed by staging CT scan (if possible) approximately every 8 weeks until 
disease progression, the subject starts a new line of therapy, the subject dies, the study closes, 
or the subject is at least 12 months from end of treatment, whichever comes first.
Finally, for Part B, regardless of disease progression or initiation of new line of 
therapy, subjects may be followed by telephone, electronic, or mail communication, or in 
person, every 3 months for up to 1 year or until the subject is lost to follow-up or dies, 
whichever occurs first. 
8.1.5
Early Treatment Termination (Parts A and B)
Subjects who discontinue study drug will be asked to return to the clinical site for a Safety 
Follow-up Visit at 28 days after their last dose of study drug. As applicable, subjects who 
discontinue study drug will be asked to complete all follow-up assessment outlined in 
Section 8.1.4 as applicable.
8.1.6
Definition of End of Study
Study completion is defined as the time when study drug administration is permanently 
discontinued due to any reason and the Safety Follow-up Visit or radiologic follow-up (when 
applicable) after the last dose of study drug has been completed. 
The final analysis of study data may be performed when the last subject treated completes at 
least 6 cycles of treatment or discontinues the study. The additional data for any subjects 
continuing to receive study treatment after the data cutoff date for the primary clinical study 
report (CSR) will be further summarized in a report upon completion of the study when all 
subjects have discontinued study treatment and all required follow-up has been completed or 
the subject has died, been lost to follow-up, or withdrawn consent to further participation in 
the study.
8.2
Rationale for Study Design and Study Drug Regimens
8.2.1
Rationale for Study Design
The primary objectives of Part A of the study are to evaluate safety and determine the MTD 
of VX-984 in combination with PLD in subjects with advanced solid tumors. Three subjects 
will be enrolled at the starting dose of VX-984 and PLD. In order to limit subjects being 
treated at a non-efficacious dose, the initial dose escalation will allow for 100% escalation 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 39 of 79
EMD Serono Research & Development Institute
until 1 subject has a treatment-related or possibly-related DLT or toxicity of CTCAE Grade 3 
or worse; or 2 subjects (who may be in different cohorts) have a toxicity of CTCAE Grade 2.
Upon occurrence of a DLT, dose escalation will be guided by BLRM with EWOC principle 
similar to that proposed by Babb et al.8 The use of BLRMs for Phase I studies has been 
advocated by the European Medicines Agency (EMEA) guideline on small populations 
(2006)9 and by Rogatko et al.10
Subjects enrolled in Part A will have any advanced solid tumor that has failed treatment with 
at least 1 line of therapy, and have no standard or approved therapy available for treatment of 
their disease or would potentially be candidates for treatment with PLD. In general, response 
rates of many advanced solid tumors to second- and third-line therapies are limited. Thus, 
there is a potential for this population to benefit from the addition of a potential 
chemotherapy-enhancing agent.
The primary objectives of Part B are to evaluate the safety, tolerability, and OR of VX-984 in 
combination with PLD in subjects with previously-treated endometrial cancer. There is no 
approved or standard treatment for advanced recurrent endometrial cancer following a 
platinum based first-line regimen, and PLD is frequently used as second-line treatment.11 In 
xenograft models using cancer cell lines or primary patient tumors, doses of VX-984 
combined with PLD significantly enhanced the anti-cancer activity of PLD when VX-984 
was administered 16 hours after PLD, and was generally well-tolerated.3 The trigger for the 
initiation of the expansion cohort will be achieving a tolerated dose of PLD at or near SOC 
doses in combination with PLD at doses above the predicted efficacious dose in Part A.
8.2.2
Rationale for Study Drug Starting Dose and Duration
The selection of a starting dose of orally-administered VX-984 was made in accordance with 
the ICH S9 Guidance for Industry.12
 
 
 
 
 
 
 
The approved single-agent dose of DOXIL®/CAELYX® is 50 mg/m2 for ovarian cancer. 13,14
To reduce the potential of increased toxicities of PLD when dosed in combination with 
VX-984, PLD will be administered at 40 mg/m2, which is frequently used in the clinic.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 40 of 79
EMD Serono Research & Development Institute
The dosing schedule for VX-984 is based on optimal timing of DNA-PK inhibition in 
relation to DNA-damaging drug exposure. Nonclinical data supports administration of 
VX-984 for 3 days starting 12 to 24 hours after the initial PLD dose. This schedule will 
minimize the potential for toxicity and is expected to cover time of the maximum 
concentration (tmax) and at least one terminal phase half-life (t1/2) of PLD in tumors. 3
8.2.3
Rationale for Study Assessments
Subjects will be monitored frequently for AEs that may be of potential consequences, based 
on nonclinical toxicology of VX-984 or based on prior experience in patients treated with 
PLD, using labs, ECGs, and echocardiograms. 
CT scans will be used periodically to monitor tumor response to treatment, and response will 
be judged using RECIST 1.1. Subjects who do not demonstrate response to therapy will 
discontinue treatment.
9
STUDY POPULATION
Eligibility will be reviewed and documented by an appropriately qualified member of the 
Investigator’s team before subjects are enrolled.
9.1
Inclusion Criteria
Subjects who meet all of the following inclusion criteria will be eligible.
1. Subjects (male and female for Part A and female for Part B) will be at least 18 year of 
age
2. Disease status
Part A
Subjects with histologically or cytologically confirmed malignant advanced solid tumors 
who have progressed on at least 1 prior chemotherapy, and for whom either
o
no standard therapy is available, or 
o
PLD at the dose and schedule being used might be considered standard of care
Part B
o
Subjects with histologically confirmed advanced primary endometrial cancer (locally 
advanced and incurable endometrial cancer that has been treated with surgery and/or 
radiation or is ineligible for such treatment), or recurrent or metastatic endometrial 
cancer, and
o
Completed 1 line of chemotherapy treatment with a platinum-containing regimen in 
the advanced setting
3. Measurable disease according to RECIST criteria (Version 1.1)
4. WHO performance status of 0 or 1
5. Life expectancy of at least 12 weeks
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 41 of 79
EMD Serono Research & Development Institute
6. Hematological and biochemical indices within the ranges shown below at screening. 
These values must be confirmed within 3 days before the first day of dosing, before study 
drug administration:
a.
Hemoglobin: ≥9.0 g/dL
b. Absolute neutrophil count: ≥2.5 ∀109/L
c.
Platelet count: ≥125 ∀109/L
d. Serum bilirubin: ≤1.5 ∀upper limit of normal (ULN)
e.
ALT, AST: ≤2 ∀(ULN)
f.
Estimated glomerular filtration rate: ≥50 mL/min
g. Prothrombin time: < 1.25 ∀ULN unless on anticoagulant therapy and discussed 
with the medical monitor
In addition, there should not be other clinically significant metabolic or hematologic 
abnormalities that are uncorrectable or that require ongoing, recurrent pharmacologic 
management (except subjects who are receiving potassium, magnesium, or other 
supplementation for an otherwise controlled condition)
7. Normal left ventricular ejection fraction on screening assessed by transthoracic 
echocardiogram or MUGA scan
8. Subject will sign and date an informed consent form (ICF)
9. Willing and able to comply with scheduled visits, treatment plan, study restrictions, 
laboratory tests, contraceptive guidelines, and other study procedures.
9.2
Exclusion Criteria
Subjects who meet any of the following exclusion criteria will not be eligible.
1. Previous radiotherapy (unless brachytherapy), endocrine therapy, chemotherapy, or 
exposure to investigational medicinal products during the 4 weeks (6 weeks for 
nitrosoureas and Mitomycin-C) or 4 drug half-lives before the planned administration of 
the first dose of study drug, whichever is greater. Previous immunotherapy during the 
4 weeks before the planned administration of the first dose of study drug
2. For Part B only: 
o
Subjects with uterine carcinosarcoma
o
Prior anthracycline therapy
o
More than 1 prior chemotherapy regimen (a subject who received first-line 
carboplatin and taxane and then receives the same taxane second-line will be 
considered to have had 1 prior chemotherapy regimen)
3. Unresolved toxicity of CTCAE Grade 2 or greater from previous anti-cancer therapy or 
radiotherapy, excluding
o
Alopecia
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 42 of 79
EMD Serono Research & Development Institute
o
Anemia or leukopenia if absolute neutrophil counts fall within limits specified in 
Inclusion Criterion 6 and is not decreasing at the time of treatment
o
Other toxicities that in the opinion of the Investigator and the sponsor should not 
exclude the subject
4. History of spinal cord compression or brain metastases, unless asymptomatic, treated, 
stable, and not requiring treatment with steroids for at least 4 weeks before the planned 
administration of the first dose of study drug. Any history of leptomeningeal metastases
5. Female subjects who are pregnant or lactating at Screening, or plan to become pregnant 
while on study or within 6 months after the last dose of study drug
6. Female subjects of childbearing potential must adhere to contraception guidelines as 
outlined in the protocol. Female subjects will be considered to be of nonchildbearing 
potential if they have undergone surgical hysterectomy or bilateral oophorectomy or have 
been amenorrheic for more than 2 years with a screening serum follicle-stimulating 
hormone (FSH) level within the laboratory’s reference range for postmenopausal females
7. Male subjects with partners of childbearing potential must agree to adhere to 
contraception guidelines
8. Male subjects with pregnant or lactating partners or partners who plan to become 
pregnant while on study or within 6 months after the planned administration of the last 
dose of study drug
9. Major surgery ≤4 weeks before first dose of study drug, or incomplete recovery from a 
prior major surgical procedure
10. Cardiac conditions as follows:
!
Clinically significant cardiovascular event within 6 months before Screening:
o
congestive heart failure
o
unstable angina pectoris
o
myocardial infarction
o
Class II/III/IV cardiac disease (New York Heart Association functional 
classification)
o
presence of severe valvular heart disease
o
presence of a ventricular arrhythmia requiring treatment
!
History of arrhythmia that is symptomatic or requires treatment (CTCAE 3), 
symptomatic or uncontrolled atrial fibrillation despite treatment, or asymptomatic 
sustained ventricular tachycardia. Subjects with atrial fibrillation controlled by 
medication are permitted
!
Uncontrolled hypertension (blood pressure ≥160/100 despite optimal therapy)
!
Second- or third-degree heart block with or without symptoms
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 43 of 79
EMD Serono Research & Development Institute
!
QTc > 450 msec (by either Fridericia’s or Bazett’s correction) not due to electrolyte 
abnormality and that does not resolve with correction of electrolytes
!
History of congenital long QT syndrome
!
History of torsades de pointes (or any concurrent medication with a known risk of 
inducing torsades de pointes)
11. Clinically-significant abnormality, including ejection fraction below normal institutional 
limits, present on transthoracic echocardiogram performed at Screening
12. Prior bone marrow transplant
13. Extensive radiotherapy (to greater than 15% of bone marrow)
14. Participation or plan of participation in another interventional clinical study while taking 
part in this study. Participation in an observational study would be acceptable
15. Any other condition that in the Investigator’s opinion would not make the subject a good 
candidate for the clinical study, including
a.
History of human immunodeficiency virus-1 (HIV-1), HIV-2, or unresolved 
hepatitis B or unresolved hepatitis C infection
b. High medical risk because of non-malignant systemic disease including active 
uncontrolled infection
16. Part B: Current active malignancies of other types, with the exception of adequately 
treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell 
carcinoma of the skin. Prior cancer in remission for 2 years or more would not be 
excluded
17. Current therapy:
!
Subjects receiving treatment with medications that are known to be moderate to 
strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) that cannot be 
discontinued at least 1 week before first dose of study drug and for the duration of the 
study
!
Subjects receiving treatment with medications that are mainly metabolized by 
CYP3A4 and have a low therapeutic index that cannot be discontinued at least 1 week 
before first dose of study drug and for the duration of the study.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 44 of 79
EMD Serono Research & Development Institute
9.3
Study Restrictions
Study restrictions are summarized in Table 9-1.
Table 9-1
Study VX15-984-001: Study Restrictions
Restricted Medication/Food/Activity
Study Period
Screening Period
Treatment Period
Food
Grapefruit/grapefruit juice
Seville or blood oranges
None allowed within 7 days 
before the first dose of study 
drug
None allowed through the Safety 
Follow-up Visit
Moderate and Strong CYP3A4 
inhibitors or inducers
None allowed within 7 days 
before the first dose of study 
drug
None allowed through the Safety 
Follow-up Visit
Anti-emetics
Allowed for symptom 
management
Prophylactic use not allowed 
during Lead-in Period of Part A. 
Allowed beyond Lead-in Period 
in Part A and throughout Part B.
Antidiarrheals
Allowed for symptom 
management
Prophylactic use not allowed 
during Lead-in Period and 
Cycle 1 of Part A. 
Allowed beyond Cycle 1 in 
Part A and throughout Part B.
Hematopoietic growth factors
Not allowed
Prophylactic use not allowed 
during Lead-in Period and 
Cycle 1 of Part A. 
Allowed beyond Cycle 1 in 
Part A and throughout Part B.
Note: Refer to the study reference manual for a complete list of medications prohibited in this study. 
9.3.1
Additional Dietary Restrictions
!
There are no restrictions on food and non-alcoholic beverages, except restrictions 
mentioned in Table 9-1.
9.3.2
Activity
!
Subjects will abstain from strenuous exercise (e.g., heavy lifting, weight training, and 
aerobics) for at least 48 hours before each blood collection for clinical laboratory tests. 
Walking at a normal pace will be permitted.
!
Subjects should avoid prolonged or intense sun exposure, sunlamps, and tanning beds. 
Use of sunscreen, clothing, and eyewear that decrease sun exposure is recommended.
9.4
Prior and Concomitant Medications
In vitro drug metabolism studies suggest that VX-984 is a substrate of CYP3A4 and its 
systemic exposure may be affected by concomitant medications that are moderate or strong 
CYP3A4 inhibitors or inducers. Restrictions for prior and concomitant medications that are 
moderate or strong inhibitors and inducers of CYP3A4 are provided in the Study Reference 
Manual. Based upon in vitro data, VX-984 is a weak to moderate inhibitor of CYP3A. 
Therefore, use of drugs that are metabolized mainly by CYP3A and have a low therapeutic 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 45 of 79
EMD Serono Research & Development Institute
index is not allowed in the study. Investigators should use standard precautions when 
prescribing medications, as with any novel therapeutic for which there is limited clinical 
experience.
!
Subjects will abstain from concomitant medications as described in Table 9-1. If a 
prohibited medication is considered medically necessary for a subject, the subject will be 
withdrawn from the study
!
Subjects should not receive prophylactic treatment with hematopoietic growth factors and 
antidiarrheal medications during the Lead-in Period and Cycle 1 of Part A. These 
treatments may be used to specifically address subject symptoms, per institutional 
practice, as long they adhere to restrictions listed in Table 9-1
!
The Investigator should refer to the package inserts for PLD for guidance on prohibited 
medications during treatment with this agent. Subjects should not use nephrotoxic or 
ototoxic medications from 7 days before the first dose of study drug through the Safety 
Follow-up Visit. Inadvertent or short-term use while in the study will not cause a subject 
to be ineligible
!
Medications taken from 28 days before the first dose of study drug will be documented as 
a prior medication. Medications taken after the first dose of study drug through the end of 
the study will be documented as concomitant medications. All medications must be 
recorded with indication, route of administration, and start and stop dates of 
administration. All subjects will be questioned about concomitant medication at each 
clinic visit.
9.5
Removal of Subjects 
Subjects may withdraw from the study at any time at their own request. Subjects may be 
withdrawn from study drug treatment at any time at the discretion of the Investigator or EMD 
Serono Research & Development Institute (the Sponsor) for safety, behavior, noncompliance 
with study procedures, or administrative reasons. If a subject has been withdrawn from study 
drug treatment, the subject will continue to be followed, provided the subject has not 
withdrawn consent. 
If a subject does not return for a scheduled visit, reasonable effort will be made to contact the 
subject. In any circumstance, reasonable effort will be made to document subject outcome. 
The Investigator will inquire about the reason for withdrawal, request that the subject return 
all unused investigational product(s), request that the subject return for a Safety Follow-up 
Visit, if applicable (see Section 8.1.5), and follow up with the subject regarding any 
unresolved AEs.
If the subject withdraws consent for the study, no further evaluations will be performed and 
no additional data will be collected. The Sponsor may retain and continue to use any data 
collected before such withdrawal of consent.
Subjects may be discontinued from study drug for toxicity or lack of efficacy, as specified in 
Section 8.1.3.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 46 of 79
EMD Serono Research & Development Institute
9.6
Replacement of Subjects
In Part A, subjects who withdraw or are withdrawn from treatment for reasons other than 
DLT before the Cycle 1 Day 28 assessment and who have not had the minimum exposure to 
study drugs described in Subject Evaluability will be replaced. Subjects who withdraw or are 
withdrawn from treatment beyond Cycle 1 will not be replaced.
For Part B, subjects who discontinue for reasons other than disease progression or are 
non-evaluable for efficacy analysis may be replaced. Subjects who discontinue for disease 
progression before the completion of Cycle 1 may also be replaced.
10
STUDY DRUG ADMINISTRATION AND MANAGEMENT
10.1
Preparation and Dispensing
Study drug may be dispensed only under the supervision of the Investigator or an authorized 
designee and only for administration to the study subjects.
Study drug will be supplied to sites as individual dosing containers of VX-984 adipic acid 
cocrystal powder (drug product intermediate) with additional adipic acid.
The final suspension will be prepared using a vehicle containing 0.5% methylcellulose, 
0.1% sodium benzoate, 0.1% benzoic acid, and adipic acid (amount varies with dose). Details 
of dose preparation, including constitution, will be given in a separate document 
(Formulation Preparation Instructions).
Individual dose concentrations of VX-984 will be bracketed between 8 mg/g and 50 mg/g in 
the suspending vehicle.
The subjects will be provided with 3 containers per dose:
!
VX-984 adipic acid cocrystal powder, 
!
dosing vehicle, and
!
vehicle to be used as rinsate.
All 3 containers will be labelled appropriately for easy administration.
10.2
Criteria for Study Drug Administration
When clinical chemistry and/or hematology laboratory testing is required as described in the 
Schedule of Assessments (Table 3-1, Table 3-2, and Table 3-3) before administration of 
chemotherapy or VX-984, the laboratory criteria specified in Table 10-1 must be met before 
dosing. To facilitate timely administration of study drug, this laboratory testing may be 
performed up to 3 days before dosing.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 47 of 79
EMD Serono Research & Development Institute
Table 10-1
Laboratory Values Required for Administration of Chemotherapy or 
VX-984
Laboratory Parameter
Cycle 1, Day 1
Day 1 of Subsequent Cycles
Hemoglobin
≥9.0 g/dL
≥7.0 g/dL
(if asymptomatic)
Absolute neutrophil value
≥2.5 ∀109/L
≥1.5 ∀109/L
Platelet count
≥125 ∀109/L
≥100 ∀109/L
AST, ALT
≤2 ∀ULN
≤2 ∀ULN
Estimated glomerular filtration 
rate
≥50 mL/min
≥45 mL/min (if no more than 
20% decrease from prior cycle)
Total bilirubin (serum)
≤1.5 ∀ULNa
≤1.5 ∀ULNa
a.
Unless subject has known or suspected Gilbert’s syndrome
10.3
Administration
VX-984, On-site and In-home:
When on-site at the clinic, subjects may receive either the suspension already mixed or 
subjects will prepare their dose in the presence of a nurse or other authorized designee. 
Subjects will also receive a rinsate container containing vehicle.
Steps for mixing and consuming the study drug are as follows: 
!
The contents of the dosing vehicle will be added to the VX-984 adipic acid cocrystal 
powder. The container will be sealed, and the contents will be shaken to mix and 
consumed immediately
!
The contents of the second vehicle container will be used as a rinsate and added to the 
residual material. The container will be sealed, and the contents will be shaken to 
ensure that no powder is left behind. The contents will be consumed immediately.
For in-home administration by the subject, a kit will be provided that contains 3 containers 
per dose needed for in-home administration. For example, if a subject will take the next 
2 doses at home, a total of 6 containers will be provided.
PLD, On-site:
PLD, supplied as single use vial: 20 mg/10 mL or 50 mg/25 mL. PLD doses up to 90 mg will 
be diluted in 250 mL of 5% Dextrose Injection, USP before administration. PLD doses 
exceeding 90 mg will be diluted in 500 mL of 5% Dextrose Injection, USP before 
administration. Diluted PLD must be refrigerated at 2° to 8°C and administered within 
24 hours.
The Investigator should refer to the DOXIL®/CAELYX® label for administration guidelines 
of PLD. Precautionary preparations should be made to prepare for serious and sometimes 
life-threatening infusion-related reactions that may occur most commonly during the first 
infusion of PLD, but may also occur in subsequent cycles. Acceptable window for 
infusion: ± 25% of the planned infusion time.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 48 of 79
EMD Serono Research & Development Institute
10.4
Method of Assigning Subjects to Treatment Groups
This is an open-label study. 
10.5
Dose Modification and Dose Delay for Toxicity
Part A:
Doses of VX-984 or PLD may be reduced beyond Cycle 1 for toxicity using the following 
guidelines:
!
For Grade 4 neutropenia or thrombocytopenia: Delay dosing until absolute neutrophil 
count ≥1500 and platelets ≥75000. The dose of VX-984 will be reduced to previous 
tolerated dose level and PLD will be reduced by 25% when dosing resumes
!
For HFS and stomatitis, modify PLD doses according to DOXIL package insert13
o
For Grade 1 HFS and stomatitis: if no previous Grade 3 or 4 HFS, no dose 
adjustment. If previous Grade 3 or 4 HFS, delay dose for up to 2 weeks, then 
decrease PLD dose by 25%
o
Grade 2, 3 and 4 HFS and stomatitis: delay dosing up to 2 weeks or until resolved 
to Grade 0 or 1, then decrease PLD dose by 25%. Discontinue treatment if no 
resolution after 2 weeks
!
For other Grade 3 non-hematologic toxicity: Do not dose until recovered to Grade < 2, 
then reduce the dose of VX-984 to the previous tolerated dose level and PLD by 25%
!
For Grade 4 non-hematologic toxicity: Do not dose until recovered to Grade < 2, then 
reduce the dose of VX-984 to the previous tolerated dose level and PLD by 25% or 
discontinue treatment
!
For dose delays of more than 1 week due to toxicity: Reduce VX-984 dose to the 
previous tolerated dose level
!
For dose delays of more than 4 weeks due to drug-related toxicity other than HFS and 
stomatitis: Discontinue treatment, unless in the opinion of the Investigator, the subject is 
experiencing clinical benefit and it is in their best interest to continue treatment. For these 
subjects treatment may continue at a reduced dose, at the discretion of the Investigator
and sponsor.
Part B:
For drug-related toxicity, the following modifications of drug dose and schedule will be 
made:
!
In case of non-hematologic Grade 3 or higher toxicity (excluding fatigue or 
nausea/vomiting/diarrhea adequately managed by supportive care), treatment will be 
interrupted and may be resumed when all toxicities have returned to Grade < 2, at the 
discretion of the Investigator
!
For the following hematologic toxicities, once the toxicity has returned to Grade < 2, 
dosing can be resumed with a 25% reduction in VX-984 dose. If, after 25% reduction of 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 49 of 79
EMD Serono Research & Development Institute
VX-984 dose, any of the below drug-related hematologic toxicities are subsequently 
observed, then, the dose of PLD will be reduced by 25%
o
Grade 4 thrombocytopenia
o
Febrile neutropenia (growth factor support, per site protocol, may be used in lieu 
of dose reduction)
o
Grade 4 neutropenia lasting more than 7 days (growth factor support, per site 
protocol, may be used in lieu of dose reduction)
!
For the following non-hematologic toxicities, once the toxicity has returned to Grade < 2, 
dosing can be resumed at a lower dose of chemotherapy. PLD dose will be reduced by 
25%. If any of the below drug-related toxicity is subsequently observed with the reduced 
dose of chemotherapy, VX-984 dose will be reduced by 25%
o
Grade 3 non-hematologic toxicity (Except for fatigue or nausea, vomiting, or 
diarrhea adequately controlled by medication)
o
Any non-hematologic toxicity requiring dose delay of more than 2 weeks.
!
For Grade 4 non-hematologic toxicity, treatment will be interrupted and may be resumed 
at a lower dose when toxicity has returned to Grade < 2 or subjects may be removed from 
the study. VX-984 dose will be reduced by 25%. In addition, the PLD dose will be 
reduced by 25%
!
For HFS and stomatitis, modify PLD doses according to DOXIL package insert13
o
For Grade 1 HFS and stomatitis: if no previous Grade 3 or 4 HFS, no dose 
adjustment. If previous Grade 3 or 4 HFS, delay dose for up to 2 weeks, then 
decrease PLD dose by 25%
o
Grades 2, 3 and 4 HFS and stomatitis: delay dosing up to 2 weeks or until 
resolved to Grade 0 or 1, then decrease PLD dose by 25%. Discontinue treatment
if no resolution after 2 weeks
!
For dose delays of more than 4 weeks due to drug-related toxicity other than HFS and 
stomatitis: Discontinue treatment, unless in the opinion of the Investigator, the subject is 
experiencing clinical benefit and it is in their best interest to continue treatment. For these 
subjects treatment may continue at a reduced dose, at the discretion of the Investigator
and sponsor.
If any toxicity not described above results in delay in dosing in any part of the study and the 
subject may be benefitting from therapy, then at the discretion of the Investigator, the dose of 
VX-984 or chemotherapy may be reduced by 25%.
10.6
Missed Doses and Study Visits
Treatment will be interrupted because of Grade 3 or higher toxicity during any cycle beyond 
Cycle 1. Treatment may be resumed as described in Section 10.5.
Study visits that are missed because of clinic or subject unavailability (e.g., for reasons of 
public holiday, clinic closure, urgent personal matter, transportation problems), should be 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 50 of 79
EMD Serono Research & Development Institute
made up when and if reasonably possible. For delayed doses, the dosing schedule should 
continue from the date of the delayed dose without omitting any doses of chemotherapy or 
any rest intervals between chemotherapy, if possible. Whenever possible, subsequent doses 
of chemotherapy should be advanced in time to synchronize with the actual date of 
administration of the delayed dose.
The relative timings of all other assessments and drug dosing may be moved to accommodate 
subject and clinic availability. Delays between sequential cycles in therapy, other than for 
reasons of toxicity, should not exceed 7 days, except as approved by the Sponsor medical 
monitor.
10.7
Stopping Rules
Stopping rules for this study are described in Section 8.1.3.
10.8
Packaging and Labeling
The Sponsor will supply the VX-984 as powder in high density polyethylene (HDPE) bottles 
with induction-sealed polypropylene caps. Study drug labeling will be in compliance with 
applicable local and national regulations. Additional details regarding packaging, labeling, 
and dispensing for VX-984 will be included in the Pharmacy Manual.
10.9
Study Drug Supply, Storage, and Handling
The Investigator, or an authorized designee (e.g., a licensed pharmacist), will ensure that all 
investigational product is stored in a secured area, under recommended storage conditions as 
outlined in the Pharmacy Manual, and in accordance with applicable regulatory 
requirements. To ensure adequate records, all study drugs will be accounted for as described 
in Section 10.10 or via the drug accountability forms as instructed by the Sponsor.
Drug supply will be sent to the site in the form of bulk bottles, with pharmacist or designated 
study staff allocating the necessary units to a subject-specific bottle. Empty bottles and caps 
will be provided by the sponsor. If a site needs to use a bottle other than those provided by 
the sponsor, the site should request prior approval from the sponsor. The site will apply a 
label to the bottles.
10.10
Drug Accountability
The pharmacist or designated study site staff will maintain information regarding the dates 
and amounts of (1) study drug received, (2) study drug dispensed to the subjects, and (3) 
study drug returned by the subjects. Subjects will be instructed to return all used and unused 
materials associated with the study drug to the site. These materials will be retained at the 
site according to instructions provided by the Sponsor or its designee until inventoried by the 
study monitor. The study monitor will review study drug records and inventory throughout 
the study.
10.11
Disposal, Return, or Retention of Unused Drug
The study site staff or pharmacy personnel will retain all materials returned by the subjects 
until the study monitor has performed drug accountability. At the end of the study, the study 
monitor will provide instructions as to the disposition of any unused investigational product. 
If the study monitor authorizes destruction at the study site, the Investigator will ensure that 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 51 of 79
EMD Serono Research & Development Institute
the materials are destroyed in compliance with applicable environmental regulations, 
institutional policy, and any special instructions provided by the Sponsor. Destruction will be 
adequately documented.
10.12
Compliance
For study drug doses administered when on-site at the clinic, doses will be administered 
under the direct supervision of the Investigator or designee. A hand-and-mouth check will be 
done after each dose administration in the clinical research unit to ensure 100% study 
treatment compliance.
For study drug doses administered during the outpatient periods of the study, drug 
accountability will be assessed at each visit by counting returned dosage units. Discrepancies 
will be discussed with the subject and recorded in the source documents. If subjects 
demonstrate continued noncompliance of study drug dosing despite educational efforts, the 
Investigator will contact the medical monitor to discuss discontinuing the subject from the 
study. 
10.13
Blinding and Unblinding
This will be an open-label study.
11
ASSESSMENTS
11.1
Timing of Assessments
The timing of assessments is shown in Table 3-1, Table 3-2, and Table 3-3.
11.2
Subject and Disease Characteristics
Subject and disease characteristics include the following: demographics, medical history, 
height, weight, type of cancer (including histologic subtype), tumor stage at baseline, date of 
cancer diagnosis, prior chemotherapy and radiation therapy, date and duration of most recent 
cancer therapy, and WHO performance status at baseline.
11.3
Pharmacokinetics
11.3.1
Blood Sampling
For the evaluation of plasma concentrations of VX-984 and PLD, plasma samples will be 
collected according to the Schedule of Assessments (Table 3-2 and Table 3-3). These 
samples may also be used for evaluations of metabolites of VX-984, for further evaluation of 
the bioanalytical method, and for analyses that provide information on the metabolic 
pathways used by or affected by VX-984.
Actual sampling times may change upon agreement of the clinical pharmacologist and 
Investigator, but the number of samples will remain the same. All efforts will be made to 
obtain the PK samples at the exact nominal time relative to dosing. Acceptable windows for 
sampling times are shown in Table 11-1. Samples collected outside of these acceptable 
windows will be considered protocol deviations. The exact time of the sample collection will 
be noted.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 52 of 79
EMD Serono Research & Development Institute
Table 11-1
Acceptable Pharmacokinetic Sampling Windows
Sampling Time
Time From Scheduled Sampling Allowed
Predose
- 120 minutes 
From 0.5 up to ≤4 hours after study drug dosing
± 15 minutes
From > 4 up to ≤72 hours after study drug 
dosing
± 120 minutes
11.3.2
Urine Sampling
Urine will be collected for measurement of VX-984 PK in the Lead-in Period according to 
the Schedule of Assessments (Table 3-1). 
Detailed instruction for urine PK sample collection, processing, handling, and storage will be 
provided in the Laboratory Manual.
11.3.3
Processing and Handling of Pharmacokinetic Samples
Detailed procedures for the collection of blood and urine samples and further procedures for 
processing and handling of samples for PK analysis will be provided in the Laboratory 
Manual. The shipment address and assay laboratory contact information will be provided to 
the investigational site before initiation of the study.
11.3.4
Bioanalysis
Samples will be analyzed using a validated analytical method in compliance with the 
Sponsor or designee standard operating procedures. A description of the assay and validation 
data will be provided in separate reports.
11.4
 
 
(Table 3-1, Table 3-2, and Table 3-3).
11.5
Exploratory 
 
 
 
 
 
 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 53 of 79
EMD Serono Research & Development Institute
 
 
 
 
 
 
 
 
 
 
11.5.2
 
 
11.6
Efficacy
Subjects with measurable disease will be assessed by standard criteria (RECIST 1.1). 
Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the 
shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. 
Refer to the RECIST 1.1 publication for additional information.15
CT scans will be read locally for all parts of the study. The applicable overall response 
category for each visit that includes disease assessment, based on evaluation of CT scan by a 
qualified radiologist local to the Investigator, will be recorded in the electronic case report 
form (eCRF). Determination of subject study disposition (i.e., discontinuation or extension of 
therapy) will be based on the interpretation of disease progression from the local evaluation 
of the CT scan.
Information regarding anatomical imaging (CT scans) will be collected according to the 
Imaging Manual. The sponsor will engage an imaging contract research organization to 
facilitate acquisition and potential interpretation of images.
In addition to the standard RECIST 1.1 assessments, anatomical images collected may be 
analyzed using image analysis techniques that enable additional insights into tumor changes 
following treatment, including, but not limited to, assessments of 3D-tumor volumes and 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 54 of 79
EMD Serono Research & Development Institute
tumor necrosis (for tumors amenable to volume and necrosis assessment). Additional 
information will be provided in the Imaging Manual. These additional imaging analyses will 
be exploratory in nature and will not be used to make subject treatment decisions or as a 
replacement of standard RECIST 1.1.
Historical CT scans may be collected and analyzed to enable assessment of historical and on-
treatment tumor growth dynamics.
CT scans expose patients to medical radiation. The scans performed in this study should be 
considered within the standard of care for the subject. It is important that all scans performed 
on a subject should be consistent. This includes use of the same scanner, acquisition 
parameters, and administration of contrast agents (to the extent it is clinically feasible).
11.7
Safety
Safety evaluations will include AEs, clinical laboratory assessments, clinical evaluation of 
vital signs, ECGs, echocardiograms, and PEs.
11.7.1
Adverse Events
All AEs will be assessed, documented, and reported in accordance with ICH GCP guidelines. 
Section 13.1 outlines the definitions, collection periods, criteria, and procedures for 
documenting, grading, and reporting AEs. A separate document that details AE CRF 
completion guidelines for Investigators as well as training will be provided.
11.7.2
Clinical Laboratory Assessments
Blood and urine samples will be analyzed at a local or central laboratory. At the Screening 
Visit, blood specimens will be collected for safety laboratory tests. Samples will be collected 
as specified in the Schedule of Assessments (Table 3-1, Table 3-2, and Table 3-3).
To facilitate timely administration of study drug, safety labs may be obtained up to 3 days 
before dosing. If labs are drawn before the day of dosing, they should be recorded as 
corresponding to the day of dosing.
Laboratory test results that are abnormal and considered clinically significant will be reported 
as AEs (see Section 13.1). 
The safety laboratory test panels are shown in Table 11-2.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 55 of 79
EMD Serono Research & Development Institute
Table 11-2
Safety Laboratory Test Panels
Serum Chemistry
Hematology
Urinalysisa
Glucose 
Blood urea nitrogenb
Creatinine
Sodium
Potassium 
Calcium 
Chloride 
Magnesium 
Bicarbonate 
Inorganic phosphate 
Total bilirubin, direct bilirubin 
ALP
AST
ALT
Total protein 
Albumin 
Creatine kinasec
Uric acidc
Hemoglobin 
Erythrocytes: 
Mean corpuscular volume
Platelets 
Reticulocytes (absolute)c
Leukocytes 
Differential (absolute and percent):
Eosinophils 
Basophils 
Neutrophils 
Lymphocytes 
Monocytes 
Coagulationc
Activated partial thromboplastin time 
Prothrombin time
Prothrombin time International 
Normalized Ratio 
Leukocyte esterase 
Nitrite 
Urobilinogen 
Urine protein 
pH
Urine blood 
Specific gravity 
Urine ketones 
Urine bilirubin 
Urine glucose 
a
If urinalysis results are positive for leukocyte esterase, nitrite, protein, or blood, microscopic 
examination of urine will be performed and results for provided for leukocytes, erythrocytes, crystals, 
bacteria, and casts.
b
If blood urea nitrogen cannot be collected, urea may be substituted.
c
Creatine kinase, uric acid, and reticulocytes (absolute) parameters will be tested only at Screening and 
Safety Follow-up. Coagulation parameters will be tested only at Screening.
Additional tests at screening: The following additional tests will be performed during 
screening to assess eligibility:
!
Serum beta-human chorionic gonadotropin (β-hCG) for all female subjects
!
Serum FSH for suspected postmenopausal female subjects only. Levels will be within the 
laboratories range for postmenopausal for subjects to be considered of non-childbearing 
potential.
Clinical laboratory assessments from screening will have no clinically significant findings 
that preclude participation in the study, as judged by the Investigator, for a subject to receive 
study drug.
Pregnancy testing for female subjects of childbearing potential (as defined in 
Section 11.7.6.1):
! Subjects in Part A receiving VX-984 with Lead-in Period will have a urine β-hCG test on 
Day -14, Day 1 of VX-984 and PLD combination therapy, and every 4 weeks thereafter 
through the Safety Follow-up Visit
! Subjects in Part A receiving VX-984 without Lead-in Period and subjects in Part B will 
have a urine β-hCG test on Day 1 of VX-984 and PLD combination therapy, and every 
4 weeks thereafter through the Safety Follow-up Visit.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 56 of 79
EMD Serono Research & Development Institute
When there are no scheduled study visits, pregnancy testing will be performed using a urine 
home pregnancy test kit provided by the study site.
If a urine pregnancy test is positive, all study drug dosing will stop and the pregnancy will be 
confirmed with a serum β-hCG test. If confirmed, the pregnancy will be reported and the 
subject will be permanently withdrawn from study drug dosing as discussed in 
Section 11.7.6.2. If a pregnancy test is positive, the procedures outlined in Section 11.7.6.2
will be followed.
Additional Evaluations: Additional clinical laboratory evaluations will be performed at other 
times if judged to be clinically appropriate.
11.7.3
Physical Examinations and Vital Signs
A PE of all body systems and vital signs assessment will be performed at screening and 
select study visits (Table 3-1, Table 3-2, and Table 3-3). At other visits, symptom-directed 
PEs and symptom-directed vital sign assessments can be performed at the discretion of the 
Investigator.
A PE includes a review of the following systems: head/neck/thyroid; eyes/ears/nose/throat 
(EENT); respiratory; cardiovascular; lymph nodes; abdomen; skin; musculoskeletal; and 
neurological. Breast, anorectal, and genital examinations will be performed when medically 
indicated. After screening, any clinically significant abnormal findings in PEs will be 
reported as AEs.
Vital signs include blood pressure (systolic and diastolic), temperature, pulse rate, and 
respiration rate. These will be assessed following a 5-minute rest in the supine position.
11.7.4
Electrocardiograms
Standard 12-lead ECGs will be performed using a machine with printout according to the 
Schedule of Assessments (Table 3-1, Table 3-2, and Table 3-3). Additional standard 12-lead 
ECGs will be performed at any other time if clinically indicated. The performance of all 
ECGs will adhere to the following guidelines:
!
The subject will be instructed to rest in the supine position for at least 5 minutes before 
having an ECG performed
!
The ECG will be performed before any other procedures that may affect heart rate, such 
as blood draws.
The ECG traces will be manually read at the study site at the Screening and Safety Follow-up 
Visits. A printout of the ECG traces will be made for safety review by the Investigator and 
maintained with source documentation. Clinically significant ECG abnormalities occurring 
during the study through the Safety Follow-up Visit will be recorded as AEs.
11.7.5
Echocardiogram
Echocardiograms will be collected from all subjects according to the Schedule of 
Assessments (Table 3-1, Table 3-2, and Table 3-3).
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 57 of 79
EMD Serono Research & Development Institute
11.7.6
Contraception and Pregnancy
11.7.6.1
Contraception
Male Subjects:
Acceptable contraceptive methods must be used from the Screening Visit through 6 months 
after the last dose of study drug, and include the following:
!
True abstinence (absence of any sexual intercourse), when in line with the preferred and 
usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, postovulation methods), and withdrawal are not acceptable methods of 
contraception
!
Condom with spermicide and the female partner must use an acceptable method of 
contraception, such as an oral, transdermal, injectable, or implanted steroid-based 
contraceptive, or a diaphragm or cervical cap with spermicide
!
Vasectomy (with a negative sperm postvasectomy semen analysis) at least 6 months 
before first dose of study drug and 1 additional acceptable contraception method.
Male subjects must not donate sperm from the Screening Visit through 6 months after the last 
dose of study drug.
Note 1: Male condom cannot be used with female condom due to risk of tearing.
Note 2: The use of birth-control methods does not apply if the female partner has a 
bilateral oophorectomy, hysterectomy, or is postmenopausal (as defined below).
Female Subjects of Nonchildbearing Potential:
Female subjects of non-childbearing potential must meet at least 1 of the following criteria:
!
Postmenopausal: Female subjects, less than 60 years of age, who have been amenorrheic 
for at least 2 years and have a serum FSH level within the laboratory’s reference range 
for postmenopausal females. Female subjects who are 60 years of age or older and who 
have been amenorrheic for greater than 2 years will be assumed to be postmenopausal
!
Documented hysterectomy or bilateral oophorectomy or both.
All other female subjects (including subjects with tubal ligations and subjects who do not 
have a documented hysterectomy) will be considered to be of childbearing potential.
Female Subjects of Childbearing Potential:
Acceptable nonhormonal, contraceptive methods must be used from the 28 days before first 
dose of study drug through 6 months after the last dose of study drug and include the 
following:
!
True abstinence (absence of any sexual intercourse), when in line with the preferred and 
usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, 
symptothermal, postovulation methods) and withdrawal are not acceptable methods of 
contraception
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 58 of 79
EMD Serono Research & Development Institute
!
Double barrier contraception such as diaphragm or cervical cap with spermicide and the 
male partner must use a condom with spermicide
!
Intrauterine device (nonhormone-releasing) in place for at least 90 days previously and 
the male partner must use a condom with spermicide
!
Bilateral tubal ligation at least 6 months previously and 1 additional acceptable 
contraception method
!
Vasectomy of the male partner (with a negative sperm postvasectomy semen analysis) at 
least 6 months before first dose of study drug and 1 additional acceptable contraception.
11.7.6.2
Pregnancy
Subjects will be counseled to inform the Investigator of any pregnancy that occurs during 
study treatment and for 90 days after the last dose of study drug(s).
If a subject or the female partner of a male subject becomes pregnant while participating in 
the study, study drug will be permanently discontinued immediately. The Investigator will 
notify the medical monitor and the Sponsor Global Patient Safety (GPS) within 24 hours of 
the site’s knowledge of the subject’s (or partner’s) pregnancy using the Pregnancy 
Information Collection Form. The subject or partner will be followed until the end of the 
pregnancy and the infant will be followed for 1 year after the birth, provided informed 
consent is obtained. A separate ICF will be provided to explain these follow-up activities. 
Pregnancy itself does not constitute an AE.
12
STATISTICAL AND ANALYTICAL PLANS
Analysis of all data, including safety, efficacy, and PK profiles, will be performed by the 
Sponsor or its designee. The results of all parts of the study will be reported in the clinical 
study report. 
The final analysis of study data will be based on all subject data of the escalation and 
expansion phases up to the time when all subjects have completed at least 6 cycles of 
treatment or discontinued the study. Within this analysis, subjects treated during the 
escalation phase will be pooled with those receiving the same dosing regimen during 
expansion phase. 
The additional data for any subjects continuing to receive study treatment after the data 
cutoff date for the primary CSR will be further summarized in a report upon completion of 
the study (see Section 8.1.6) when all subjects have discontinued study treatment and all 
required follow-up has been completed or the subject has died, been lost to follow-up, or 
withdrawn consent to further participation in the study.
For subjects undergoing intra-subject escalation to doses other than their initially received 
dose level, their post-escalation data will be listed.
A detailed analysis plan for the analysis of safety and efficacy data, and PK profiles will be 
presented in a statistical analysis plan (SAP) before the database is locked for analysis.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 59 of 79
EMD Serono Research & Development Institute
12.1
Sample Size and Power
For Part A, no formal statistical power calculations were performed to determine sample size. 
It is estimated that 50 subjects will be enrolled in Part A including at least 6 subjects treated 
at the MTD level. The actual number of subjects will depend on the number of dose 
levels/cohorts that are tested.
For Part B, assuming a historical ORR of 10% among subjects with endometrial cancer 
treated with PLD as second-line therapy, 16 a sample size of 40 subjects treated with VX-984 
in combination with PLD in Part B will provide a power of 41% and 90% CI of (10.4%, 
33.2%) with a target ORR of 20% and a power of 70% and 90% CI of (14.2%, 38.7%) with a 
target ORR of 25%, assuming an exact binomial test and an actual 2-sided significance level 
of 0.03.
Table 12-1
Power Consideration With Historical Response Rate of 10%
N
Treatment Response Rate
Power (%)
40
20%
40.7
25%
70.0
30%
88.9
12.2
Analysis Sets
For Part A:
!
The DLT Evaluable Set is defined as all subjects in the Safety Set of Part A who either 
meet the minimum exposure criterion and have sufficient safety evaluations (as 
determined by the Investigators and sponsor), or have had a DLT during Cycle 1 
(including the Lead-in Period)
A subject is considered to have met the minimum exposure criterion at a dose level if the 
subject received PLD on Day 1 and 3 doses of VX 984 within 5 days with the first dose 
of VX-984 on Day 2. Subjects who do not have a DLT during Cycle 1 are considered to 
have sufficient safety evaluations if they have been observed through the end of Cycle 1 
following the administration of PLD and VX-984, and are considered by both the sponsor 
and Investigators to have enough safety data to conclude that a DLT did not occur
!
The Safety Set is defined as all subjects who received at least 1 dose of study drug. The 
Safety Set will be used for safety analyses
!
The Full Analysis Set is defined as all subjects who received at least 1 cycle of study 
drug and have a baseline scan. The Full Analysis Set will be used for efficacy analyses.
For Part B:
!
The Safety Set is defined as all subjects who received at least 1 dose of study drug. The 
Safety Set will be used for safety analyses
!
The Full Analysis Set is defined as all subjects who received at least 1 cycle of study 
drug and have a baseline scan. The Full Analysis Set will be used for the primary and 
secondary efficacy analyses.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 60 of 79
EMD Serono Research & Development Institute
12.3
Statistical Analysis
The primary objective of this study is evaluation of safety (Parts A and B) and assessment of 
ORR in subjects with advanced endometrial cancer (Part B). The secondary objective is 
evaluation of anti-tumor activity based on radiological assessments of subjects. 
The Sponsor Biometrics Department or designee will analyze the safety and efficacy data.
Methodological and related details (e.g., missing data) will be provided in the SAP.
This section presents a summary of the planned statistical analyses of efficacy and safety for 
this study. Statistical analysis details will be provided in the SAP for this study, which will be 
finalized before clinical database lock.
12.3.1
General Considerations
Continuous data will be summarized (by dose group and by nominal study day, if applicable) 
using the following descriptive summary statistics: the number of subjects (n), mean, 
standard deviation (SD), standard error (SE), median, minimum value (min), and maximum 
value (max). Categorical data will be summarized using counts and percentages. All subject 
data, including those derived, will be presented in the subject data listings; listings will 
display all subjects who were enrolled, regardless of whether or not they received study drug.
Analysis details will be presented in the study SAP.
12.3.2
Background Characteristics
12.3.2.1
Subject Disposition
The number and percentage of subjects in each disposition category (e.g., enrolled, included 
in Safety Set, included in DLT Evaluable Set, included in Full Analysis Set, discontinuing 
treatment, and discontinuing study, with a breakdown of the reasons for discontinuation) will 
be summarized by dose group, by concurrent regimen and study part, and overall.
12.3.2.2
Demographics and Baseline Characteristics
The following demographics and baseline characteristics will be summarized by dose group, 
by concurrent regimen and study part, and overall for the Safety Set: sex, race, age, weight, 
height, body mass index (BMI), type of primary malignancy, tumor stage (tumor-node-
metastases), WHO performance status, time elapsed since cancer diagnosis, prior treatment 
with chemotherapy, prior treatment with radiation, duration of most recent cancer therapy, 
and medical history.
No statistical tests will be carried out to evaluate any baseline imbalance between dose 
groups.
12.3.2.3
Prior and Concomitant Medications
Medications taken 14 days before the Screening Visit and up to the Safety Follow-up Visit 
will be summarized by preferred term using the World Health Organization-Drug Dictionary 
Enhanced (WHO-DDE) for the Safety Set as frequency tables in 2 parts:
1. Prior medication: medication that started before the first dose of study drug, regardless of 
when dosing of the medication ended
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 61 of 79
EMD Serono Research & Development Institute
2. Concomitant medication: medication received at or after the first dose of study drug, 
medication that was received before initial dosing and continued after initial dosing of 
study drug, or medication with missing stop date.
Medication that started before the first dose of study drug and continued after the first dose of 
study drug will be summarized as prior medication and separately as concomitant 
medication. Medications with a missing start date will be considered to have a start date 
before the first dose of study drug.
12.3.2.4
Study Drug Exposure and Compliance
Total number of cycles is defined as the maximum number of treatment cycles that a subject 
receives. Total cumulative dose (mg) is the sum of the actual doses that the subject receives 
across cycles. Total planned dose (mg) is the sum of the planned doses. The total number of 
cycles, total cumulative dose (mg), and total planned dose (mg) will be summarized. The 
study drug exposure will be summarized based on the Safety Set.
12.3.3
Determination of the MTD
The determination of the MTD is based on an adaptive BLRM guided by the EWOC 
principle using the methodology described in detail in Section 12.3.3.2. The MTD will be 
further evaluated for anti-tumor activity and overall tolerability during the dose expansion 
phase of the trial.
After the dose expansion phase (Part B), the final recommended dose for future development 
will be based on considerations of the MTD estimated by the BLRM, and on an overall 
clinical assessment of all available safety, tolerability, PK, and PD data from all cycles at all 
different dose levels tested, in both phases of the study. If it is determined that treatment at a 
dose of VX-984 in combination with PLD lower than the MTD established during the dose 
escalation of the study is better tolerated, and has a better PK/PD or efficacy profile based on 
clinical considerations, then that dose may be used in further development.
12.3.3.1
MTD
The MTD is defined as the highest dose combination for a given schedule that causes DLTs 
in no more than 33.3% of subjects during the first cycle of treatment. Estimation of the MTD 
during the dose escalation phase of the study will be based upon the posterior distribution of 
the incidence of DLT in Cycle 1 in subjects in the DLT Evaluable Set. The corresponding 
methodology is described in Section 12.3.3.2.The variable of interest for the determination of 
MTD is the frequency of DLTs associated with the administration of VX-984 in combination 
with PLD during the first cycle of treatment.
12.3.3.2
Statistical Model and Method of Analysis
An adaptive BLRM with ≥2 parameters, guided by the EWOC principle, will be used to 
make dose recommendations and estimate the MTD during the escalation phase of the study, 
with the following 2 exceptions:
!
For cohorts requiring 3 or more evaluable subjects, if only 2 evaluable subjects are 
available for assessment (all others drop out), and neither subject has had a 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 62 of 79
EMD Serono Research & Development Institute
treatment-related or possibly-related toxicity greater than CTCAE Grade 1, then 
2 subjects will be considered sufficient for decision-making
!
If the first 2 subjects in a cohort have DLTs, no additional subjects will be enrolled into 
that cohort until the Bayesian model has been updated with this new information. 
Likewise, the model will be re-evaluated if 2 subjects in a cohort have DLTs before the 
enrollment of any additional subjects.
The DLT relationship in the escalation part of the study will be described by the following 
BLRM:
	
, , … ,  = log() +  log 
∗ + ! "#

#$
#
Under-dosing:

() ∈[0.00, 0.166)
Target toxicity:      

() ∈[0.166, 0.333)
Excessive toxicity: 

() ∈[0.333, 1.00]
where logit(π) = ln(π/(1 - π)), where π is the probability of a DLT.
Prior specifications
Prior for (log(α), log(β)): A vague bivariate normal prior for the model parameters 
(log(α),log(β)) is elicited based on prior guesses (medians) from nonclinical data and wide 
confidence intervals for the probabilities of a DLT at each dose.
12.3.3.3
Dose Recommendation
Part A
After each cohort of subjects the posterior distribution for the model parameters will be 
obtained through Gibbs’ sampling procedures by updating the prior distribution with the 
most up-to-date DLT information. Based on the posterior distribution of all model 
parameters, the corresponding posterior distributions for the probabilities of DLT at different 
dose levels are obtained. The results of this analysis are summarized in terms of the estimated 
probabilities that the true rate of DLT at each dose level will have of lying in each of the 
following intervals:
• [0, 0.166) 
under-dosing
• [0.166, 0.333) 
targeted toxicity
• [0.333, 1.00] 
excessive toxicity
Following the principle of EWOC, after each cohort of subjects the recommended dose is the 
one with the highest posterior probability of the DLT rate falling in the target interval 
[16.6%, 33.3%) among the doses fulfilling EWOC, i.e., it is unlikely (< 25% posterior 
probability) that the DLT rate at the dose falls in the excessive toxicity interval.
Note that the dose that maximizes the posterior probability of targeted toxicity is the best 
estimate of the MTD, but it may not be an admissible dose according to the overdose 
criterion if the amount of data is insufficient. If vague prior information is used for the 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 63 of 79
EMD Serono Research & Development Institute
probabilities of DLT in the early stages of the study, this escalation procedure will reflect a 
conservative strategy.
The dose recommended by the adaptive BLRM may be regarded as guidance and 
information to be integrated with a clinical assessment of the toxicity profiles observed at the 
time of the analysis in determining the next dose level to be investigated.
The final recommended dose will be based on considerations of the MTDs estimated by the 
BLRM and on an overall clinical assessment of all available safety, tolerability, PK, and PD 
data from all cycles at all different dose levels tested.
Part B
Upon completion of the first cycle of treatment for at least 10 subjects within the dose 
expansion phase (Part B), if the observed DLT rate exceeds 33.3%, the BLRM will be re-run 
to confirm that the estimated MTD still satisfies the overdose criteria of the model. If the 
dose fails to satisfy the criteria, a change to the dose under study may be made according to 
the BLRM recommendation after review of the clinical data.
12.3.4
Efficacy Analysis
Efficacy data will be summarized by dose group, by concurrent regimen and study part, and 
overall. Efficacy data may also be summarized by type of primary malignancy.
12.3.4.1
Analysis of Primary Variables
For Part B, the primary approach to analyze the best overall response and overall response at 
each scheduled assessment will be based on the Full Analysis Set. The proportion of subjects 
achieving best overall response of (CR or PR), with exact 90% CI, will be provided. Also, 
the overall response at each scheduled assessment visit will be summarized. 
Methodological details will be provided in the study SAP.
12.3.4.2
Analysis of Secondary Efficacy Variables
The proportion of subjects achieving a given categorical efficacy endpoint will be 
summarized by dose group, by concurrent regimen and study part, and separately for 
all subjects combined. For each proportion, a 90% CI will be reported using the exact 
method.
! Tumor response at scheduled assessment visit
! Disease control at scheduled assessment visit: disease control is defined as having CR, 
PR, or SD.
A supportive analysis will depict maximum percent decrease of the sum of target tumor 
length using a waterfall plot. The waterfall plot will show the bar for the subject with the 
largest positive change on the left, and the bar for the subject with the largest negative 
change on the right.
Time-to-event endpoints, such as PFS and OS, will be estimated via the Kaplan-Meier 
method if the number of events is adequate. For subjects achieving objective response (CR or 
PR), the response duration will be estimated. Methods that accommodate different censoring 
approaches will be specified with details in the SAP for the study.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 64 of 79
EMD Serono Research & Development Institute
Overall tumor response, target tumor, and non-target tumor assessment over time will be 
presented in an individual subject data listing. 
12.3.4.3
Analysis of Other Variables
Not applicable
12.3.5
Safety Analysis
The overall safety profile of VX-984 will be assessed in terms of the following primary 
(safety) endpoints: 
!
Incidence of treatment-emergent adverse events (TEAEs)
!
Incidence of DLTs (Part A)
!
Clinical laboratory values
!
ECG outcomes
!
Echocardiogram outcomes
!
Vital signs.
Safety data will be summarized by dose group, by concurrent regimen and study part, and 
overall. In general, safety analyses will be based on the Safety Set. The summary of DLTs 
will be based on the DLT Evaluable Set.
For safety variables, the scheduled Day 1, predose measurement will be used as the baseline 
value, when available; otherwise, the baseline value will be defined as the Day -1 
measurement. If none of these values is available, the baseline value will be defined as the 
value at the Screening Visit.
All safety data will be presented in individual subject data listings.
12.3.5.1
Adverse Events
AEs will be coded according to MedDRA. The number and percentage of subjects 
experiencing an AE will be summarized by the MedDRA system organ class and preferred 
term, as well as by dose group, concurrent regimen and study part, and overall. AEs will be 
classified as pre-treatment or treatment-emergent.
Pre-treatment AEs are defined as AEs that were reported or worsened after signing the ICF 
up to the start of study drug dosing.
Treatment-emergent AEs are defined as AEs that were reported or worsened on or after the 
start of study drug dosing through the 28-day Safety Follow-up Visit.
Only TEAEs will be summarized in tables. All summaries of TEAEs will be presented by the 
severity of the AE and relationship to the study drug. Some rules that will apply to the 
summarization of AEs are (1) a subject with multiple occurrences of the same AE or a 
continuing AE will only be counted once; (2) only the maximum severity level will be 
presented in the severity summary; and (3) only the worst relationship level will be presented 
in the relationship summary.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 65 of 79
EMD Serono Research & Development Institute
AEs leading to death, serious adverse events (SAEs), dose interruption, and permanent 
discontinuation will be listed separately. All AEs through the Safety Follow-up Visit will be 
listed in an individual subject data listing, including pre-treatment AEs. 
12.3.5.2
Clinical Laboratory Assessments
All statistical analyses of laboratory values will be performed using SI units. Hematology and 
clinical chemistry results will be summarized by dose group, concurrent regimen and study 
part, and overall at each scheduled time point. The number and percentage of subjects with 
shift changes from baseline based on the CTCAE toxicity grades will be tabulated. A listing 
of abnormal individual subject hematology and clinical chemistry values from scheduled and 
unscheduled time points will be provided. Grade 3 or higher toxicity laboratory values will 
be provided in an individual subject data listing. Urinalysis results will be listed only in 
individual subject data listings. These results will not be summarized. Clinically significant 
abnormal laboratory findings will be reported as AEs. 
12.3.5.3
Electrocardiogram
A summary of raw values and change from baseline values will be provided by dose group, 
concurrent regimen and study part, and overall at each scheduled visit for the following ECG 
measurements: PR, QT, QRS, and QTc intervals and heart rate. In addition, the number and 
percentage of subjects by maximum on-treatment value of QT/QTc intervals, categorized as 
≤450 msec, > 450 msec and ≤480 msec, > 480 msec and ≤500 msec, and > 500 msec, as 
well as maximum on-treatment change from baseline value of QT/QTc intervals, categorized 
as ≤30 msec, > 30 msec and ≤60 msec, and > 60 msec, will be provided. Clinically 
significant abnormal findings will be reported as AEs.
12.3.5.4
Echocardiogram
A summary of raw values and change from baseline values will be provided by dose group, 
concurrent regimen and study part, and overall at each scheduled visit for echocardiogram 
measurements (including left ventricular ejection fraction [LVEF]). In addition, the number 
and percentage of subjects by maximum on treatment decrease from baseline value in LVEF, 
categorized as 0 to ≤10%, > 10% and ≤20%, and > 20%, will be provided. Clinically 
significant abnormal findings will be reported as AEs.
12.3.5.5
Vital Signs
The following vital signs will be summarized by dose group, concurrent regimen and study 
part, and overall at each scheduled time point: systolic and diastolic blood pressure (mmHg), 
body temperature, pulse rate (bpm), and respiratory rate (breaths per minute). Clinically 
significant abnormal findings in vital signs will be reported as AEs.
12.3.5.6
Physical Examination
PE results will be presented in individual subject data listings only. Clinically relevant results 
identified after screening will be reported as AEs.
12.3.5.7
Other Safety Analysis
For Part A, incidence of DLTs will be presented by dose cohort.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 66 of 79
EMD Serono Research & Development Institute
12.3.6
Handling of Missing Values/Censoring/Discontinuations
! Subjects continuing to receive treatment will have time-to-event data (e.g., PFS) censored 
at the date of last radiological disease assessment before the cutoff date
! Partial or complete responses reported before any additional anti-cancer therapy will be 
considered as responses in the calculation of the ORR irrespective of the number of 
missed assessments before response
! Subjects with a best overall response of “Unknown” or “Not Assessed” per RECIST 1.1 
will be considered as non-responders in estimating the ORR
! Continuing events (e.g., AEs, concomitant medication, etc.) will be summarized using the 
data cut-off date as the date of completion, with an indication within listings that the 
event is continuing
! For subjects who discontinue the study with ongoing events, the discontinuation date will 
be used as the completion date of the event with the appropriate censoring as described 
in the above bullet
! The reason for discontinuation from study will be summarized and listed, along with 
dates of first and last study drug, duration of exposure to study drug, and date of 
discontinuation for each subject, by dose group and expansion arm. Other missing data 
will be noted as missing in appropriate tables/listings.
12.3.7
Interim and IDMC Analyses
12.3.7.1
Interim Analysis
Interim analyses may be conducted for the purpose of data review and regulatory updates.
12.3.7.2
IDMC Analysis
Not applicable
12.4
Clinical Pharmacology Analysis
12.4.1
Pharmacokinetic Analysis
Upon receipt of bioanalytical data, VX-984 PK will be assessed on an ongoing basis during 
the dose escalation phase in Part A using standard noncompartmental analysis methods. 
When possible, PK results for VX-984 will be reviewed along with safety data to inform 
dose escalation. 
Details of the analyses will be provided in a SAP.
 
 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 67 of 79
EMD Serono Research & Development Institute
 
 
13
PROCEDURAL, ETHICAL, REGULATORY, AND ADMINISTRATIVE 
CONSIDERATIONS
13.1
Adverse Event and Serious Adverse Event Documentation, 
Severity Grading, and Reporting
13.1.1
Adverse Events
13.1.1.1
Definition of an Adverse Event
An AE is defined as any untoward medical occurrence in a subject during the study; the 
event does not necessarily have a causal relationship with the treatment. This includes any 
newly occurring event or worsening of a preexisting condition (e.g., increase in its severity or 
frequency) after the ICF is signed. 
An AE is considered serious if it meets the definition in Section 13.1.2.1. 
13.1.1.2
Clinically Significant Assessments
Study assessments including laboratory tests, ECGs, PEs, and vital signs, will be assessed 
and those deemed a clinically significant worsening from baseline documented as an AE. 
When possible, a clinical diagnosis for the study assessment will be provided, rather than the 
abnormal test result alone (e.g., urinary tract infection, anemia). In the absence of a 
diagnosis, the abnormal study assessment itself will be listed as the AE (e.g., bacteria in urine 
or decreased hemoglobin).
An abnormal study assessment is considered clinically significant if the subject has 1 or more 
of the following:
!
Concomitant signs or symptoms related to the abnormal study assessment
!
Further diagnostic testing or medical/surgical intervention
!
A change in the dose of study drug or discontinuation from the study.
Repeat testing to determine whether the result is abnormal, in the absence of any of the above 
criteria, does not necessarily meet clinically significant criteria. The determination of 
whether the study assessment results are clinically significant will be made by the 
Investigator.
A laboratory value that is Grade 4 will not automatically be an SAE. A Grade 4 laboratory 
value will be an SAE if the clinical status of the subject indicates a life-threatening AE.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI
CCI
CCI


Protocol VX15-984-001, Version 4.0
Page 68 of 79
EMD Serono Research & Development Institute
13.1.1.3
Documentation of Adverse Events
All AEs will be collected from the time ICF is signed until the following time points:
!
For subjects who do not enroll: until time of screen failure (e.g., screen failure, 
withdrawal of consent)
!
For enrolled subjects who have a Safety Follow-up Visit: through the Safety Follow-up 
Visit
!
For enrolled subjects who do not have a Safety Follow-up Visit, the earliest of 28 days 
after the last dose of study drug.
All subjects will be queried, using non-leading questions, about the occurrence of AEs at 
each study visit. When possible, a constellation of signs and/or symptoms will be identified 
as 1 overall event or diagnosis. All AEs for enrolled subjects will be recorded in the CRF and 
source document. AEs for subjects who are screened but not subsequently enrolled in the 
study will be recorded only in the subject’s source documents. The following data will be 
documented for each AE:
!
Description of the event
!
Classification of “serious” or “nonserious”
!
Date of first occurrence and date of resolution (if applicable)
!
Toxicity grade
!
Causal relationship to study drug(s) 
!
Action taken 
!
Outcome 
!
Concomitant medication or other treatment given
!
Indication of DLT (Part A).
13.1.1.4
Adverse Event Severity
The Investigator will determine and record the severity of all serious and non-serious AEs. 
The guidance available at the following website will be consulted: CTCAE, Version 4.0, 
Cancer Therapy Evaluation Program, 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm (Accessed 
August 2012). The severity of an AE that does not appear in the CTCAE will be determined 
according to the definitions in Table 13-1. 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 69 of 79
EMD Serono Research & Development Institute
Table 13-1
Grading Scale for AEs That Are Not in CTCAE Scale
Classification
Definition
Grade 1
Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated
Grade 2
Moderate; minimal, local, or noninvasive intervention indicated; limiting age-appropriate 
instrumental activities of daily living (ADL)a
Grade 3
Severe or medical significant but not immediately life-threatening; hospitalization of 
prolongation of hospitalization indicated; disabling; limiting self-care ADLb
Grade 4
Life-threatening consequences; urgent intervention indicated
Grade 5
Death related to AE
Note: A semi-colon indicates ‘or’ within the description of the grade.
a
Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc.
b
Self-care ADL refers to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden.
13.1.1.5
Adverse Event Causality
Every effort will be made by the Investigator to assess the relationship of the AE, if any, to 
the study drug(s). Causality will be classified using the categories presented in Table 13-2.
Table 13-2
Classifications for AE Causality
Classification
Definition
Related
There is an association between the event and the administration of 
investigational study drug, a plausible mechanism for the event to be related to 
the investigational study drug and causes other than the investigational study 
drug have been ruled out, and/or the event re-appeared on re-exposure to the 
investigational study drug.
Possibly related
There is an association between the event and the administration of the 
investigational study drug and there is a plausible mechanism for the event to be 
related to investigational study drug, but there may also be alternative etiology, 
such as characteristics of the subject’s clinical status or underlying disease.
Unlikely related
The event is unlikely to be related to the investigational study drug and likely to 
be related to factors other than investigational study drug. 
Not related
The event is related to an etiology other than the investigational study drug (the 
alternative etiology will be documented in the study subject’s medical record).
13.1.1.6
Study Drug Action Taken
The Investigator will classify the study drug action taken with regard to the AE. The action 
taken will be classified according to the categories shown in Table 13-3.
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 70 of 79
EMD Serono Research & Development Institute
Table 13-3
Classifications for Study Drug Action Taken With Regard to an AE
Classification
Definition
Dose not changed
Study drug dose not changed in response to an AE
Dose reduced
Study drug dose reduced in response to an AE
Drug interrupted
Study drug administration interrupted in response to an AE 
Drug withdrawn
Study drug administration permanently discontinued in response to an AE
Not applicable
Action taken regarding study drug administration does not apply. 
“Not applicable” will be used in circumstances such as when the investigational 
treatment had been completed before the AE began and no opportunity to decide 
whether to continue, interrupt, or withdraw treatment is possible.
13.1.1.7
Adverse Event Outcome
An AE will be followed until the Investigator has determined and provided the final 
outcome. The outcome will be classified according to the categories shown in Table 13-4.
Table 13-4
Classifications for Outcome of an AE
Classification
Definition
Recovered/Resolved
Resolution of an AE with no residual signs or symptoms
Recovered/ Resolved 
With Sequelae
Resolution of an AE with residual signs or symptoms
Not Recovered/Not 
Resolved (Continuing)
Either incomplete improvement or no improvement of an AE, such that it 
remains ongoing
Fatal
Outcome of an AE is death. “Fatal” will be used when death is at least possibly 
related to the AE.
Unknown
Outcome of an AE is not known (e.g., a subject lost to follow-up)
13.1.1.8
Treatment Given
The Investigator ensures adequate medical care is provided to subjects for any AEs, 
including clinically significant laboratory values related to study drug. In addition, the 
Investigator will describe whether any treatment was given for the AE. “Yes” is used if any 
treatment was given in response to an AE, and may include treatments such as other 
medications, hospitalization, surgery, or physical therapy. “No” indicates the absence of any 
kind of treatment for an AE.
13.1.2
Serious Adverse Events
13.1.2.1
Definition of a Serious Adverse Event
An SAE is any AE that meets any of the following outcomes:
!
Fatal (death, regardless of cause, that occurs during participation in the study or occurs 
after participation in the study and is suspected of being a delayed toxicity due to 
administration of the study drug)
!
Life-threatening, such that the subject was at immediate risk of death from the reaction as 
it occurred
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 71 of 79
EMD Serono Research & Development Institute
!
Inpatient hospitalization or prolongation of hospitalization
!
Persistent or significant disability/incapacity (disability is defined as a substantial 
disruption of a person’s ability to conduct normal life functions)
!
Congenital anomaly or birth defect
!
Important medical event that, based upon appropriate medical judgment, may jeopardize 
the subject or may require medical or surgical intervention to prevent 1 of the outcomes 
listed above (e.g., an allergic bronchospasm requiring intensive treatment in an 
emergency room or at home).
If a subject has a hospitalization or procedure (e.g., surgery) for an event or condition that 
occurred before the subject signed the ICF, and the hospitalization or procedure was planned 
before the subject signed the ICF, the hospitalization or procedure will not be considered to 
indicate an SAE, unless an AE caused the hospitalization or procedure to be rescheduled 
sooner or to be prolonged relative to what was planned. In addition, hospitalizations clearly 
not associated with an AE (e.g., social hospitalization for purposes of respite care) will not be 
considered to indicate an SAE.
Clarification will be made between the terms “serious” and “severe,” because they are not 
synonymous. The term “severe” is often used to describe the intensity (severity) of a specific 
event, as in mild, moderate, or severe myocardial infarction. The event itself, however, may 
be of relatively minor medical significance, such as a severe headache. This is not the same 
as “serious,” which is based on subject/event outcome or action described above, and is 
usually associated with events that pose a threat to a subject’s life or functioning. 
Seriousness, not severity, serves as a guide for defining expedited regulatory reporting 
obligations.
13.1.2.2
Documentation of Serious Adverse Events
All SAEs that occur after obtaining informed consent and assent (where applicable) through 
the Follow-up Visit, regardless of causality, will be reported by the Investigator to the 
Sponsor GPS. In addition, all SAEs that occur after the Safety Follow-up Visit and are 
considered related to study drug(s) will be reported to the Sponsor GPS within 24 hours.
SAEs will be recorded on the Sponsor Organized Safety Information Collection Form 
(hereafter referred to as the “SAE Form”) using a recognized medical term or diagnosis that 
accurately reflects the event. SAEs will be assessed by the Investigator for relationship to the 
investigational study drug(s) and possible etiologies. On the Clinical Trials SAE Form, 
relationship to study drug(s) will be assessed only as related (includes possibly related) or not 
related (includes unlikely related), and severity assessment will not be required. For the 
purposes of study analysis, if the event has not resolved at the end of the study reporting 
period, it will be documented as ongoing. For purposes of regulatory safety monitoring, the 
Investigator is required to follow the event to resolution and report to the Sponsor the 
outcome of the event using the Sponsor Clinical Trials SAE Form.
13.1.2.3
Reporting Serious Adverse Events
The Investigator is responsible for notifying the sponsor or designee in writing within 
24 hours of identifying an SAE, regardless of relationship to the investigational study drug,
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 72 of 79
EMD Serono Research & Development Institute
using the SAE Report Form following specific completion instructions. Names, addresses,
and telephone and fax numbers for SAE reporting will be included in the study specific SAE 
Report Form. Investigators are asked to report any new information on previously reported 
SAEs as follow-up report as soon as it becomes available to ensure timely reporting to health 
authorities. 
In exceptional circumstances, an SAE (or follow-up information) may be reported by 
telephone; in these cases, a written report must be sent immediately thereafter by fax or
e-mail. 
Relevant pages from the eCRF may be provided in parallel (for example, medical history, 
concomitant drugs). Additional documents may be provided by the Investigator, if available 
(for example, laboratory results, hospital report, autopsy report). In all cases, the information 
provided on the SAE Report Form must be consistent with the data about the event recorded 
in the eCRF.
The Investigator must respond to any request for follow-up information (eg, additional 
information, outcome, final evaluation, other records where needed) or to any question the 
Sponsor/designee may have on the AE within the same timelines as those noted above for 
initial reports. This is necessary to ensure prompt assessment of the event by the Sponsor or 
designee and (as applicable) to allow the Sponsor to meet strict regulatory timelines 
associated with expedited safety reporting obligations.
Requests for follow-up will usually be made via the responsible monitor, although in 
exceptional circumstances the Global Patient Safety department may contact the Investigator
directly to obtain further information or to discuss the event.
13.1.2.4
Expedited Reporting and Investigator Safety Letters
The Sponsor is responsible for reporting suspected, unexpected, serious adverse reactions 
(SUSARs) involving the study drug(s) to all regulatory authorities and participating 
Investigators in accordance with ICH Guidelines and/or local regulatory requirements, as 
applicable. In addition, the Sponsor, or authorized designee, will be responsible for the 
submission of safety letters to central independent ethics committees (IECs). 
It is the responsibility of the Investigator or designee to promptly notify the local institutional 
review board (IRB)/local IEC of all unexpected serious adverse drug reactions involving risk 
to human subjects.
13.2
Administrative Requirements
13.2.1
Ethical Considerations
The study will be conducted in accordance with the current ICH GCP Guidelines, which are 
consistent with the ethical principles founded in the Declaration of Helsinki, and in 
accordance with local applicable laws and regulations. The IRB/IEC will review all 
appropriate study documentation to safeguard the rights, safety, and well-being of the 
subjects. The study will only be conducted at sites where IRB/IEC approval has been 
obtained. The protocol, Investigator's Brochure, sample ICF, advertisements (if applicable), 
written information given to the subjects (including diary cards), safety updates, annual 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 73 of 79
EMD Serono Research & Development Institute
progress reports, and any revisions to these documents will be provided to the IRB/IEC by 
the Investigator or the Sponsor, as allowable by local applicable laws and regulations.
13.2.2
Subject Information and Informed Consent
After the study has been fully explained, written informed consent will be obtained from the 
subject or legal representative or guardian (if applicable), before study participation. The 
method of obtaining and documenting the informed consent and assent (if applicable) and the 
contents of the consent will comply with ICH GCP and all applicable laws and regulations 
and will be subject to approval by the Sponsor or its designee.
13.2.3
Investigator Compliance
No modifications to the protocol will be made without the approval of both the Investigator
and the Sponsor. Changes that significantly affect the safety of the subjects, the scope of the 
investigation, or the scientific quality of the study (i.e., efficacy assessments) will require 
IRB/IEC notification before implementation, except where the modification is necessary to 
eliminate an apparent immediate hazard to human subjects. The Sponsor will submit all 
protocol modifications to the required regulatory authorities.
When circumstances require an immediate departure from procedures set forth in the 
protocol, the Investigator will contact the Sponsor to discuss the planned course of action. If 
possible, contact will be made before the implementation of any changes. Any departures 
from protocol will be fully documented in the source documentation and in a protocol 
deviation log. 
13.2.4
Access to Records
The Investigator will make the office and/or hospital records of subjects enrolled in this study 
available for inspection by the Sponsor or its representative at the time of each monitoring 
visit and for audits. The records will also be available for direct inspection, verification, and 
copying, as required by applicable laws and regulations, by officials of the regulatory health 
authorities (FDA and others). The Investigator will comply with applicable privacy and 
security laws for use and disclosure of information related to the research set forth in this 
protocol. 
13.2.5
Subject Privacy
To maintain subject confidentiality and to comply with applicable data protection and 
privacy laws and regulations, all CRFs, study reports, and communications relating to the 
study will identify subjects by assigned subject numbers and access to subject names linked 
to such numbers shall be limited to the site and the study doctor and shall not be disclosed to 
the Sponsor. As required by applicable laws and regulations in the countries in which the 
study is being conducted, the Investigator will allow the Sponsor and/or its representatives 
access to all pertinent medical records to allow for the verification of data gathered in the 
CRFs/SAE forms and the review of the data collection process. The FDA and regulatory 
authorities in other jurisdictions, including the IRB/EC, may also request access to all study 
records, including source documentation, for inspection.
For sites participating in the study in the US, and in accordance with the Health Insurance 
Portability and Accountability Act (HIPAA) and associated regulations, an executed HIPAA 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 74 of 79
EMD Serono Research & Development Institute
authorization shall be obtained by the site from each subject (or the legal representative of 
the subject) before research activities may begin. Each HIPAA authorization shall comply 
with all HIPAA requirements including authorization allowing the site access to and use of 
the subject’s personally identifiable health information, authorization for the site to disclose 
such information to the Sponsor, the FDA, and other parties requiring access under the 
protocol, and statements as to the purpose for which such information may be used and for 
how long.
13.2.6
Record Retention
The Investigator will maintain all study records according to ICH GCP guidelines and/or 
applicable local regulatory requirement(s), whichever is longest, as described in the Clinical 
Trial Agreement. If the Investigator withdraws from the responsibility of keeping the study 
records, custody will be transferred to a person willing to accept the responsibility and the 
Sponsor will be notified.
13.2.7
Study Termination
At any time, the Sponsor may terminate this study in its entirety or may terminate this study 
at any particular site. In addition, for reasonable cause, either the Investigators or their 
IRBs/IECs may terminate the study at their center.
Conditions that may lead to reasonable cause and warrant termination include, but are not 
limited to:
!
Subject or Investigator noncompliance
!
Unsatisfactory subject enrollment
!
Lack of adherence to protocol procedures
!
Lack of evaluable and/or complete data
!
Potentially unacceptable risk to study subjects
!
Decision to modify drug development plan
!
Decision by the FDA or other regulatory authority.
Written notification that includes the reason for the clinical study termination is required.
13.3
Data Quality Assurance
The Sponsor or its designated representative will conduct a study site visit to verify the 
qualifications of each Investigator, inspect clinical study site facilities, and inform the 
Investigator of responsibilities and procedures for ensuring adequate and correct study 
documentation.
The Investigator is required to prepare and maintain adequate and accurate case histories 
designed to record all observations and other data pertinent to the study for each study 
participant. Study data for each enrolled subject will be entered into a CRF by study site 
personnel using a secure, validated web-based electronic data capture (EDC) application. The 
Sponsor will have read-only access to site-entered clinical data in the EDC application. 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 75 of 79
EMD Serono Research & Development Institute
Instances of missing, discrepant, or uninterpretable data will be queried with the Investigator
for resolution. Any changes to study data will be made to the CRF and documented in an 
audit trail, which will be maintained within the clinical database.
13.4
Monitoring
Monitoring and auditing procedures developed or approved by the Sponsor will be followed 
to comply with GCP guidelines. On-site checking of the CRFs/SAE Forms for completeness 
and clarity, cross-checking with source documents, and clarification of administrative matters 
will be performed.
The study will be monitored by the Sponsor or its designee. Monitoring will be done by 
personal visits from a representative of the Sponsor, or designee (study site monitor), who 
will review the CRFs/SAE Forms and source documents. The study site monitor will ensure 
that the investigation is conducted according to the protocol design and regulatory 
requirements.
13.5
Electronic Data Capture
The Sponsor will provide the study sites with secure access to and training on the EDC 
application sufficient to permit study site personnel to enter or correct information in the 
CRFs on the subjects for which they are responsible. 
A CRF will be completed for each enrolled study subject. It is the Investigator’s 
responsibility to ensure the accuracy, completeness, clarity, and timeliness of the data 
reported in the subject’s CRF. Source documentation supporting the CRF data will indicate 
the subject’s participation in the study and will document the dates and details of study 
procedures, AEs, other observations, and subject status.
The Investigator, or designated representative, will complete the CRF as soon as possible 
after information is collected. 
The audit trail entry will show the user’s identification information and the date and time of 
any correction. The Investigator will provide formal approval of all the information in the 
CRFs, including any changes made to the CRFs, to endorse the final submitted data for the 
subjects for whom the Investigator is responsible. 
The Sponsor will retain the CRF data and corresponding audit trails. A copy of the final 
archival CRF in the form of a CD or other electronic media will be placed in the 
Investigator’s study file.
13.6
Publications and Clinical Study Report
13.6.1
Publication of Study Results
Any and all scientific, commercial, and technical information disclosed by the Sponsor in 
this protocol or elsewhere will be considered the confidential and proprietary property of the 
Sponsor. The Investigator shall hold such information in confidence and shall not disclose 
the information to any third party except to such of the Investigator’s employees and staff as 
have been made aware that the information is confidential and who are bound to treat it as 
such and to whom disclosure is necessary to evaluate that information. The Investigator shall 
not use such information for any purpose other than determining mutual interest in 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 76 of 79
EMD Serono Research & Development Institute
performing the study and, if the parties decide to proceed with the study, for the purpose of 
conducting the study.
The Investigator understands that the information developed from this clinical study will be 
used by the Sponsor in connection with the development of the study drug and other drugs 
and diagnostics, and therefore may be disclosed as required to other clinical Investigators, 
business partners and associates, the FDA, and other government agencies. The Investigator
also understands that, to allow for the use of the information derived from the clinical study, 
the Investigator has the obligation to provide the Sponsor with complete test results and all 
data developed in the study.
No publication or disclosure of study results will be permitted except under the terms and 
conditions of a separate written agreement between the Sponsor and the Investigator and/or 
the Investigator’s institution.
13.6.2
Clinical Study Report 
A clinical study report, written in accordance with the ICH E3 Guideline, will be submitted 
in accordance with local regulations. 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


Protocol VX15-984-001, Version 4.0
Page 77 of 79
EMD Serono Research & Development Institute
14
REFERENCES
1
Davidson D, Amrein L, Panasci L, Aloyz R. Small molecules, inhibitors of DNA-PK, 
targeting DNA repair, and beyond. Front Pharmacol. 2013;4:5.
2
Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson CJ, Cano C, et al. 
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and 
PI-3K. Mol Cancer Ther. 2012 Aug;11(8):1789-98.
3
Vertex Pharmaceutical Incorporated. VX-984 Investigator’s Brochure, Version 3.0. 
17 August 2017.
4
Surveillance, Epidemiology and End Results, 2012.
5
CancerMPact Patient Metrics, Kantar Health, May 2015.
6
CancerMPact Treatment Architecture:US Endometrial Cancer, Kantar Health, 
Version 1.1. June 2014.
7
NCCN Clinical Practice Guidelines in Oncology (NCCN Guideline®). Uterine 
Neoplasms. Version 2. 2017.
8
Babb J, Rogatko A, Zacks S. Cancer Phase I Clinical Trials: Efficient dose escalation 
with overdose control. Statist Med. 1998;17:1103-20.
9
European Medicines Agency. Committee for Medicinal Products for Human Use. 
Guideline on clinical trials in small populations. London: July 2006.
10
Rogatko A, Schoeneck D, Joans W, Tighiouart M, Khuri FR, Porter A. Translation of 
innovative designs into Phase I trials. J of Clin Onc. 2007;25(31):4982-86.
11
Bregar A, Robinson K, Dizon DS. Update on chemotherapeutic management of 
endometrial cancer. Clin Adv Hematol Oncol. 2014; 12 (10):659-665.
12
International Conference on Harmonization (ICH) of Technical Requirements for 
Registration of Pharmaceuticals for Human Use. Safety Guideline S9: Nonclinical 
Evaluation for Anticancer Pharmaceuticals. 29 October 2009.
13
DOXIL® (doxorubicin hydrochloride liposome injection) Package Insert. Janssen 
Products. Horsham, PA, USA. Revised: April 2015.
14
CAELYX® INJECTION Product Information. Janssen-Cilag Pty Ltd. Macquarie 
Park, Australia. Revised: October 2013.
15
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent, D, Ford R, et al. New 
response criteria in solid tumours: Revised RECIST criteria guideline (Version 1.1). 
Eur J Cancer. 2009;45:228-47.
16
Muggia FM. Liposomal encapsulated anthracylines: new therapeutic horizons. Curr 
Oncol Rep.2001;3(2):156-62. 
'RFXPHQW1R

2EMHFW1R

CCI
PPD
CCI


PPD
PPD
PPD
PPD
PPD
CCI
CCI
PPD


Protocol VX15-984-001, Version 4.0
Page 79 of 79
EMD Serono Research & Development Institute
15.2
Investigator Signature Page
Protocol #:
VX15-984-001
Version #:
4.0
Version 
Date:
21 August 2017
Study Title: An Open-Label, Phase I, First-in-Human Study of the Safety, Tolerability, and 
Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With 
Chemotherapy in Subjects With Advanced Solid Tumors
I have read Protocol VX15-984-001, Version 4.0 and agree to conduct the study according to 
its terms. I understand that all information concerning VX-984 and this protocol supplied to 
me by EMD Serono Research & Development Institute is confidential. 
Printed Name
Signature
Date
'RFXPHQW1R
2EMHFW1R
$XJXVW
PPD
PPD
CCI
PPD
CCI

SAP_001.pdf: 
VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
1/36
Integrated Analysis Plan
Clinical Trial Protocol 
Identification No.
VX15-984-001
EMD Serono Internal Study Number: MS201926-0001
Title
An Open-Label, Phase I, First in Human Study of the Safety, 
Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of 
VX-984 in Combination With Chemotherapy in Subjects With 
Advanced Solid Tumors
Trial Phase
Phase I
Investigational Medicinal 
Product(s)
Active substance: VX-984 (EMD Serono internal compound code: 
M9831)
Activity: DNA-dependent protein kinase (DNA-PK) inhibitor
Strength and Route of Administration: VX-984 suspension (in 
0.5% methyl cellulose) for oral administration
Dose: up to 3000 mg
Clinical Trial Protocol Version
21 August 2017 / Version 4.0 including Amendment 1 and 2
Integrated Analysis Plan 
Author
Coordinating Author
, Merck
 
Function
Author(s) / Data Analyst(s)
, 
, Merck
Integrated Analysis Plan
Date and Version
26 January 2018 / Version 1.0
Integrated Analysis Plan 
Reviewers
Function
Name
, 
, Merck
, Merck
 
, Merck
, Merck
, Merck
, Merck
, Merck
, Merck
, Merck
, Merck
, Merck
This document is the property of Merck KGaA, Darmstadt, Germany, or one of its affiliated companies.
It is intended for restricted use only and may not - in full or part - be passed on, reproduced, published or used without express 
permission of Merck KGaA, Darmstadt, Germany or its affiliate. 
Copyright © 2018 by Merck KGaA, Darmstadt, Germany or its affiliate. All rights reserved.
'RFXPHQW1R

2EMHFW1R

PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
CCI
CCI
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
2/36
Approval Page
Integrated Analysis Plan: MS201926-0001
An Open-Label, Phase I, First in Human Study of the Safety, Tolerability, and 
Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy in 
Subjects With Advanced Solid Tumors
Merck responsible
Date
, 
Via ELDORADO approval process
, 
Via ELDORADO approval process
'RFXPHQW1R

2EMHFW1R

PPD
PPD
CCI
CCI
PPD
PPD


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
3/36
1
Table of Contents
Integrated Analysis Plan ......................................................................................................1
Approval Page
....……………………………………………………………………..2
1
Table of Contents..................................................................................3
2
List of Abbreviations and Definition of Terms ....................................5
3
Modification History ............................................................................7
4
Purpose of the Integrated Analysis Plan...............................................7
5
Objectives and Endpoints .....................................................................7
6
Overview of Planned Analyses.............................................................8
6.1
Final Analysis .......................................................................................8
7
Changes to the Planned Analyses in the Clinical Trial Protocol..........8
8
Protocol Deviations and Analysis Sets.................................................9
8.1
Definition of Protocol Deviations.........................................................9
8.2
Definition of Analysis Sets...................................................................9
9
General Specifications for Data Analyses ..........................................10
10
Trial Subjects......................................................................................12
10.1
Disposition of Subjects and Discontinuations....................................12
10.2
Protocol Deviations ............................................................................14
11
Demographics and Other Baseline Characteristics.............................14
11.1
Demographics.....................................................................................14
11.2
Medical History ..................................................................................15
11.3
Other Baseline Characteristics............................................................15
11.4
Disease History...................................................................................16
12
Previous or Concomitant Medications/Procedures.............................16
12.1
Previous Medications..........................................................................17
12.2
Concomitant Medications...................................................................18
12.3
Concurrent Procedures........................................................................18
13
Treatment Compliance and Exposure.................................................19
14
Efficacy Analyses ...............................................................................23
14.1
Analysis of Best Overall Response.....................................................23
15
Safety Analyses ..................................................................................25
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
4/36
15.1
MTD (Primary Endpoint) ...................................................................25
15.2
Adverse Events ...................................................................................26
15.2.1
All Adverse Events.............................................................................26
15.2.2
Adverse Events Leading to Treatment Discontinuation.....................28
15.3
Deaths, Other Serious Adverse Events, and Other Significant 
Adverse Events ...................................................................................29
15.3.1
Deaths .................................................................................................29
15.3.2
Serious Adverse Events......................................................................29
15.3.3
Other Significant Adverse Event........................................................30
15.4
Clinical Laboratory Evaluation...........................................................30
15.5
Vital Signs ..........................................................................................33
15.6
Other Safety or Tolerability Evaluations............................................33
15.6.1
ECOG Performance Status .................................................................33
15.6.2
Electrocardiogram...............................................................................33
15.6.3
Echocardiogram..................................................................................34
16
Analyses of Other Endpoints..............................................................35
16.1
Pharmacokinetics................................................................................35
17
References...........................................................................................35
18
Appendices .........................................................................................36
18.1
Safety Laboratory Test Panels............................................................36
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
5/36
2
List of Abbreviations and Definition of Terms
AE
Adverse Event
ATC
Anatomical Therapeutic Chemical
BLRM
Bayesian logistic regression model
BMI
Body Mass Index
BOR
Best Overall Response
BSA
Body Surface Area
CI
Confidence Interval
CRF
Case Report Form
CR
Complete Response
CSR
Clinical Study Report
CT
Computed Tomography
CTC
Common Terminology Criteria
CV
Coefficient of Variation
DCR
Disease Control Rate
DLT
Dose-Limiting Toxicity
ECG
Electrocardiogram
ECOG
Eastern Cooperative Oncology Group
FAS
Full Analysis Set
IAP
Integrated Analysis Plan
ICH
International Conference on Harmonization
LVEF
Left Ventricular Ejection Fraction
Max
Maximum
Min
Minimum
Mean
Arithmetic Mean
Median
Median
MedDRA
Medical Dictionary for Regulatory Activities
MTD
Maximum Tolerated Dose
NCI-CTCAE
National Cancer Institute – Common Terminology Criteria for Adverse 
Events
NE
Not Evaluable
ORR
Objective Response Rate
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
6/36
PAS
Pharmacokinetic Analysis Set
PD
Progressive Disease
PLD
Pegylated Liposomal Doxorubicin
PT
Preferred Term
PK
Pharmacokinetic
PR
Partial Response
Q1
25th Percentile
Q3
75th Percentile
QD
Once Daily
QTcF
QT interval with Frederica’s correction
RECIST
Response Evaluation Criteria In Solid Tumors
SAE
Serious Adverse Event
SAF
Safety
SCR
Screening
SD
Stable Disease
SDTM
Study Data Tabulation Model
SOC
System Organ Class
StDev
Standard Deviation
SOC
System Organ Class
TEAE
Treatment Emergent Adverse Event
UNK
Unknown
WHO-DD
World Health Organization Drug Dictionary
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
7/36
3
Modification History
Unique
Identifier for
Version
Date of
IAP Version
Author
Changes from the Previous Version
1.0
26 January 2018
First version.
4
Purpose of the Integrated Analysis Plan
The purpose of this Integrated Analysis Plan (IAP) is to document technical and detailed 
specifications for the final analysis of data collected for protocol MS201926-0001. Results of the 
analyses described in this IAP will be included in the Clinical Study Report (CSR). Additionally, 
the planned analyses identified in this IAP will be included in regulatory submissions or future 
manuscripts. Any post-hoc, or unplanned analyses performed to provide results for inclusion in 
the CSR but not identified in this prospective IAP will be clearly identified in the CSR. 
The IAP is based upon section 12 (Statistics) of the trial protocol and protocol amendments and is 
prepared in compliance with International Conference on Harmonization (ICH) E9.
5
Objectives and Endpoints
Objective
Endpoint
IAP 
section
Primary
Objective
!
To evaluate the safety and tolerability 
of VX-984 (EMD Serono internal 
compound code: M9831) administered 
alone and in combination with 
pegylated liposomal doxorubicin (PLD) 
in subjects with advanced solid tumors
!
Safety parameters, including adverse 
events (AEs), dose-limiting toxicities 
(DLTs), clinical laboratory values 
(serum chemistry and hematology), 
vital signs, echocardiogram, and 
electrocardiogram (ECG) assessments
15
!
To determine the maximum tolerated 
dose (MTD) of VX-984 in combination 
with PLD in subjects with advanced 
solid tumors.
!
MTD of VX-984 in combination with 
PLD.
15.1
Secondary 
Objective
!
To evaluate the pharmacokinetics 
(PK) of VX-984 when administered 
alone and in combination with PLD in 
subjects with advanced solid tumors
!
Plasma PK parameter estimates of 
VX-984, administered alone and in 
combination with PLD, derived from 
plasma concentration-time data
16.1
!
To evaluate the PK of PLD when 
administered in combination with 
VX-984 in subjects with advanced 
solid tumors
!
Plasma PK parameter estimates of 
PLD administered in combination with 
VX-984, derived from plasma 
concentration-time data
16.1
!
To evaluate preliminary antitumor 
activity of VX-984 in combination with 
PLD in subjects with advanced solid 
tumors.
!
Preliminary evidence of anti-tumor 
activity, including tumor response as 
evaluated by Response Evaluation 
Criteria in Solid Tumors (RECIST) 1.1 
and tumor markers.
14.1
'RFXPHQW1R

2EMHFW1R

CCI
CCI
PPD


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
8/36
Objective
Endpoint
IAP 
section
Exploratory
Objective
!
 
 
 
 
 
 
!
To assess tumor response by tumor 
volume and tumor necrosis in subjects 
administered VX-984 in combination 
with PLD
!
To assess correlations between prior 
treatment response and treatment 
outcome.
!
 
 
!
Tumor response as assessed by tumor 
volume and tumor necrosis using 3D 
computed tomography (CT) scans
!
Tumor response as assessed by 
historical and on-treatment tumor 
growth dynamics
!
 
 
 
 
16.2
6
Overview of Planned Analyses
There are no interim analyses planned for this study.
6.1
Final Analysis
All final, planned analyses identified in the Clinical Trial Protocol and in this IAP will be 
performed only after the last subject has completed the treatment phase of the trial with all trial 
data in-house, all data queries resolved, and the database locked.
A data review meeting will be held prior to database lock. In addition, no database can be locked 
until this IAP has been approved.
7
Changes to the Planned Analyses in the Clinical Trial Protocol
The following changes were made in this IAP.
!
Due to management decision, Part B from the protocol will not be further pursued. Therefore 
only Part A from the protocol is covered in this IAP.  
!
Analysis of exploratory endpoints from the protocol will not be performed.
!
Listings will be presented based on the same analysis population as used in corresponding 
tables, which deviates from the requirement from the protocol: “listings will include all 
subjects who were enrolled, regardless of whether or not they received study treatment.”
!
Analysis of PK will not be performed, concentrations of VX-984 and PLD will only be listed 
by subject and nominal time.
!
The definition of Full Analysis Set (FAS) from the protocol, to be used for efficacy analyses,
is not used in this IAP. The updated version of FAS is defined in Section 8.2.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
CCI
CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
9/36
Definition of FAS per protocol: The FAS is defined as all subjects who received at least 1 cycle 
of study drug and have a baseline scan.
8
Protocol Deviations and Analysis Sets
8.1
Definition of Protocol Deviations
Protocol deviations will be collected by site monitoring and included in clinical trial management 
system log, no analysis planned. 
8.2
Definition of Analysis Sets 
Screening Analysis Set (SCR)
The SCR includes all subjects who provided informed consent.
Safety Analysis Set (SAF)
The SAF will include all enrolled subjects who received at least 1 dose of study treatment. 
Analyses performed on the SAF will consider subjects as treated.
Dose-Limiting Toxicity Evaluable Set (DLT)
The DLT will include all subjects in the SAF who either meet the minimum exposure criterion and 
have sufficient safety evaluations (as determined by the Investigators and sponsor) or have had a 
DLT during Cycle 1.  
Subjects who do not have a DLT during Cycle 1 will be excluded from the DLT Evaluable Set if 
the subject does not satisfy either of the following criteria: 
!
Minimum exposure criterion
A subject is considered to have met the minimum exposure criterion at a dose level if the
subject received PLD on Day 1, and 3 doses of VX-984 within 5 days with the first dose of 
VX-984 on Day 2. 
!
Completion of  Cycle 1
A subject is considered to have sufficient safety evaluations if the subject has been observed 
through the end of Cycle 1, which is defined as up to 28 days after the start of study treatment
from Cycle 1.
Subjects who have been replaced by Safety Monitoring Committee decision will also be excluded 
from this analysis set.
Full Analysis Set (FAS)
The FAS will include all enrolled subjects who received at least 1 dose of study treatment.  
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
10/36
As the FAS is identical to the SAF, the term FAS/SAF will be used to reflect that those analysis 
sets contain the same subjects.
Pharmacokinetic Analysis Set (PAS)
The PAS will include of all subjects who receive at least 1 dose of VX-984 or PLD and provide at 
least one measurable post-dose concentration of VX-984 or one measurable post-dose 
concentration of PLD. Subjects will be analyzed according to the actual treatment they received. 
All PK listings will be based on this analysis set.
Use of analysis sets is described in Table 2. 
Table 2
Summary of Analysis and Associated Analysis Set
Analyses
SCR
FAS/SAF
DLT
PAS
Dispositions and deaths

Baseline Assessments

Past and Concomitant Therapies

Compliance and Exposure

Efficacy

Safety: MTD (Primary endpoint)

Safety and Tolerability

PK

9
General Specifications for Data Analyses
Unless otherwise indicated, summary tables will be presented by dose group and overall based on 
the analysis set of interest; listings will be presented using the same analysis sets as corresponding 
tables.
Data handling after cut-off date:
Data after cut-off do not undergo the cleaning process. The only exceptions are the date of death 
and the date last known to be alive, per the source data from the “Long-Term Follow-Up” case 
report form (CRF) page. 
Data other than the date of death and the date last known to be alive obtained after the cut-off will 
not be displayed in any listings or used for summary statistics, e.g. laboratory values of samples 
taken after data cut-off, AEs with onset date after data cut-off, etc. will not be included in any 
analysis or listing. 
Pooling of centers:
Because of the high number of participating centers and the anticipated small number of subjects 
enrolled in each center, data will be pooled across centers. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
11/36
Presentation of continuous and qualitative variables:
Continuous variables will be summarized using descriptive statistics, i.e. 
! Number of subjects, number of subjects with non-missing values (n)
! Arithmetic mean (Mean), standard deviation (StDev)
! Median, 25th Percentile - 75th Percentile (Q1-Q3)
! Minimum (Min), maximum (Max)
If there are missing values, the number of subject counts and percentage should be indicated by a 
0 (0.0).
Missing statistics, e.g. when they cannot be calculated, should be presented as “nd”. For example, 
if n=1, the standard deviation cannot be computed and should be presented as “nd”.
Qualitative variables will be summarized by counts and percentages.
Unless otherwise stated the calculation of proportions will be based on the number of subjects in
the analysis set of interest. Therefore counts of missing observations will be included in the 
denominator and presented as a separate category.
In case the analysis refers only to certain visits, percentages will be based on the number of subjects 
still present in the trial at that visit, unless otherwise specified.
Presentation of PK Concentration Data
VX-984 and PLD concentration data will only be listed.
Presentation of PK Data
No PK parameter data will presented. 
Definition of treatment day:
Treatment day is defined relative to the start of study treatment (either VX-984 or PLD) from 
Cycle 1.
Treatment Day 1 is defined as the day of the first administration of study treatment from Cycle 1. 
The day before is defined as Treatment Day -1 (no Treatment Day 0 is defined). Per protocol, the
day of first administration of study treatment in Lead-in Period is Treatment Day -14. 
Definition of baseline:
Baseline is defined as the last non-missing measurement prior to the first administration of study 
treatment (either VX-984 or PLD, whatever is earlier), including the Lead-in Period if available.  
Definition of duration:
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
12/36
Duration will be calculated by the difference of start and stop date + 1 (e.g. survival time (days) = 
date of death – date of randomization + 1) (if not otherwise specified).
The time since an event (e.g. time since first diagnosis) will be calculated as reference date minus 
date of event.  
Unscheduled visits:
Data collected at unscheduled visits will be included and analyzed for both safety and efficacy 
analyses in the same fashion as the data collected at scheduled visits except where otherwise noted.
Assessments from unscheduled visits will be used for the derivation of baseline values and worst 
on-treatment values. However, descriptive statistics by nominal visit or time point for safety 
endpoints such as laboratory measurements, ECGs and vital signs will include only data from 
scheduled visits per protocol. 
Conversion factors:
The following conversion factors will be used to convert days into months or years: 1 month = 
30.4375 days, 1 year = 365.25 days.
Handling of missing data:
Unless otherwise specified, missing data will not be replaced. 
In all subject data listings imputed values will be presented. In all listings imputed information 
will be flagged. 
Missing statistics, e.g. when they cannot be calculated, should be presented as “nd”. For example, 
if n=1, the measure of variability (StdDev) cannot be computed and should be presented as “nd”.
SAS version:
If not stated otherwise, analyses will be performed using SAS® Software version 9.4 or higher.
10
Trial Subjects
The subsections in this section include specifications for reporting subject disposition and 
treatment/trial discontinuations.
10.1
Disposition of Subjects and Discontinuations
Analysis Set: SCR
A primary table of subject disposition will be provided by dose group and overall:
!
Number of screened subjects (overall column only)
!
Number of subjects discontinued prior to treatment start (either VX-984 or PLD)
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
13/36
!
Number of subjects who continued beyond screening
!
Number of subjects who were treated in Lead-in Period
!
Number of subjects who were treated in Lead-in Period or Treatment Period
!
Number of subjects who completed treatment of VX-984 (discontinuation due to progressive 
disease or death)
!
Number of subjects who completed treatment of PLD (discontinuation due to progressive 
disease or death)
!
Number of subjects discontinued from VX-984 (discontinuation reasons other than progressive 
disease or death), overall and by reason
!
Number of subjects discontinued from PLD (discontinuation reasons other than progressive 
disease or death), overall and by reason 
!
Number of subjects who entered the Long-Term Follow-up Period 
!
Number of subjects alive in the Long-Term Follow-up Period, by subgroups of alive status
(subjects alive without progressive disease or new anticancer therapy; subjects progressed; 
subjects started new anticancer therapy; subjects withdrew consent from the Long-Term 
Follow-up Period.)
!
Number of subjects who completed the trial (including Follow-up Period, per “End of Follow-
Up” page from CRF).
!
Number of subjects discontinued from trial (including Follow-up Period) overall and by reason 
(per “End of Follow-Up” CRF page).
A second summary table on analysis sets will be generated by dose group and overall, unless 
specified otherwise:
!
Number of subjects in SCR (overall column only)
!
Number of subjects in FAS/SAF
!
Number of subjects in DLT
!
Number of subjects in PAS
A third summary table will display the number of subjects overall, in each country and in each site 
(per analysis set).
A listing of subject disposition will include the following information (as applicable): dose group, 
subject identification number, date of informed consent form, reason for screen failure, date of 
first and last dose of study treatment (VX-984 and PLD respectively), inclusion or exclusion to the 
analysis set of: SCR, FAS/SAF and DLT.
A second listing will include the following trial discontinuation information: dose group, subject 
identification number, end of trial status (completed, ongoing, discontinued), the reason for trial 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
14/36
discontinuation, the date of trial termination, trial duration (with respect to the date of informed 
consent), and the date of first and last dose of study treatment (VX-984 and PLD respectively).
A third listing will include the following VX-984 discontinuation information: dose group, subject 
identification number, end of treatment status (completed, ongoing, discontinued), the reason for 
VX-984 discontinuation, and the date of first and last dose of VX-984.
A fourth listing will include the following PLD discontinuation information: dose group, subject 
identification number, end of treatment status (completed, ongoing, discontinued), the reason for 
PLD discontinuation and the date of first and last dose of PLD.
In addition, a listing including long-term follow-up information will be provided with the 
following information: dose group, subject identification number, date of contact, live status, date 
of progression, date of a new therapy, date of withdrawal from long-term follow-up and date lost 
to follow-up.
10.2
Protocol Deviations
As indicated in Section 8.1, protocol deviation data will not be analyzed.
A listing on subjects excluded from the DLT will be produced, indicating the reason for exclusion.
11
Demographics and Other Baseline Characteristics
11.1
Demographics
Analysis Set: FAS/SAF
Demographic characteristics will be summarized using the following information from the 
“Demography” CRF pages. 
!
Gender: male, female 
!
Race: White, Black or African American, Asian, Native Hawaiian or Other Pacific Islander, 
American Indian or Alaska Native, not collected and other 
!
Ethnicity: Hispanic or Latino, not Hispanic or Latino and not collected
!
Age (years): summary statistics 
!
Age categories:
o
< 65 years, ≥ 65 years
o
65-74 years, 75-84 years, ≥85 years
Specifications for computation:
! Age (years) = (date of given informed consent - date of birth + 1) / 365.25
In case of missing day for at least one date, but month and year available for both dates: 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
15/36
o
For the derivation of age, the day of informed consent and the day of birth will be set to 
1 and the formula above will be used
In case of missing month for at least one date, but year available for both dates: 
o
For the derivation of age, the day and the month of informed consent and the day and 
month of birth will be set to 1 and the formula above will be used
All relevant demographic data will be presented in data listings.
11.2
Medical History
Analysis Set: FAS/SAF
The medical history will be summarized from the “Medical History” CRF page, using the latest
version of Medical Dictionary for Regulatory Activities (MedDRA), preferred term (PT) as event 
category and MedDRA system organ class (SOC) body term as Body System category. 
Medical history will be displayed in terms of frequency tables: ordered by primary SOC and PT 
in alphabetical order by dose group and overall.
A supportive listing of medical history data by subject will include all the relevant data fields as 
collected on the “Medical History” CRF pages.
11.3
Other Baseline Characteristics
Analysis Set: FAS/SAF
Information on other baseline characteristics are collected from “Vital Signs”, “ECOG
Performance Status” and “Primary Malignancy” pages from CRF. The following characteristics 
will be summarized at baseline by dose group and overall.
! Height at Baseline (cm): summary statistics 
! Weight at Baseline (kg): summary statistics 
! Body mass index (BMI) at baseline (kg/m2): summary statistics
! Eastern Cooperative Oncology Group (ECOG) performance status: 0, 1, 2, 3, 4, 5
! Summary of primary malignancy will include the following variables:
o
Number of subjects with at least one of primary malignancy
o
Primary malignancy: endometrial cancer, non-small cell lung cancer, small cell lung 
cancer, breast cancer, ovarian cancer, colorectal cancer, lymphoma, prostate cancer, 
other
o
Histopathological grade of primary malignancy: G1, G2, G3, GX, other
o
TNM staging at diagnosis: T, N, M and associated sub-categories
o
Stage at diagnosis: IA, IB, IIA, IIB, III, IIIA, IIIB, IV, other
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
16/36
o
Time elapsed since diagnosis of primary malignancy (months): summary statistics
Specifications for computation:
!
BMI (kg/m2) = weight(kg)/[height(m)]2
Baseline 
characteristics 
with 
respect 
to 
vital 
signs, 
physical 
examinations, 
and 
hematology/biochemistry will be part of Section 15 (Safety Evaluation).
All relevant baseline characteristics data will be presented in data listings.
11.4
Disease History
Analysis Set: FAS/SAF
The prior anticancer treatments and procedures are collected under “Prior anti-cancer therapy”, 
“Prior radiotherapy” and “Prior cancer surgery” pages from the CRF.
Summary of prior anticancer therapy/radiotherapy will include the following variables:
!
Type of therapy: chemotherapy, hormonal therapy, immunotherapy, investigational therapy, 
other
!
Regimen number of prior anticancer therapy: neoadjuvant, adjuvant, regimen 1,…, regimen 
10, unknown
!
Best response to regimen from prior anticancer therapy: complete response (CR), partial 
response (PR), stable disease (SD), progressive disease (PD), not evaluable (NE), unknown
!
Last recorded response to regimen from prior anticancer therapy: CR, PR, SD, PD, NE, 
unknown
!
Time elapsed since most recent anticancer therapy (months): summary statistics
!
Duration of most recent anticancer therapy (months): summary statistics
!
Location of radiotherapy: brain, breast, lung, pleura, head and neck, esophagus, spinal cord, 
vertebrae, lymph nodes, bone, other
The listings of prior anticancer therapies will also be provided: a) listing of prior anticancer
therapy; b) listing of prior radiotherapy and c) listing of prior cancer surgery. These will include 
subject identifier and all the relevant collected data-fields on the corresponding CRF pages.
12
Previous or Concomitant Medications/Procedures
Previous or concomitant medications will be summarized from the CRF page of “Previous and 
Concomitant medications”, using the analysis population as indicated below.  
Handling of missing data:
For identification of previous or concomitant medications/procedures, no formal imputation will 
be performed on missing or incomplete dates. Rules presented in Tables 3 and Table 4 will be used 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
17/36
to define if a medication/procedure is considered as a previous, concomitant or both previous and 
concomitant medication/procedure.
Table 1: 
Stopping rules for medication/procedure end dates
End date of medication/procedure
Stopping rule
Day
Month
Year
UNK
UNK
UNK
After treatment start (ongoing)
UNK
UNK
< Treatment start (year)
Before treatment start
UNK
UNK
≥ Treatment start (year)
After treatment start
UNK
< Treatment start (month and year)
Before treatment start
UNK
≥ Treatment start (month and year)
After treatment start
< Treatment start (complete date)
Before treatment start
≥ Treatment start (complete date)
After treatment start
UNK = unknown.
Table 2: 
Rules to define previous and/or concomitant medications
UNK = unknown.
12.1
Previous Medications
Analysis Set: FAS/SAF
Previous medications are medications, other than study medications and pre-medications for 
study treatment, which started before the date of first dose of study treatment (including the Lead-
in Period, if any), regardless of when dosing of the medication ended. 
Start date of medication/procedure
Stopping rule 
(see Table 3 )
Medication/procedure
Day
Month
Year
UNK
UNK
UNK
Before treatment start
Previous
UNK
UNK
UNK
After treatment start
Previous and concomitant
UNK
UNK
≤ Treatment start (year)
Before treatment start
Previous
UNK
UNK
≤ Treatment start (year)
After treatment start
Previous and concomitant
UNK
UNK
> Treatment start (year) and ≤ 
Treatment end + 30 days (year)
After treatment start
Concomitant
UNK
≤ Treatment start (month and year)
Before treatment start
Previous
UNK
≤ Treatment start (month and year)
After treatment start
Previous and concomitant
UNK
> Treatment start (month and year) and ≤ 
Treatment end + 30 days (month and year)
After treatment start
Concomitant
≤ Treatment start (date)
Before treatment start
Previous
≤ Treatment start (date)
After treatment start
Previous and concomitant
> Treatment start (date) and ≤ Treatment end + 30 days 
(date)
After treatment start
Concomitant
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
18/36
To summarize previous medications, Anatomical Therapeutic Chemical (ATC) -2nd level and 
preferred term will be tabulated as given from the latest version of World Health Organization 
Drug Dictionary (WHO-DD) dictionary. In case multiple ATCs are assigned to a drug, all ATC-2nd
level will be used for reporting.  
In case the date values will not allow to unequivocally allocate a medication to previous
medication, the medication will be considered as previous medication.
Previous medications will also be listed. The listing will include: subject identification number, 
dose group and all corresponding collected data-fields on the corresponding CRF page.
12.2
Concomitant Medications 
Analysis Set: FAS/SAF
Concomitant treatments are medications, other than study medications, which are taken by 
subjects any time on-trial (on or after the first day of trial drug treatment for each subject, including 
the Lead-In Period, if any) or within 30 days after last dose of trial drug. 
To summarize concomitant medications, ATC-2nd level and preferred term will be tabulated as 
given from the latest version of WHO-DD dictionary. In case multiple ATCs are assigned to a 
drug, all ATC-2nd level will be used for reporting. In case the date values will not allow to 
unequivocally allocating a medication to concomitant medication the medication will be 
considered as concomitant medication.
Medications that started before first dose of study treatment from the Lead-in Period, and 
continued after the first dose of study treatment from the Lead-in Period will be summarized as 
previous medications and separately as concomitant medications.
All relevant concomitant medication data will be listed, including flags for those medications that 
started after 30 days of the last dose of study treatment (VX-984 or PLD).
12.3
Concurrent Procedures
Analysis Set: FAS/SAF
Concurrent procedures, which were undertaken any time during the on-treatment period, will be 
listed according to the CRF page “Non-Pharmacological Treatment or Procedures”.  
In case the date values will not allow to unequivocally allocating a procedure to concurrent 
procedure, the procedure will be considered as concurrent procedure.  
A listing of concurrent procedures will be created with the relevant information collected on the 
corresponding CRF page, including flags for procedures that took place prior to, on or after the 
date of first dose of study treatment (VX-984 or PLD), or after 30 days of the last dose of study 
treatment (VX-984 or PLD).
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
19/36
13
Treatment Compliance and Exposure
Analysis Set: FAS/SAF
All dosing calculations and summaries will be based on “Study Drug Administration: 984” and 
“Study Drug Administration: PLD” CRF pages. 
!
VX-984 is taken by consumption of dosing powder once daily (QD) on Days -14 to -12 as a 
single agent during a 14-day Lead-in Period, and Days 2 to 4 in a 28-day treatment cycle.  
!
PLD is administered by infusion to be taken on Day 1 in a 28-day treatment cycle.  
Unless specified otherwise, Treatment Period refers to the dosing period that started from Cycle 1 
Day 1 (Treatment Day 1); and Lead-in Period refers to the dosing period prior to Treatment Day1, 
(See the definition of Treatment Day in Section 9).
Total number of infusions of PLD
Total number of infusions is calculated as the sum of the actual number of infusions that a subject 
received across cycles. The actual number of infusions will be counted directly based on the 
infusions reported from the CRF, regardless of infusion delays, interruptions, or any other types 
of deviations from the protocol required schedules. An infusion is regarded to be administered, if 
either the actual dose received is > 0 mg or the duration of the infusion is > 0 minutes.
!
PLD during the Treatment Period: per protocol a subject will receive 1 infusion in a 28-day 
treatment cycle.
Total number of administrations of VX-984
Total number of administrations is calculated as the sum of the actual number of administrations 
that a subject received during a period. The actual number of administrations will be counted 
directly based on the administrations reported from the CRF. A dose is regarded to be administered 
if the actual dose received is > 0 mg.
!
VX-984 during the Lead-in Period: per protocol a subject will receive 3 administrations from 
the Lead-in Period;
!
VX-984 during the Treatment Period: per protocol a subject will receive 3 administrations in 
a 28-day treatment cycle.
Total number of cycles
Total number of cycles (during the treatment period) is defined as the maximum number of cycles 
that a subject received across treatment cycles. The number of treatment cycles will be counted 
based on the data directly from the CRF.  
!
VX-984 during the Treatment Period: a cycle with at least one administration of VX-984 will 
be counted per subject.   
Total cumulative dose
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
20/36
Total cumulative dose (mg) will be derived separately for Lead-in Period and Treatment Period.  
!
VX-984 during the Lead-in Period
It is calculated as the sum of the individual actual dose amount that a subject received during
the Lead-in Period, where the individual actual dose amount is taken directly from the “Dose 
level administered (mg)” on the CRF page of “Study Drug Administration: 984” at each dosing 
day.
!
VX-984 during the Treatment Period
It is calculated as the sum of the individual actual dose amount that a subject received across 
treatment cycles, where the individual actual dose amount is taken directly from the “Dose 
level administered (mg)” on the CRF page of “Study Drug Administration: 984” at each dosing 
day.
!
PLD during the Treatment Period
PLD is only administered during the treatment cycles. It is calculated as the sum of the 
individual actual dose amount that a subject received across treatment cycles, where the 
individual actual dose amount is taken directly from the “Dose level administered (mg)” on 
the CRF page of “Study Drug Administration: PLD” at each dosing day.
Total planned dose
Total planned dose (mg) will be derived separately for Lead-in Period and Treatment Period.   
!
VX-984 during the Lead-in Period
It is the sum of the individual planned dose that a subject will receive from the Lead-in Period, 
where the individual planned dose is taken directly from the “Planned dose (mg)” on the CRF 
page of “Study Drug Administration: 984” at each dosing day.
!
VX-984 during the Treatment Period
It is the sum of the individual planned dose that a subject will receive across treatment cycles, 
where the individual planned dose level is taken directly from the “Planned dose (mg)” on the 
CRF page of “Study Drug Administration: 984” at each dosing day.
!
PLD during the Treatment Period
It is the sum of the individual planned dose that a subject will receive across treatment cycles, 
where the individual planned dose level is taken directly from the “Body surface area (BSA)
adjusted dose amount (mg)” on the CRF page of “Study Drug Administration: PLD” at each 
dosing day.  
If any individual planned dosing amount is not collected from the CRF, then the planned dose 
amount will be derived as follows at each dosing day:
BSA adjusted planned dose (mg) = planned dose level (mg/m2) × BSA (m²)
The BSA reported on the CRF will be used. In case BSA is missing at a particular visit, the 
latest BSA available prior to that visit will be used for calculation.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
21/36
Duration of therapy – VX-984
The duration of VX-984 will be calculated based on the dosing received from the Lead-in Period 
(if not omitted) and the Treatment Period. A dose of VX-984 is regarded to be administered, if the 
actual dose received is > 0 mg.
!
During a 14-day Lead-in Period, VX-984 will be administered QD on Days -14 to -12 as a 
single agent. Hence, the duration for VX-984 during the Lead-in Period will be calculated as:
Duration (weeks) = date of last dose - date of first dose + 12
7

where the dates of first dose and last dose are those implemented during the Lead-in Period. 
!
During a 28-day cycle, VX-984 will be administered QD on Days 2 to 4 in combination with 
PLD. Hence, the duration for VX-984 during a treatment cycle will be calculated as:
Duration (weeks) = date of last dose - date of first dose + 26
7

where the dates of first dose and last dose are those implemented during treatment cycles.
Duration of therapy – PLD
!
During a 28-day treatment cycle, PLD infusion will be administered on Day 1 only. Hence, the 
duration for PLD will be calculated as:
Duration (weeks) = date of last dose - date of first dose + 28
7

A dose of PLD is regarded to be administered, if either the actual dose received is > 0 mg, or the 
duration of the infusion is > 0 minutes.
Dose intensity 
!
Dose intensity (mg/2 week) of VX-984 from Lead-in Period
VX-984 administered on Days -14 to -12 during a 2-week Lead-in Period will be calculated as
Dose intensity = Total Cumulative dose (mg) of VX-984 from Lead-in Period
Duration of Lead-in Period (in weeks)/2

!
Dose intensity (mg/4 week) of VX-984  administered on Days 2 to 4 in a 4-week treatment 
cycle will be calculated as
Dose intensity = Total Cumulative dose (mg) of VX-984 from Treatment Period
Duration of Treatment Period (in weeks)/4

!
Dose intensity (mg/4 week) of PLD administered on Day 1 in a 4-week treatment cycle will 
be calculated as
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
22/36
Dose intensity = Total Cumulative dose (mg) of PLD from Treatment Period
Duration of Treatment Period (in weeks)/4

Relative Dose intensity 
The relative dose intensity (%) is calculated as the dose intensity (mg/week) divided by the total 
planned dose intensity (mg/week) of the same dosing period, which is calculated as:
Total planned dose intensity (mg/4 week) = 
Total planed dose (mg) 
Duration of a therapy (in weeks)/4
Relative dose intensity will be calculated in a similar way as dose intensity based on respective
study treatment and dosing period:
!
Relative dose intensity (mg/week) of VX-984 from Lead-in Period will be calculated as

Dose Intensity of VX-984 from Lead-in Period (mg/2 week)
Total planned dose intensity of VX-984 from Lead-in Period (mg/2 week)
!
Relative dose intensity (%) of VX-984 from Treatment Period will be calculated as

Dose Intensity of VX-984 from Treatment Period (mg/4 week)
Total planned dose intensity of VX-984 from Treatment Period (mg/4 week)
!
Relative dose intensity (%) of PLD from Treatment Period will be calculated as

Dose Intensity of PLD from Treatment Period(mg/4 week)
Total planned dose intensity of PLD from Treatment Period (mg/4 week)
The following drug exposure related parameters will be provided by study treatment and dose 
group:
! Total Number of administrations of VX-984
o
VX-984 from Lead-in Period
o
VX-984 from Treatment Period
! Total number of infusions of PLD from Treatment Period
! Total number of cycles of VX-984 from Treatment Period
! Total cumulative dose (mg) of VX-984
o
VX-984 from Lead-in Period
o
VX-984 from Treatment Period
! Total cumulative dose (mg) of PLD from Treatment Period
! Total planned dose (mg) of VX-984
o
VX-984 from Lead-in Period
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
23/36
o
VX-984 from Treatment Period
! Total planned dose (mg) of PLD from Treatment Period
! Duration (weeks) of VX-984 from Treatment Period and by subcategories of: ≤4 weeks, > 4 
– 8 weeks, > 8 – 12 weeks, > 12 – 16 weeks, > 16 weeks
! Duration (weeks) of PLD from Treatment Period and by subcategories of: ≤4 weeks, > 4 – 8 
weeks, > 8 – 12 weeks, > 12 – 16 weeks, > 16 weeks
! Dose intensity of VX-984
o
Dose intensity (mg/2 week) VX-984 from Lead-in Period
o
Dose intensity (mg/4 week) VX-984 from Treatment Period
! Dose intensity (mg/4 week) of PLD from Treatment Period
! Relative dose intensity (%) of VX-984 and by subcategories of: < 60%, ≥60% - < 80%, ≥80% 
- < 90%, ≥90% - ≤110%, > 110%
o
VX-984 from Lead-in Period
o
VX-984 from Treatment Period
! Relative dose intensity (%) of PLD from Treatment Period and by subcategories of: < 60%, ≥
60% - < 80%,  ≥80% - <90%, ≥90% - ≤110%, > 110%
14
Efficacy Analyses
14.1
Analysis of Best Overall Response
Analysis Set: FAS/SAF
The best overall response (BOR) will be defined as the best response per RECIST 1.1 across all 
time points until determination of PD, using the Investigator reported overall response per time 
point and excluding assessments after further anticancer therapy  Clinical deterioration will not be 
considered as documented disease progression.
Tumor assessments are based on local evaluations by the Investigator according to RECIST 1.1 
criteria. Local evaluations of target, non-target and new lesions are used to assess BOR. The date 
of the overall response assessment is the earliest date for imaging of target, non-target and new 
lesions of images taken at that response assessment.
BOR will be defined as the best response across all time points (for example, a subject who has 
SD at the first assessment, PR at the second assessment, and PD at the last assessment has a BOR 
of PR). The order to obtain the BOR is the following: CR, PR, SD, PD and NE.
When SD is believed to be the best response, it must also meet the protocol-specified minimum 
6 weeks from first day of treatment. If the minimum time is not met, the subject’s BOR depends 
on the subsequent assessments. For example, a subject who has SD at the first assessment, PD at 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
24/36
the second assessment and does not meet the minimum duration for SD, will have a BOR of PD. 
The same subject lost to follow-up after the first SD assessment would be considered NE for BOR.
If a subject has missing baseline tumor assessment and/or no tumor assessment on-treatment, BOR 
will be NE.
The confirmed BOR will be also analyzed. In this case, CR and PR need to be confirmed at a 
subsequent assessment, at least 4 weeks after initial overall response assessment of CR/PR. 
Confirmed BOR will be derived as described in RECIST 1.1 guidance, see Table 5 below.
Both confirmed and unconfirmed BOR will be summarized by tabulating the number and 
percentage of subjects with CR, PR, SD, PD or NE as BOR. The table will also include the 
objective response rate (ORR), disease control rate (DCR) and the corresponding 90% 
Clopper-Pearson confidence intervals (Clopper & Pearson, 1934). The ORR will be defined as the 
rate of subjects who achieve either a CR or PR. The DCR will be defined as the rate of subjects 
who achieve either a CR, PR or SD.
The listing of tumor assessments (including e.g. lesion number, description and location, type of 
lesion, imaging date, assessment method, diameter (mm), sum of diameter of target lesions (mm), 
BOR (confirmed and unconfirmed) will be provided by subject as recorded from the “Target 
Lesions”, “Sum of Diameters”, “Non-Target Lesions”, “New Lesions” and “Assessment of disease 
based on imaging” CRF pages.
Table 3
BOR when confirmation of CR/PR is required
Overall response 
first time point
Overall response 
subsequent time pointa
Confirmed BOR
CR
CR
CR
CR
PR
SD, if minimum criteria for SD duration met at first time 
point. Otherwise PD
CR
SD
SD, if minimum criteria for SD duration met at first time 
point. Otherwise PD.
CR
PD
SD, if minimum criteria for SD duration met at first time 
point. Otherwise PD.
CR
NE
SD, if minimum criteria for SD duration met at first time 
point. Otherwise NE.
PR
CR
PR
PR
PR
PR
PR
SD
SD, if minimum criteria for SD duration met at subsequent 
time point.  Otherwise NE
PR
PD
SD, if minimum criteria for SD duration met at first time 
point. Otherwise PD.
PR
NE
SD, if minimum criteria for SD duration met at first time 
point. Otherwise NE.
NE
NE
NE
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
25/36
a Subsequent time point is not necessarily the direct subsequent scan (e.g. PR-SD-PR will have PR as confirmed 
BOR).
A spider graph will display the percentage change from baseline in sum of longest diameter of 
target lesion against the date for each subject, overall and per dose level.
A swimmer plot displaying some key radiological milestones will be produced for each dose group
separately. For each subject, the time from treatment start until end of follow-up will be 
represented (from treatment start to last date known to be alive or date of death). In addition, 
following information will be displayed: time to best overall unconfirmed response (CR, PR or 
SD), time of confirmation of response, time to progression and status at the end of the follow-up 
(alive or dead). 
In addition, a waterfall plot representing the best percentage change in tumor size from baseline 
per subject will be provided. The BOR will also be presented as an annotation on each vertical bar.
15
Safety Analyses
The subsections in this section include specifications for summarizing safety endpoints that are 
common across clinical trials such as adverse events (AEs), laboratory tests and vital signs.
Definition of on-treatment period
On-treatment period is defined as the date from the first dose of study treatment (either VX-984 or 
PLD, including the Lead-in Period if available), until the minimum (last dose of study treatment + 
30 days, date of death).  
15.1
MTD (Primary Endpoint)
Analysis Set: DLT
The maximum tolerated dose (MTD) is defined as the highest dose combination for a given 
schedule that causes DLTs in no more than 33.3% of subjects by the end of Cycle 1. The DLT 
information will be based on “Adverse Events” CRF page with “Dose limiting toxicity?” = Yes.
The end of Cycle 1 is defined as 28 days after the start of study treatment from Cycle 1 Treatment 
Day 1.
A summary table of DLTs during the first cycle of study treatment, including the Lead-in Period,
will be provided by dose group and overall with:
!
Number of subjects with no DLT 
!
Number of subjects with one or more DLTs
The listing of DLTs will also be provided.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
26/36
15.2
Adverse Events
Analysis Set: FAS/SAF
AEs will be summarized based on the information collected from the “Adverse Events” CRF page.
!
Pretreatment AEs are defined as AEs that were reported or worsened after signing the informed 
consent form up to the start of study treatment (either VX-984 or PLD), including the Lead-in 
Period if available. 
!
Treatment-emergent adverse events (TEAEs) are defined as those events with onset dates 
occurring within the on-treatment period as defined in Section 15.
!
Serious Adverse Events (SAEs): serious adverse events (serious adverse event = yes).
!
Adverse Events Leading to permanent treatment discontinuation: (action taken = drug 
withdrawn).
!
Adverse Events Leading to temporary treatment discontinuation: (action taken = drug 
interrupted).
!
Adverse Events Leading to dose reduction: (action taken with study drug = dose reduced).
!
Adverse Events Leading to Death: adverse event leading to death (AEs with Grade 5 or 
outcome “fatal” if Grade 5 not applicable).
All analyses described in Section 15.2 will be based on TEAEs if not otherwise specified.
Incomplete AE-related dates will be handled as follows:
!
In case the onset date is missing completely or missing partially but the onset month and year, 
or the onset year are equal to the start of study drug then the onset date will be replaced by the 
minimum of start of study drug and AE resolution date. 
!
In all other cases the missing onset day or missing onset month will be replaced by 1.
!
Incomplete stop dates will be replaced by the last day of the month (if day is missing only), if 
not resulting in a date later than the date of subject's death. In the latter case the date of death 
will be used to impute the incomplete stop date. 
!
In all other cases the incomplete stop date will not be imputed. If stop date of AE is after date 
of cut-off outcome of AE is ongoing at cut-off. 
!
Further information after cut-off (e.g. fatal outcome) might be taken from Safety database and 
included separately into the CSR.
15.2.1
All Adverse Events
AEs will be summarized by worst severity (according to National Cancer Institute – Common 
Terminology Criteria for Adverse Events [NCI-CTCAE] of the latest version) per subject, using 
the MedDRA preferred term as event category and primary system organ class (SOC) body term 
as Body System category. 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
27/36
Unless otherwise stated, AEs will be displayed in terms of frequency tables: PT and primary SOC 
in alphabetical order. 
If an AE is reported for a given subject more than once during treatment, the worst severity and 
the worst relationship to study treatment will be tabulated.
AEs related to study treatment are those events with relationship missing, possibly related or 
related.
In case a subject had events with missing and non-missing grades, the maximum of the non-
missing grades will be displayed.
The following overall frequency tables will be prepared. In addition the tables will be provided by 
PT and primary SOC in alphabetical order:
!
Any TEAE 
!
Any related TEAEs
o
VX-984 or PLD related TEAEs 
o
VX-984 related TEAEs
o
PLD related TEAEs
!
Any serious TEAEs 
!
Any non-serious TEAEs
!
Any related serious TEAEs
o
VX-984 or PLD related serious TEAEs 
o
VX-984 related serious TEAEs 
o
PLD related serious TEAEs 
!
Any TEAE by NCI-CTCAE severity grade (∀3, ∀4) 
!
Any related TEAE by NCI-CTCAE severity grade (∀3, ∀4) 
o
VX-984 or PLD related TEAE by NCI-CTCAE severity grade (∀3, ∀4) 
o
VX-984 related TEAE by NCI-CTCAE severity grade (∀3, ∀4) 
o
PLD related TEAE by NCI-CTCAE severity grade (∀3, ∀4) 
!
TEAEs leading to death (AEs with Grade 5 or outcome “fatal” if Grade 5 not applicable) 
!
Any related TEAEs leading to death (AEs with Grade 5 or outcome “fatal” if Grade 5 not 
applicable) 
o
VX-984 or PLD related TEAEs leading to death 
o
VX-984 related TEAEs leading to death
o
PLD related TEAEs leading to death 
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
28/36
The listing for all AEs (whether treatment-emergent or not) will include all the data fields as 
collected on the “Adverse Events” CRF pages. 
!
Dose group
!
Subject identification number
!
First and last dose dates of VX-984
!
First and last dose date of PLD
!
Reported Term with SOC and PT
!
Start and end date with their corresponding treatment day
!
Treatment Emergent Adverse Events flag (N/Y)
!
Related to VX-984 flag (N/Y)
!
Related to PLD flag (N/Y)
!
Serious Adverse Events flag (N/Y)
!
DTL flag (N/Y)
!
CTCAE Grade
!
Action taken on VX-984 
!
Action taken on PLD 
!
Outcome of AE
Clinical trial.gov and EudraCT requirements
Summary tables for non-serious AEs excluding SAEs applying frequency threshold of 5% will be 
provided by dose group and overall.
15.2.2
Adverse Events Leading to Treatment Discontinuation
The following overall frequency tables will be prepared for the AE actions. In addition, tables by 
PT and primary SOC in alphabetical order will also be provided:
TEAEs leading to temporary discontinuation
!
TEAEs leading to temporary discontinuation of either study treatment (either VX-984 or PLD)
!
TEAEs leading to temporary discontinuation of both study treatments (VX-984 and PLD)
!
TEAEs leading to temporary discontinuation of VX-984
!
TEAEs leading to temporary discontinuation of PLD
TEAEs leading to permanent discontinuation
!
TEAEs leading to permanent discontinuation of either study treatment (either VX-984 or PLD)
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
29/36
!
TEAEs leading to permanent discontinuation of both study treatments (VX-984 and PLD)
!
TEAEs leading to permanent discontinuation of VX-984 
!
TEAEs leading to permanent discontinuation of PLD
TEAEs leading to dose reduction 
!
TEAEs leading to dose reduction of either study treatment (either VX-984 or PLD)
!
TEAEs leading to dose reduction of both study treatments (VX-984 and PLD)
!
TEAEs leading to dose reduction of VX-984 
!
TEAEs leading to dose reduction of PLD
15.3
Deaths, Other Serious Adverse Events, and Other Significant 
Adverse Events
Analysis Set: FAS/SAF
15.3.1
Deaths
All deaths, deaths within 30 days after last dose, and deaths within 60 days after first dose of study 
treatment, will be tabulated based on information from the “Long-Term Follow-Up” CRF page. 
! Number of deaths 
! Number of deaths within 30 days after last dose of study treatment (VX-984 or PLD, whatever 
is later)
! Number of deaths within 60 days after first dose of study treatment (VX-984 or PLD, whatever 
is earlier)
In addition, date of death will be provided in individual subject data listing together with selected 
dosing information (date of first/last administration of study treatment). 
!
Listing of deaths 
Will include columns for:
! AEs with fatal outcome (list preferred terms of AEs with outcome = fatal)
! flag for death within 30 days of last dose of study treatment (VX-984 or PLD, whatever is later)
! flag for death within 60 days of first dose of study treatment (VX-984 or PLD, whatever is 
earlier)
15.3.2
Serious Adverse Events
SAEs will be summarized for each dose group and overall by SOC and PT in alphabetical order 
(please refer to Section 15.2.1 for items to be listed).
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
30/36
For these AEs, subject listings of SAEs will be provided in addition.
15.3.3
Other Significant Adverse Event
Not applicable.
15.4
Clinical Laboratory Evaluation
Analysis Set: FAS/SAF
Laboratory values (including corresponding normal ranges) from a local lab will be used for in the 
analyses. A complete list of laboratory tests is presented in the Appendix 18.1.
Laboratory results will be classified according to the latest version of NCI-CTC as provided by the 
local laboratory. Additional laboratory results that are not part of NCI-CTC will be presented 
according to the categories: below normal limits, within normal limits and above normal limits
(according to the laboratory normal ranges).
The worst on-treatment grade (i.e. on or after first study treatment administration and within 30
days after last study treatment administration) will be summarized considering only subjects with 
post baseline laboratory samples: Laboratory tests by NCI-CTC grade (0, 1, 2, 3, 4, any).
NCI-CTC gradable and non-grade lab tests are shown in Table 6 and Table 7.
Tables for NCI-CTC gradable parameters:
! Number and percentage of subjects with any, NCI-CTC grade 0, 1, 2, 3, 4, and grade of 3 or 4 
laboratory abnormalities under treatment – (worst case)
! Shifts in toxicity grading baseline to worst on-treatment
The highest NCI-CTC grade during the on-treatment period is considered as the worst grade for 
the summary. 
Table 4
NCI-CTC gradable parameters
Category
Parameter 
(LBTEST)
Parameter 
code 
(LBTESTCD)
Name in NCI-CTC
Direction of 
abnormality
Serum chemistry
Electrolytes
Calcium
CA
Hypocalcemia/Hypercalcemia
Low/High
Electrolytes
Magnesium
MG
Hypomagnesemia/
Hypermagnesemia
Low/High
Electrolytes
Phosphorus 
(Phosphate)
PHOS
Hypophosphatemia
Low
Electrolytes
Potassium
K
Hypokalemia/Hyperkalemia
Low/High
Electrolytes
Sodium
SODIUM
Hyponatremia/Hypernatremia
Low/High
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
31/36
Category
Parameter 
(LBTEST)
Parameter 
code 
(LBTESTCD)
Name in NCI-CTC
Direction of 
abnormality
Enzymes/cardial
Creatinine 
Phosphokinase
CK
CPK increased
High
Enzymes/liver
Alanine 
Aminotransferase
ALT
Alanine Aminotransferase 
increased
High
Enzymes/liver
Alkaline Phosphatase
ALP
Alkaline Phosphatase 
increased
High
Enzymes/liver
Aspartate 
Aminotransferase
AST
Aspartate Aminotransferase 
increased
High
Enzymes/liver
Gamma-
glutamyltransferase
GGT
GGT increased
High
Enzymes/liver
Total bilirubin
BILI
Blood bilirubin increased
High
Metabolism
Glucose
GLUC
Hypoglycemia/
Hyperglycemia
Low/High
Metabolism
Uric acid (1) 
URATE
Hyperuricemia
High
Plasma proteins
Albumin
ALB
Hypoalbuminemia
Low
Renal/kidney
Creatinine
CREAT
Creatinine increased
High
Renal/kidney
Creatinine Clearance
CREATCLR
part of Chronic kidney disease
Low
Hematology
Platelets
Platelets Count
PLAT
Platelet count decreased
Low
Red blood cells
Hemoglobin
HGB
Anemia/Hemoglobin 
increased
Low/High
White blood 
cells/differential
White Blood Cell 
Count
WBC
White blood cell 
decreased/Leukocytosis
Low/High
White blood 
cells/differential
Absolute Lymphocytes 
Count
LYM
Lymphocyte count 
decreased/increased
Low/High
White blood 
cells/differential
Absolute Neutrophils 
Count
NEUT
Neutrophil count decreased
Low
(1) According to CTCAE grade, if uric acid value is between ULN and 590 μmol/L it should be graded as follows:
o
Grade 1 if there are no physiologic consequences
o
Grade 3 if there are physiologic consequences
a For a programming perspective, values between ULN and 590 μmol/L will all be graded as Grade 1 (if any physiologic 
consequences are observed, it should be completed as an adverse event).
b Final analysis will be based on the actual data received for the trial, discrepancy with the CTC gradable and 
non-gradable parameters does not constitute a requirement for IAP amendment. 
Tables for non-CTC gradable parameters:
! Number of subjects with shifts from baseline to worst on-treatment post-baseline normal 
categories.
The normal categories based on the normal range will be produced with the following categories 
for all hematology and blood chemistry parameters:
o
Baseline: Low/Normal/High/Missing/Overall
o
Worst On-trial: Low/Normal/High/Missing/Overall
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
32/36
Table 7:
NCI-CTC Non-gradable parameters
Category
Parameter 
(LBTEST)
Parameter code 
(LBTESTCD)
Direction of 
abnormality
Serum chemistry
Enzymes/cardial
Lactate dehydrogenase
LDH
High
Plasma proteins
Total protein
PROT
Low
Renal/kidney
Blood Urea Nitrogen
BUN
High
Hematology
Red blood cells
Hematocrit 
HCT
High/Low
Red blood cells
Mean Corpuscular Hemoglobin
MCH
High/Low
Red blood cells
Mean Corpuscular Hemoglobin 
Concentration
MCHC
High/Low
Red blood cells
Mean Corpuscular Volume
MCV
High/Low
Red blood cells
Red blood cells (Erythrocytes)
RBC
High/Low
Red blood cells
Reticulocytes
RETI
High/Low
White blood cells/differential
Basophils
BASOLE
High
White blood cells/differential
Eosinophils
EOSLE
High
White blood cells/differential
Monocytes
MONOLE
High/Low
Normal category includes low values for high parameters and high values for low parameters.
Subjects without post baseline laboratory samples will be excluded from analyses with respect to 
values after the baseline.
All CTC gradable and non-CTC gradable parameters will be listed for each measurement. 
Parameters will be grouped by category.
Listings will include at least the following items:
! Dose group
! Subject identification number
! First/last dosing date of VX-984 and PLD
! Parameters
! Visit
! Date (Treatment day)
! Analysis value
! SI unit
! Change from baseline
! Reference range status (Low, Normal, High)
! CTC grade (with associated CTC name)
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
33/36
! Baseline flag (Yes/No)
! Worst value on-treatment flag (Yes/No)
In addition, a listing displaying parameters with at least one value with grade ≥ 3 will be provided. 
For each subject, only parameters where at least one value has grade ≥3 will be displayed (all 
visits for the corresponding parameter will be displayed).
Coagulation parameters
All coagulation parameters will be tested only at Screening, and will be presented in a listing only.
Urinalysis
All urinalysis and microscopic analysis will be presented in listings only.
15.5
Vital Signs
Analysis Set: FAS/SAF
All relevant data as collected from “Vital Signs” CRF pages will be presented in listings. 
15.6
Other Safety or Tolerability Evaluations
15.6.1
ECOG Performance Status
Analysis Set: FAS/SAF
The listing will include all of the data from the “WHO Performance Status” CRF section.
15.6.2
Electrocardiogram
Analysis Set: FAS/SAF
Electrocardiogram values based on “ECG” CRF section will be used for summary statistics and 
shift tables by dose group and overall at each scheduled visit.
Descriptive statistics for numeric ECG measures of RR interval, PR interval, QRS interval, QT 
interval, QTcF interval (QT interval with Frederica’s correction) and HR will be summarized by 
time point. The number of subjects and percentage for categorical ECG parameters will also be 
summarized by time point.  
The QTcF interval is derived as follows: 
Frederica’s Correction (QTcF) 
3 RR
QT
QTc f #
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
34/36
where: RR = RR-interval measured in seconds.
The following frequency table will be presented for ECG parameters:
! Shift from normal baseline result to any abnormal on-treatment result
! Summary of observed values and changes from baseline 
! Summary of categorical measures by time point
! Summary of maximum on-treatment QTcF values
o
≤450 ms
o
> 450 ms and ≤ 480 ms
o
> 480 ms and ≤500 ms
o
> 500 ms
! Summary of maximum on-treatment QTcF changes from baseline
o
≤30 ms
o
> 30 ms and ≤ 60 ms
o
> 60 ms
Two listings will display all ECG results, one on qualitative results and another one on quantitative 
results. All visits and time points will be included in listings. 
15.6.3
Echocardiogram
Analysis Set: FAS/SAF
Echocardiogram values based on “Transthoracic Echocardiogram” CRF section will be used for
summary statistics and shift tables by dose group and overall at each scheduled visit.
Descriptive statistics by treatment and time (mean, StDev, median, min and max) relevant for left 
ventricular ejection fraction (LVEF) will be provided.  
! Summary of LVEF values and changes from baseline by visit
! Summary of maximum LVEF on-treatment decrease from baseline value
o
0 to ≤10%
o
> 10% and ≤20%
o
> 20%
The number and percentage of subjects by overall interpretation will also be summarized at each 
scheduled visit. 
All relevant data will be presented in listings.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
35/36
16
Analyses of Other Endpoints
16.1
Pharmacokinetics
Analysis Set: PAS
Concentration listings of VX-984 and PLD will be created using the computer program Phoenix®
WinNonlin® version 6.4, or higher (
 
). 
The following Listings will be provided.
Listings
!
Individual VX-984 plasma concentrations by group
!
Individual VX-984 urine concentrations, urine void volume and amount excreted
!
Individual PLD concentrations
The Phoenix WinNonlin NCA Core Output will be provided in a separate listing.
17
References
1. Babb J, Rogatko A, Zacks S. Cancer phase I clinical trials: Efficient dose escalation with 
overdose control. Stat Med 1998;17(10):1103-20.
2. Neuenschwander B, Branson M, Gsponer T. Critical aspects of the Bayesian approach to Phase 
I cancer trials. Stat Med 2008;27(13):2420-39.
3. Clopper, C. J., & Pearson, E. S. (1934). The Use of Confidence or Fiducial Limits Illustrated 
in the Case of the Binomial. Biometrika, 26, 404–413.
'RFXPHQW1R

2EMHFW1R

CCI
CCI
PPD


VX-984/M9831
VX-984 First in Human Study
MS201926-0001
                  Version 1.0
36/36
18
Appendices
18.1
Safety Laboratory Test Panels
Serum Chemistry
Hematology
Urinalysisa
Glucose 
Blood urea nitrogenb
Creatinine
Sodium
Potassium 
Calcium 
Chloride 
Magnesium 
Bicarbonate 
Inorganic phosphate 
Total bilirubin, direct bilirubin 
ALP
AST
ALT
Total protein 
Albumin 
Creatine kinasec
Uric acidc
Hemoglobin 
Erythrocytes: 
Mean corpuscular volume
Platelets 
Reticulocytes (absolute)c
Leukocytes 
Differential (absolute and percent):
Eosinophils 
Basophils 
Neutrophils 
Lymphocytes 
Monocytes 
Coagulationc
Activated partial thromboplastin time 
Prothrombin time
Prothrombin time International 
Normalized Ratio 
Leukocyte esterase 
Nitrite 
Urobilinogen 
Urine protein 
pH
Urine blood 
Specific gravity 
Urine ketones 
Urine bilirubin 
Urine glucose 
a
If urinalysis results are positive for leukocyte esterase, nitrite, protein, or blood, microscopic examination of 
urine will be performed and results for provided for leukocytes, erythrocytes, crystals, bacteria, and casts.
b
If blood urea nitrogen cannot be collected, urea may be substituted.
c
Creatine kinase, uric acid, and reticulocytes (absolute) parameters will be tested only at Screening and Safety 
Follow-up. Coagulation parameters will be tested only at Screening.
'RFXPHQW1R

2EMHFW1R

CCI
CCI


Document No. 
Object No. 
ELECTRONIC SIGNATURES
Signed by
Meaning of Signature
Server Date
(dd-MMM-yyyy HH:mm ‘GMT’Z)
&7306,$33KDVH,0DLQ7H[W%RG\9HUVLRQ
%XVLQHVV$SSURYDO
-DQ*07
%XVLQHVV$SSURYDO
-DQ*07
PPD
PPD
CCI
CCI